

No: 18/2026/CV-MP

Hanoi, June 05, 2026

INFORMATION DISCLOSURE

**To: - State Securities Commission;
- Hanoi Stock Exchange**

1. Company Name: **MEDIPLANTEX NATIONAL PHARMACEUTICAL
JOINT STOCK COMPANY**

- Stock Code: MED
- Address: No. 358, Giai Phong Road, Phuong Liet Ward, Ha Noi City.
- Person responsible for information disclosure: Mr. Mai Nhat Thanh

Type of information disclosure: ☐ Periodic ☒ Extraordinary ☐ As required

2. Information Disclosure Contents:

- Invitation Letter and Meeting Materials of the 2026 Annual General Meeting of Shareholders

3. This information was published on the company's website on June 5, 2026 at the link: <http://www.mediplantex.com/cổ-dòng/công-bố-thông-tin>

We hereby commit that the information published above is accurate and are fully legally responsible for the content of the published information./.

**MEDIPLANTEX NATIONAL PHARMACEUTICAL
JOINT STOCK COMPANY**

GENERAL DIRECTOR



Mai Nhat Thanh

MEETING INVITATION NOTICE
THE 2026 ANNUAL GENERAL MEETING OF SHAREHOLDERS
MEDIPLANTEX NATIONAL PHARMACEUTICAL JOINT STOCK
COMPANY

Dear: Shareholders of Mediplantex National Pharmaceutical Joint Stock Company

The Board of Directors of Mediplantex National Pharmaceutical Joint Stock Company hereby respectfully announces and cordially invites shareholders to attend the 2026 Annual General Meeting of Shareholders (the “AGMS”) with the following details:

- 1. Time:** 8:30 a.m., Friday, June 26, 2026
- 2. Meeting Format:** The Meeting will be held online with electronic voting via the platform available at <https://med.ezgsm.fpts.com.vn/>.
- 3. Attendance Venue:** Shareholders or their duly authorized representatives may attend the Meeting online from any location of their choice, provided that they are able to access the online General Meeting platform and cast votes electronically at <https://med.ezgsm.fpts.com.vn/>.
- 4. Meeting Administration Venue:** No. 358 Giai Phong Road, Phuong Liet Ward, Hanoi, Vietnam.
- 5. Agenda:** The Meeting shall discuss and consider the approval of the following matters:
 - Report of the Board of Directors on its performance in 2025 and the proposed operational plan for 2026;
 - Report of the Board of Management on the 2025 business and production results and the implementation plan for 2026;
 - Report of the Board of Supervisors on its 2025 activities and supervisory work, along with the proposed plan for 2026;
 - Approval of the audited financial statements for the year 2025;
 - Selection of an independent auditing firm for the 2026 financial statements;
 - Approval of the profit distribution plan and dividend payout ratio for 2025, and the proposed profit distribution plan and dividend payout ratio for 2026;
 - Approval of the remuneration of the Board of Directors and the Board of Supervisors for 2025, and approval of the remuneration plan for 2026;
 - Approval of amendments and supplements to the Company's Charter on Organization and Operation;
 - Approval of the dismissal and election of an additional member of the Board of Directors for the 2024 – 2029 term;
 - Other matters within the authority of the General Meeting;
- 6. Participants:** All shareholders listed in the register of securities holders of Mediplantex National Pharmaceutical Joint Stock Company, as finalized by the Vietnam Securities Depository and Clearing Corporation on May 28, 2026, and individuals duly authorized by such shareholders, are eligible to attend the General Meeting.
- 7. Registration for Attendance and Voting:**
 - Shareholders attending the Meeting are requested to access <https://med.ezgsm.fpts.com.vn/> to register for attendance using the login credentials, including the Username and Password, provided in the Meeting Invitation Notice sent to each shareholder.

Note: Shareholders are responsible for maintaining the confidentiality of their login credentials to ensure that only authorized shareholders may attend and vote at the General Meeting of Shareholders. The Company shall not be liable for any issues arising from a shareholder's loss or disclosure of such login information.

 - Shareholders may exercise their voting rights at <https://med.ezgsm.fpts.com.vn/> under the “Voting – Election” section. The electronic voting system will be opened at least one (01)

day prior to the official commencement of the Meeting, enabling shareholders and their authorized representatives to register attendance, vote, and participate in elections. The system will remain open until the Presidium announces the closure of the relevant voting agenda item or declares the adjournment of the Meeting

- In the case of authorization to attend the Meeting, shareholders are requested to prepare and submit the original Letter of Authorization to the address specified in Section 10 no later than **3:00 PM on June 23, 2026**, so that the Company may provide login credentials to the authorized representative. Alternatively, shareholders may register an authorization online through the system at <https://med.ezgsn.fpts.com.vn/> (the “**Authorization**” section.)
- The eligibility of shareholders or their authorized representatives to attend the Meeting shall be determined based on the shareholder records as of the record date provided by the Vietnam Securities Depository and Clearing Corporation (VSDC) and the authentication results from the online Meeting system. In the event of any dispute or complaint regarding attendance eligibility or voting rights, the Chairman of the Meeting shall have the authority to make a final decision based on the supporting documents provided by the parties and the applicable laws and regulations.

***Note:** A valid Letter of Authorization must be the original document, signed by both the authorizer and the authorized person, and stamped with the company seal in the case of institutional shareholders.*

8. General Meeting Documents:

The meeting agenda and documents are fully uploaded and regularly updated on the website of Mediplantex National Pharmaceutical Joint Stock Company at: <https://www.mediplantex.com/>. Additionally, shareholders can view and download the meeting documents at the website: <https://med.ezgsn.fpts.com.vn/> (under the “**Documents**” section). Shareholders are kindly requested to review the documents in advance.

9. Other Matters:

To ensure the thorough preparation of the General Meeting, shareholders or groups of shareholders holding at least 5% of the Company’s total voting shares who wish to propose additions to the meeting agenda are kindly requested to submit their proposals in writing to the Company no later than **3:00 PM on June 23, 2026**.

In the event that shareholders do not receive the Meeting Invitation due to objective reasons, they shall still retain the right to attend the Annual General Meeting of Shareholders. Shareholders who have not received the Meeting Invitation are kindly requested to contact the Company for assistance if necessary.

10. Address for Document Submission and Support Contact:

MEDIPLANTEX NATIONAL PHARMACEUTICAL JOINT STOCK COMPANY

No. 358 Giai Phong Street, Phuong Liet Ward, Hanoi

Phone: 024.38643363 / 091.611.7939 - Email: trang.chuh@mediplantex.com

Respectfully inviting esteemed shareholders to attend the meeting to ensure the success of the General Meeting.

Hanoi, June 5, 2026

**ON BEHALF OF THE BOARD OF DIRECTORS
CHAIRMAN**



Nguyen Ngoc Xuan Trang

**AGENDA OF THE 2026 ANNUAL GENERAL MEETING OF SHAREHOLDERS
MEDIPLANTEX NATIONAL PHARMACEUTICAL JOINT STOCK COMPANY**

Time: 8:30 AM, Friday, June 26, 2026.

Venue: The General Meeting will be held online via electronic voting. Shareholders or authorized representatives can participate in the online General Meeting from any location with an Internet connection. The broadcasting hub for the Chairperson, the Presidium, and the Organizing Committee (the administrative venue) is located at: No. 358 Giai Phong Street, Phuong Liet Ward, Hanoi.

AGENDA

Time	Detailed Agenda	Execution
8:00 - 8:30	Instructions for Shareholders on Online Attendance and E-Voting	The Organizing Committee
	Report on Delegate Eligibility Verification	The Delegate Eligibility Committee
8:30 - 9:15	Opening of the meeting and introduction of delegates	The Organizing Committee
	Approval of the Meeting Agenda, Working and Voting-Election Regulations, the Presidium, and the Vote Counting Committee	
9:15 - 10:15 Reports & Proposals	Report of the Board of Directors on its performance in 2025 and the proposed operational plan for 2026.	Representative of the Board of Directors
	Report of the Board of Management on the 2025 business and production results and the implementation plan for 2026.	Representative of the Board of Management
	Report of the Board of Supervisors on the 2025 activities, supervisory work and the proposed plan for 2026.	Representative of the Board of Supervisors
	Proposal for the approval of the 2025 audited financial statements;	Representative of the Board of Directors
	Proposal for the selection of an independent auditing firm for the 2026 financial statements;	Representative of the Board of Supervisors
	Proposal for the approval of the profit distribution plan and dividend payout ratio for 2025, and the proposed profit distribution plan and dividend payout ratio for 2026;	Representative of the Board of Directors
	Proposal for the approval of remuneration for the Board of Directors and the Board of Supervisors for 2025 and the plan for 2026;	Representative of the Board of Directors
	Proposal for the approval of the amendments and supplements to the Charter on Organization and Operation of the Company;	Representative of the Board of Directors
	Approval of the Dismissal and Election for the Additional Members of the Board of Directors for the 2024–2029 Term	Representative of the Board of Directors
	Other matters within the authority of the General Meeting of Shareholders.	Representative of the Board of Directors
10:15 - 10:30	Discussion of the reports and proposals	Chairperson of the General Meeting
10:30 - 11:00	Conduct voting on the matters submitted to the General Meeting of Shareholders and elect an additional member to the Board of Directors for the 2024–2029 term	
11:00 - 11:15	Announcement of the voting and election results at the General Meeting of Shareholders	Ballot Counting Committee
11:15 - 11:35	Presentation of the draft Minutes and Resolutions of the Meeting	Secretariat
11:35 - 12:00	Approval of the Minutes and Resolutions of the Meeting	Chairperson of the General Meeting
	Conclusion and declaration of the Meeting's closure	

**LETTER OF AUTHORIZATION
ATTEND THE 2026 ANNUAL SHAREHOLDER MEETING**

To: MediPlantex National Pharmaceutical Joint Stock Company (MED)

Shareholder information

Shareholder's name:

Legal representative (for organizations):

ID Card/Passport/Business Registration Certificate No.: Issued on at

Address:

Total number of shares represented or owned: shares

(In words: shares)

Information of the authorized party

Name of individual/organization: Shareholder code (if any):

ID Card/Passport/Business Registration Certificate No.: Issued on at

Address:

Number of authorized shares:

(In words: shares)

Note: In the event that a shareholder is unable to attend and cannot authorize someone else to represent them, please authorize a member of the company's Board of Directors from the list below:

No.	Full name	Position	Check the box	Number of authorized shares
01	Nguyen Ngoc Xuan Trang	Board Member		
02	Tran Nguyen Hoang Phuc	Board Member		
03	Tran Nguyen Hoang An	Board Member		
04	Thai Khac Minh	Independent Board Member		

(Note: Please mark (X) next to the name of the member you choose to authorize. Only authorize one person to authorize all of your shares; if you wish to authorize multiple people, please specify the number of shares you authorize for each member.)

Authorization details:

- The authorized party is entitled to represent the authorizing party in attending and voting on matters at the 2026 Annual General Meeting of Shareholders of MediPlantex Central Pharmaceutical Joint Stock Company to exercise all rights and obligations at the General Meeting of Shareholders related to the authorized shares.
- We assume full responsibility for this authorization and commit to strictly complying with all applicable laws and regulations, as well as the Articles of Organization and Operation of MediPlantex Central Pharmaceutical Joint Stock Company, and will not file any further claims.

Note:

- The authorized representative is not allowed to delegate their shareholding (or that of the authorizing party) to another person, and must bring their ID card/citizen identification card/passport when attending meetings.
- If either the authorizing party or the authorized party is an organization, the signature of the legal representative and the organization's seal must be included.
- This letter of authorization is only valid if it is an original document with the live signatures of both parties. This letter of authorization will expire upon the conclusion of the 2026 Annual General Meeting of Shareholders of MediPlantex Central Pharmaceutical Joint Stock Company.

Shareholder/Authorizing Party

(Signature and full name, seal if applicable)

Date ____ month ____ year 2026

Authorized Party

(Signature and full name, seal if applicable)

**MEDIPLANTEX NATIONAL
PHARMACEUTICAL JSC**

No.: 01/2026/QĐ-HĐQT

DRAFT

THE SOCIALIST REPUBLIC OF VIETNAM
Independence – Freedom – Happiness

Hanoi, June , 2026

DECISION

**Regarding the Establishment of the Shareholder Eligibility Verification Committee
for the 2026 Annual General Meeting of Shareholders**

**THE BOARD OF DIRECTORS OF MEDIPLANTEX NATIONAL
PHARMACEUTICAL JOINT STOCK COMPANY**

- Pursuant to the Law on Enterprises No. 59/2020/QH14 passed by the National Assembly of the Socialist Republic of Vietnam, on June 17, 2020, and effective as of January 1, 2021;
- Pursuant to the Charter on the organization and operation of Mediplantex National Pharmaceutical Joint Stock Company, as amended and supplemented for the 12th time on June 26, 2024;
- Based on the proposal of the General Director of the Company.

DECIDES

Article 1. To establish the Shareholder Eligibility Verification Committee to serve the 2026 Annual General Meeting of Shareholders of Mediplantex National Pharmaceutical Joint Stock Company, comprising the following members:

1. Ms. **Bui Thi Tuyet Lan** – Head of the Committee
2. Ms. **Nguyen Thi Hoang Yen** – Member

The Shareholder Eligibility Verification Committee shall automatically dissolve upon completion of its assigned duties.

Article 2. The Committee is tasked with verifying the eligibility of shareholders attending the 2026 Annual General Meeting of Shareholders in accordance with applicable laws and the Company's Charter.

Article 3. This Decision takes effect from the date of signing. The General Director of Mediplantex National Pharmaceutical Joint Stock Company, the Head of the Organizing Committee of the 2026 Annual General Meeting of Shareholders, and the individuals named in Article 1 shall be responsible for implementing this Decision.

Recipients:

- BOD;
- As stated in Article 3;
- Archived: Office.

**ON BEHALF OF THE BOARD OF DIRECTORS
CHAIRMAN**

Nguyen Ngoc Xuan Trang

**MEDIPLANTEX NATIONAL
PHARMACEUTICAL JSC**

THE SOCIALIST REPUBLIC OF VIETNAM
Independence – Freedom – Happiness



No.: 01/2026/TTr – HDQT

Hanoi, June 05, 2026

PROPOSAL

**Regarding the Approval of the Presidium
for the 2026 Annual General Meeting of Shareholders**

To: The General Meeting of Shareholders

Mediplantex National Pharmaceutical Joint Stock Company

To facilitate the administration, recording of meeting contents, and vote counting at the General Meeting of Shareholders, the Board of Directors of Mediplantex National Pharmaceutical Joint Stock Company respectfully proposes to the General Meeting for approval the list of the Presidium for the 2026 Annual General Meeting of Shareholders, as follows:

List of Presidium:

- | | |
|----------------------------|-------------|
| - Mr. Thai Khac Minh | Chairperson |
| - Mr. Tran Nguyen Hoang An | Member |
| - Mr. Mai Nhat Thanh | Member |

Respectfully proposes to the General Meeting of Shareholders for consideration and approval./.

Recipients:

- As above;
- BOD, BOS;
- Archived: Office, BOD Office.

**ON BEHALF OF THE BOARD OF DIRECTORS
CHAIRMAN**

Nguyen Ngoc Xuan Trang

**MEDIPLANTEX NATIONAL
PHARMACEUTICAL JSC**

SOCIALIST REPUBLIC OF VIETNAM
Independence – Freedom – Happiness

No.: 02/TTr-HĐQT

DRAFT



Hanoi, June 05, 2026

PROPOSAL

**Regarding the Approval of the Vote Counting Committee
for the 2026 Annual General Meeting of Shareholders**

**To: The General Meeting of Shareholders of Mediplantex National Pharmaceutical
Joint Stock Company**

In order to carry out the counting of voting ballots and election ballots at the General Meeting of Shareholders, the Board of Directors of Mediplantex National Pharmaceutical Joint Stock Company respectfully proposes to the General Meeting of Shareholders for approval the list of members of the Vote Counting Committee for the 2026 Annual General Meeting of Shareholders as follows:

List of Vote Counting Committee Members:

1. Ms. **Ha Thi Bich Hanh** – Head of the Committee
2. Ms. **Duong Thi Minh Nguyet** – Member

Respectfully proposes to the General Meeting of Shareholders for consideration and approval./.

Recipients:

- As stated above;
- BOD, BOS;
- Archived: Office, BOD Office.

**ON BEHALF OF THE BOARD OF DIRECTORS
CHAIRMAN**

Nguyen Ngoc Xuan Trang

Hanoi, June 5, 2026



**WORKING AND VOTING REGULATIONS
OF THE 2026 ANNUAL GENERAL MEETING OF SHAREHOLDERS
MEDIPLANTEX NATIONAL PHARMACEUTICAL JOINT STOCK COMPANY**

Pursuant to:

- *The Law on Enterprise No. 59/2020/QH14 was passed by the National Assembly of the Socialist Republic of Vietnam on June 17, 2020, amended and supplemented by Law No. 03/2022/QH15 passed by the National Assembly of the Socialist Republic of Vietnam on January 11, 2022, and its implementing guidelines;*
- *The Law on Securities No. 54/2019/QH14, passed by the National Assembly of the Socialist Republic of Vietnam on November 26, 2019, and its implementing guidelines; amended by Law No. 56/2024/QH15, passed by the National Assembly of the Socialist Republic of Vietnam on November 29, 2024, and its implementing guidelines.*
- *The Charter on Organization and Operation issued together with Resolution of the General Meeting of Shareholders No. 01/2024/NQ-GMS/MED dated June 26, 2024 of Mediplantex National Pharmaceutical Joint Stock Company;*
- *The Internal Regulations on Corporate Governance issued together with Resolution of the General Meeting of Shareholders No. 01/2024/NQ-GMS/MED dated June 26, 2024 of Mediplantex National Pharmaceutical Joint Stock Company.*

2026 Annual General Meeting of Shareholders of Mediplantex National Pharmaceutical Joint Stock Company ("MED", "the Company") was held and conducted in accordance with the following Working and Voting Regulations:

Article 1. Purpose

- To ensure that the procedures, principles of conduct, and voting at the Annual General Meeting of Shareholders of Mediplantex National Pharmaceutical Joint Stock Company are carried out in accordance with regulations and in a successful and orderly manner.
- To ensure that the resolutions of the General Meeting of Shareholders reflect the unified will of the General Meeting, safeguard the legitimate rights and interests of

shareholders, and comply with applicable laws.

Article 2. Scope of Regulation and Subjects of Applicable

- **Scope of Regulation:** These Regulations shall apply to the organization of the 2025 Annual General Meeting of Shareholders of Mediplantex National Pharmaceutical Joint Stock Company.
- **Subjects of Application:** All delegates and authorized representatives attending the MED Annual General Meeting of Shareholders must comply with the provisions set forth in these Regulations, the Company's Charter, and the prevailing laws and regulations.

Article 3. Definitions

In these Regulations, the following terms are understood as follows:

1. **Shareholders:** are individuals who own at least one share of Mediplantex National Pharmaceutical Joint Stock Company and whose names are on the list of shareholders entitled to attend the General Meeting of Shareholders on May 28 , 2026. Provided by the Vietnam Securities Depository and Clearing Corporation.
2. **The company or MED :** refers to Mediplantex National Pharmaceutical Joint Stock Company.
3. **Delegates are shareholders and/or their (valid) authorized representatives attending the 2026 Annual General Meeting of Shareholders of Mediplantex National Pharmaceutical Joint Stock Company.**
4. **Online General Meeting:** This is a form of organizing a shareholders' general meeting that uses electronic means to transmit images and sound via the internet, allowing shareholders in many different locations to attend the meeting, discuss, and vote on meeting issues.
5. **The online General Meeting venue** includes the main venue and other locations. The main venue is where the Presidium attends and presides over the meeting, while the other locations are where shareholders log into the EzGSM System using their access accounts provided by MED to participate in the online General Meeting.
6. **Electronic voting:** This refers to shareholders casting votes and elections through the EzGSM system as stipulated in these Regulations.
7. **Electronic means:** are means that operate based on electrical, electronic, digital, magnetic, wireless transmission, optical, electromagnetic or similar technologies.

8. **Online registration for the General Meeting** : This refers to shareholders using their login information to access the system and register to attend the General Meeting online as stipulated in these Regulations and MED 's guidelines .
9. **Login Information** : This includes the **Username** and **Password** provided by MED to each shareholder in the Meeting Invitation Notice. Shareholders are responsible for keeping their login information and other identifying factors (if any) secure to ensure that only they have the right to use the login information to attend and vote on the system.
10. **Electronic voting system or online General Meeting of Shareholders system**: is a system that supports the organization of the General Meeting of Shareholders, providing delegates with tools to exercise their related rights when attending the General Meeting of Shareholders (including online delegate registration, proxy attendance, online voting and election, etc.);
11. **System Opening Time** : This is the time when shareholders can access, register to attend the online General Meeting, and vote on the items to be voted on at the meeting. The system will close access upon notification from the Chairman or the Organizing Committee of the General Meeting.
12. **Cumulative voting** is a method of cumulative voting where Delegates concentrate their votes on one (01) candidate or divide the votes equally among the maximum number of candidates according to the number of Board of Directors/Supervisory Board members to be elected; After dividing equally, the corresponding number of votes for each candidate is rounded down to the nearest whole number. Any remaining odd votes (if any) will be discarded;
13. **The total number of representative voting ballots** is understood to be the number of ballots with voting rights, including the number of ballots owned by a Delegate and/or authorized by one or more other Delegates;
14. **Total number of votes for board members** This is understood as the total number of representative voting ballots multiplied by the number of elected Board of Directors members.

In these Regulations, the following terms shall have the meanings set out below:

1. “Shareholder” means a person owning at least one share of Mediplantex National Pharmaceutical Joint Stock Company and whose name appears on the list of shareholders entitled to attend the General Meeting of Shareholders, finalized as of May 28, 2026 and provided by the Vietnam Securities Depository and Clearing Corporation (VSDC).

2. "Company" or "MED" means Mediplantex National Pharmaceutical Joint Stock Company.
3. "Delegate" means a shareholder and/or the duly authorized representative of a shareholder attending the 2026 Annual General Meeting of Shareholders of Mediplantex National Pharmaceutical Joint Stock Company.
4. "Virtual General Meeting" means a form of General Meeting of Shareholders conducted through electronic means for the transmission of images and audio via the Internet, enabling shareholders located in different places to attend the Meeting, discuss matters, and exercise their voting rights.
5. "Venue of the Virtual General Meeting" includes the principal venue and other venues. The principal venue is the location where the Presidium attends and presides over the Meeting, while the other venues are locations where shareholders access the EzGSM System using the login credentials provided by MED in order to attend the Virtual General Meeting.
6. "Electronic Voting" means the exercise by shareholders of their voting rights and election rights through the EzGSM System in accordance with these Regulations.
7. "Electronic Means" means equipment, devices, or methods operating on electrical, electronic, digital, magnetic, wireless transmission, optical, electromagnetic, or similar technologies.
8. "Registration for Attendance at the Virtual General Meeting" means the use by a shareholder of the Login Credentials to access the system and register for attendance at the Virtual General Meeting in accordance with these Regulations and the instructions issued by MED.
9. "Login Credentials" include a Username and Password uniquely provided by MED to each shareholder in the Meeting Invitation Notice. Shareholders are responsible for maintaining the confidentiality of their Login Credentials and any other identification factors (if any) to ensure that only the shareholder is entitled to use such credentials to attend and vote through the system.
10. "Electronic Voting System" or "Online General Meeting System" means the system supporting the organization of the General Meeting of Shareholders and providing Delegates with tools to exercise their rights in connection with attendance at the General Meeting of Shareholders, including online registration, proxy appointment, electronic voting, and online election procedures.
11. "System Opening Time" means the time from which shareholders may access the system, register for attendance at the Virtual General Meeting, and vote on matters submitted for approval at the Meeting. Access to the system shall be closed in

accordance with the announcement of the Chairperson or the Organizing Committee of the Meeting.

12. "Equal Distribution of Cumulative Votes" means a method of cumulative voting whereby Delegates may allocate all of their votes to one (01) candidate or distribute their votes equally among a number of candidates not exceeding the number of members of the Board of Directors or the Supervisory Board to be elected. Following such distribution, the number of votes allocated to each candidate shall be rounded down to the nearest whole number. Any remaining fractional votes shall be disregarded.
13. "Total Number of Represented Voting Rights" means the total number of voting rights represented by a Delegate, including voting rights attached to shares owned by the Delegate and/or voting rights validly authorized by one or more other Delegates.
14. "Total Number of Votes for the Election of Members of the Board of Directors" means the Total Number of Represented Voting Rights multiplied by (x) the number of members of the Board of Directors to be elected.

Article 4. Conditions and procedures for conducting the General Meeting of Shareholders *(According to the Company's Charter)*

1. The General Meeting of Shareholders (GMS) shall be convened when the attending shareholders represent more than 50% of the total voting shares.
2. In the event that the required number of shareholders is not present within thirty (30) minutes from the scheduled opening time of the meeting, a second meeting invitation must be issued within thirty (30) days from the intended date of the first GMS. The reconvened GMS shall only be conducted if the attending shareholders and authorized representatives represent at least 33% of the total voting shares.
3. If the second meeting cannot be held due to the absence of the required number of attendees within thirty (30) minutes from the scheduled start, a third meeting invitation must be issued within twenty (20) days from the intended date of the second GMS. In this case, the GMS shall be convened regardless of the number of shareholders or authorized representatives in attendance and shall be deemed valid, with the authority to decide on all matters originally proposed for approval at the first GMS.
4. The system for organizing online meeting and electronic voting must meet the following conditions:
 - The system must be maintained to operate safely and stably, ready to meet the connectivity and participation requirements of shareholders.
 - The main venue must ensure adequate sound, lighting, internet connection, power

supply, electronic equipment, and other facilities as required by the nature of the online meeting.

- Ensure information security and maintain the confidentiality of access accounts to the System. All information received and provided on the System must adhere to information security principles and comply with the regulations of the Law on Cybersecurity.
- Electronic data from the online conference program must be recorded, stored, and used in accordance with regulations.

Article 5. Registration for Attendance at the Online General Meeting of Shareholders

1. Participants:

Shareholders of MED holding voting shares (according to the list of shareholders finalized on the record date of May 28, 2026) shall have the right to attend the General Meeting of Shareholders in person or authorize their representatives to attend on their behalf. Where a shareholder is an individual, he/she may authorize only one other individual to attend the Meeting on his/her behalf. Where a shareholder is an organization entitled under applicable laws to appoint more than one authorized representative to attend the Meeting, the number of shares and voting rights represented by each authorized representative must be clearly specified. An authorized representative who has been authorized to attend the Meeting may not further delegate such authority to a third party..

2. Technology requirements:

Delegates shall attend the Online General Meeting of Shareholders and conduct electronic voting through the website: med.ezgsm.fpts.com.vn. Delegates attending the Online General Meeting of Shareholders must have an electronic device with Internet access to ensure their ability to follow the proceedings of the Meeting and participate in electronic voting, including but not limited to computers, mobile phones, tablets, and other Internet-enabled electronic devices..

3. Method of Attendance:

- For shareholders:

Each shareholder listed in the register of shareholders entitled to attend the 2026 Annual General Meeting of Shareholders as of May 28, 2026 shall be provided with one (01) unique username and one (01) corresponding password for access to the General Meeting and participation in electronic voting.

Such username and password shall be provided to each shareholder together with the Notice of Invitation to the General Meeting of Shareholders. Upon receipt of the Notice containing information relating to the access account, shareholders shall be responsible for maintaining the confidentiality of such information to ensure that only the shareholder may access and vote through the Electronic Voting System.

The Company recommends that, upon receipt of the login credentials, including at minimum the username and password, shareholders promptly access the system and change their password in order to enhance account security.

A shareholder who registers to attend the Online General Meeting after the Meeting has officially commenced may still register and shall be entitled to vote and participate in elections upon completion of the registration process. The Chairperson shall not be required to suspend the Meeting, and the validity of any voting conducted prior to such registration shall remain unaffected.

- For authorized representatives of shareholders:

Shareholders and authorized representatives of organizational shareholders may attend the Meeting directly or authorize one or more individuals or organizations to attend the Online General Meeting and participate in electronic voting on their behalf.

Such authorization must be made in writing. The power of attorney shall be prepared in accordance with applicable civil laws and must clearly specify the name of the authorizing shareholder; the name of the authorized individual or organization; the number of shares represented; the scope and content of authorization; the term of authorization; and the signatures of both the authorizing party and the authorized party.

The individual or organization authorized to attend the General Meeting of Shareholders must submit the original valid power of attorney to the Company no later than 3:00 p.m. on June 23, 2026 so that the Company may provide login credentials for access to the Online General Meeting System.

Where the authorized representative is not a shareholder of MED, upon receipt of a duly executed authorization document from both the authorizing party and the authorized party, MED shall provide a username and password to the authorized representative, enabling him/her to exercise the rights and perform the obligations delegated under the authorization.

Mediplantex National Pharmaceutical Joint Stock Company shall provide login credentials to the authorized representative via email or by other means based on the registration information provided by the shareholder. The shareholder shall bear full

responsibility for the authorization information submitted to MED.

Where the authorized representative is also a shareholder of the Company, such representative shall use his/her own access account (as stated in the Company's Notice of Invitation) to attend the Meeting and exercise the voting rights authorized by the shareholder at the General Meeting of Shareholders.

- **Revocation of Authorization:**

A shareholder may revoke an authorization by submitting an official written notice of revocation to the Company prior to the official commencement of the Meeting.

The effective time of such revocation shall be determined based on the time at which the Company receives the written notice of revocation.

A revocation of authorization shall not be effective if the authorized representative has successfully completed online attendance registration through the Electronic Voting System in accordance with Article 6 of these Regulations or has already cast a vote on any matter included in the agenda of the General Meeting of Shareholders.

4. Reissuance of Login Credentials.

Where a shareholder requests the reissuance of login credentials, the Organizing Committee may require the shareholder to provide personal identification information, including at a minimum: For individual shareholders: Citizen Identification Card/Passport number, mobile phone number, email address, and permanent or temporary residential address (or correspondence address); For organizational shareholders: Enterprise Registration Certificate number, contact telephone number, and registered head office address. The Company may resend the username and password to the shareholder via email or by other means based on the registration information provided by the shareholder, enabling the shareholder to attend and vote at the Meeting..

Article 6. Method of recording the attendance of delegates at the online General Meeting of Shareholders

1. Delegates are considered to have attended the General Meeting online from the moment they successfully register to attend the meeting online through the Electronic Voting System, as per the Guidelines for Attending the 2026 Annual General Meeting of Shareholders posted on the Company's website.
2. Delegates are considered to have participated in the online Congress validly and fully when they do so in one of the following ways:
 - Attending the Online Congress: I have logged in and registered to attend the meeting

on the online congress system via the following link : med.ezgsm.fpts.com.vn , using the username and password provided by the Company during the General Meeting until the end of the voting period.

- In the event that a delegate has logged in and registered to attend but does not vote by the time of voting, the shareholder will still be considered to have attended the General Meeting and will be deemed to have not voted, in accordance with the procedures, content of the meeting, voting results, and meeting minutes.

Article 7. Rights and obligations of delegates when attending the online General Meeting of Shareholders

1. Attend the General Meeting online and vote on all matters of the General Meeting as stipulated in the Charter of Organization and Operation of Mediplantex National Pharmaceutical Joint Stock Company, this Regulation, and the guidelines on the company's website.
2. Have the right to express their opinions and participate in discussions at the Congress as stipulated in Article 12 of these Regulations.
3. Comply with the instructions of the Presidium and refrain from causing disruption or disorder during the Congress.
4. Delegates must prepare and use appropriate online meeting equipment with an internet connection to ensure they can follow the proceedings of the online Congress.
5. All electronic voting results of delegates are considered to reflect the will of the delegates. Voting results obtained electronically have the same legal validity as voting at a face-to-face congress.
6. Delegates may use the login information provided by MED to access, participate in, and electronically vote on all voting and election matters of the Congress. Delegates are responsible and have no right to complain if they leave the system for any reason or allow others to use their login information to access the system during the Congress, from the time the system opens for registration, discussion, and voting until it closes.
7. Delegates are responsible for keeping their login information secure to ensure that only shareholders have the right to attend and vote electronically on the system. The company will provide maximum support in ensuring delegates can attend and vote at the General Meeting of Shareholders, but will not be responsible for any issues arising from shareholders losing their login information. In the case of proxy attendance, both the shareholder and the authorized person are responsible for the authorization and the results of electronic voting based on the provided login information.

8. In cases where delegates, after registering to attend the online General Meeting, are unable to participate continuously until the end of the program, they may vote on matters requiring shareholder approval before logging out of the system.

Article 8. Presidium

1. The Presidium consists of one Chairman and two members. The Chairman of the Board of Directors or a member of the Board of Directors authorized by the Chairman of the Board of Directors shall be the Chairman of the Presidium and the Chairperson of the 2026 Annual General Meeting of Shareholders of MED. The remaining members shall be nominated by the Chairperson and approved by the General Meeting of Shareholders
2. In case the Chairperson is absent or temporarily unable to perform duties, the remaining members shall elect one among themselves to act as the Chairperson of the meeting according to the majority rule. In the event that no Chairperson is elected, the Head of the Board of Supervisors shall preside over the process for the General Meeting of Shareholders to elect a Chairperson of the meeting, and the person who receives the highest number of votes shall act as the Chairperson of the meeting
3. Duties of the Presidium:
 - a. To preside over the activities of the General Meeting of Shareholders in accordance with the Agenda proposed by the Board of Directors and approved by the General Meeting;
 - b. To guide the Delegates and the Meeting in discussing the matters included in the agenda;
 - c. To present draft resolutions and provide conclusions on necessary issues for the General Meeting to vote on;
 - d. To respond to matters requested by the General Meeting;
 - e. To address any issues arising during the course of the Meeting.
3. Principles of operation of the Presidium: The Presidium shall operate on the principles of collectivity, democratic centralism, and decision-making by majority vote.

Article 9. Secretariat of the General Meeting

1. The Secretariat of the General Meeting consists of 2 members nominated by the Chairman (through the General Meeting Organizing Committee); they are responsible to the Presidium and the General Meeting of Shareholders for their duties and operate under the direction of the Presidium.

2. The Secretariat's responsibilities:

- a. Assist the Presidium in verifying the credentials of delegates attending the meeting (when necessary);
- b. Assist the Presidium in announcing draft documents, conclusions, and resolutions of the Congress, and send notifications from the Presidium to delegates when requested;
- c. Compile the opinions of shareholders during the online General Meeting and submit them to the Presidium;
- d. Record fully and truthfully the entire content and proceedings of the Congress, as well as the issues that were approved or are still being considered, in the Congress Minutes;
- e. Prepare meeting minutes and draft resolutions on issues adopted at the Congress;
- f. Assist the Chairperson in announcing information related to the General Meeting of Shareholders and notifying the Shareholders' Delegates in accordance with legal regulations and the Company's Articles of Association.

Article 10. Delegate Eligibility Verification Committee

1. The Delegate Eligibility Verification Committee of the General Meeting shall consist of two (02) members, including one (01) Head of the Committee and one (01) member. The Committee shall be established by the Board of Directors and introduced to the General Meeting by the Presidium. The Delegate Eligibility Verification Committee shall be accountable to the Presidium and the General Meeting of Shareholders for the performance of its duties.
2. Duties of the Delegate Eligibility Verification Committee:
 - a. To examine and verify the eligibility of Delegates registering to attend the Online General Meeting in accordance with applicable laws, the Company's Charter on Organization and Operation, and these Regulations.
 - b. To report to the Online General Meeting on the percentage of attending Delegates. The Delegate Eligibility Verification Committee shall rely on the login information associated with the Delegates' access accounts as the basis for determining attendance at the Online General Meeting.
 - c. If the Meeting is attended by Delegates representing more than fifty percent (50%) of the total voting shares, the General Meeting of Shareholders of MED shall be duly convened and entitled to proceed.

Article 11. Vote Counting Committee

1. The Vote Counting Committee of the General Meeting shall consist of 02 members, including 01 Head and 01 members, who are nominated by the Chairperson (through the Meeting Organizing Committee) and approved by the General Meeting.
2. Duties of the Vote Counting Committee:
 - a. Disseminate the principles, regulations, and guidelines on the voting procedures;
 - b. Verify and record voting cards, prepare vote counting minutes, announce results; submit the minutes to the Chairperson for approval of voting and election results;
 - c. Promptly notify the Meeting Secretary of the voting results;
 - d. Review and report to the General Meeting any violations of voting regulations or complaints regarding the voting results;
 - e. Prepare the vote counting minutes and be accountable to the Presidium and the General Meeting of Shareholders in the performance of their duties.

Article 12. Discussion at the General Meeting

1. Principle:
 - a. Discussions will only be conducted within the stipulated time and will be limited to the issues presented in the agenda of the Shareholders' General Meeting;
 - b. Shareholders conduct discussions as instructed by the Chairperson during the online General Meeting;
 - c. Shareholders can participate in discussions at the online General Meeting by submitting their opinions through the direct connection methods guided by the company on the company website. The Secretariat is responsible for compiling the shareholders' opinions and sending them to the Presiding Board, while also recording the shareholder's name, shareholder code (if any), and the content of the question;
2. Responding to the delegates' questions:
 - a. Based on the discussion comments submitted by the delegates, the Chairperson or a member designated by the Chairperson will address the delegates' comments.
 - b. In case of time constraints, questions that were not answered directly at the General Meeting will be answered by the company to shareholders through appropriate means.

Article 13. Voting on Matters Submitted to the General Meeting

1. Voting period

- a. Shareholders may cast their votes from the time the voting function becomes active

on the System (at least one (01) day prior to the official opening of the General Meeting) until the voting period is declared closed by the Chairperson of the Meeting. Where a shareholder has already cast a vote but wishes to change his/her voting decision, such change must be made before the voting period closes. The last voting instruction recorded by the System before the closing of the voting period shall be deemed valid and shall be included in the vote-counting results.

- b. Prior to the closing of the voting period, shareholders may only view their own voting results. Upon the closing of the voting period, the overall voting results for each agenda item shall be announced by the Presidium or the Vote Counting Committee.

2. Voting method

- a. Shareholders shall use the Login Information provided by the Company in the Notice of Invitation to access the System at <https://med.ezgsm.fpts.com.vn> in accordance with the instructions published on the Company's website at <https://www.mediplantex.com> and cast their votes electronically
- b. For each matter submitted for approval, a Delegate shall select one (01) of the following voting options: “**Approve**”, “**Disapprove**”, or “**Abstain**”, and then click the “**Vote**” button to save and submit the voting result to the System. Before the voting period closes, a Delegate may change his/her voting decision by selecting another voting option and clicking the “**Change Vote**” button to confirm the final voting instruction. If a Delegate fails to click the confirmation button to submit the vote through the Electronic Voting System before the voting period closes, such voting card shall be deemed not returned in respect of the relevant agenda item. Where a Delegate does not select any voting option, such Delegate shall be deemed to have declined to exercise his/her voting right and not to have participated in voting on that matter. The corresponding voting rights shall not be included in the total number of votes participating in the voting for that matter.
- c. Depending on the proceedings and agenda of the General Meeting, voting on matters submitted to the General Meeting may be conducted in multiple voting rounds. Shareholders attending the Online General Meeting shall comply with the voting period applicable to each voting round as announced by the Chairperson and notified through the Electronic Voting System. Shareholders shall cast votes on all matters included in the same voting round.

- d. An invalid voting card is a voting card containing one or more agenda items on which no voting opinion has been indicated by the Delegate. The Electronic Voting System shall issue a warning in the event of an invalid voting card. Shareholders shall be responsible for correcting and resubmitting a valid voting card. Invalid voting cards shall not be recorded by the System, and the relevant shareholder shall be deemed present but not to have voted on the relevant matter (i.e., a non-returned vote).
- e. A Delegate may change his/her voting result multiple times but may not revoke a vote once cast. The Electronic Voting System shall only recognize the final voting instruction recorded at the time the voting period closes for each voting round as determined by the Chairperson. The voting results for each agenda item shall be reported to the General Meeting by the Vote Counting Committee immediately after completion of the vote-counting process.
- f. During the conduct of the General Meeting, the Chairperson shall announce the closing time of voting on the System so that shareholders may exercise their rights accordingly. Where a shareholder encounters technical difficulties in casting votes through the System, such shareholder may contact the hotline announced by the Organizing Committee for guidance and assistance. Upon closure of voting for a particular matter on the System, shareholders shall no longer be entitled to cast votes or modify any voting instruction relating to that matter. The voting results recorded by the System based on the shareholder's Login Credentials shall be deemed final and conclusive, and no complaint, dispute, or legal action relating thereto shall be accepted.

3. Voting rules:

- a. Each share owned or represented shall carry one (01) vote.
- b. Pursuant to Clause 1, Article 21 of the Company's Charter, resolutions on the following matters shall be approved if they receive affirmative votes representing at least sixty-five percent (65%) of the total voting rights of all shareholders attending and voting at the General Meeting:
 - Amendments and supplements to the Company's Charter;
 - Types of shares and the total number of shares to be offered for sale;
 - Merger, reorganization, or dissolution of the Company;
 - Investments or transactions involving the sale of assets with a value equal to or exceeding thirty-five percent (35%) of the total assets recorded in the Company's most recently audited financial statements;

- Changes to the Company's business lines, industries, or business sectors.
- c. Except for the matters specified above, all other resolutions shall be approved if they receive affirmative votes representing more than fifty percent (50%) of the total voting rights of all shareholders attending and voting at the General Meeting, except in cases otherwise provided for in Clause 1, Article 21 of the Company's Charter and Clauses 3, 4, and 6 of Article 148 of the Law on Enterprises.

4. Vote Counting Method and Voting Results

- a. The vote counting committee, approved by the General Meeting of Shareholders, is responsible for verifying the results of the electronic voting to compile the final voting results.
- b. The electronic voting system records the number of ballots issued, the number of ballots received, the number of ballots not received, and the percentage of the total votes cast by all shareholders attending and voting at the meeting.
- c. All ballots received and recorded by the electronic voting system are valid.
- d. Each delegate's vote is recorded by the system as follows: the number of votes in favor, the number of votes against, and the number of abstentions.
- e. The voting results are announced by the Presidium or the Vote Counting Committee immediately at the online Congress.

Article 15. Election of additional members to the Board of Directors

1. Election method:

The voting for the election of additional members to the Board of Directors for the 2024-2029 term will be conducted using the cumulative voting method. Accordingly:

- Each delegate has a total number of votes corresponding to the total number of shares they represent multiplied by the number of additional members elected to the Board of Directors for the 2024-2029 term.
- Delegates may allocate all or part of their total votes to one or more individuals, but not exceeding the number of members approved by the General Meeting of Shareholders.
- The elected members of the Board of Directors are determined by the number of votes received, from highest to lowest, starting with the candidate with the highest number of votes until the required number of members is elected. If two or more candidates receive the same number of votes, a re-election will be held among those candidates, or a selection will be made based on other criteria approved by the General Meeting of Shareholders.

2. Election Ballot:

Each ballot for the election of members of the Board of Directors may be used to elect up to the maximum number of Board members to be elected, as approved by the General Meeting of Shareholders.

Each ballot for electing board members has two columns: "Cumulative voting" and "Number of votes". Shareholders should cast their votes according to the following instructions:

Case 1: If the Delegate casts all their votes for one person (01) candidate

Delegates should check the box in the "Allocate votes equally" column for the respective selected candidates.

Case 2: If the delegate does not vote for any candidate.

Delegates should leave the "Equally Selected" and "Number of Votes" columns blank, **and NOT** mark any symbols for all candidates.

3. Online Election Procedure:

The election voting period shall commence when the Electronic Voting System is activated and shall continue until the Chairperson of the General Meeting or the Vote Counting Committee announces the close of the election voting period. Delegates who exercise their voting rights from the time the Electronic Voting System is activated shall be counted as attending the Online General Meeting of Shareholders.

After completing the election ballot, the Delegate shall click the "Vote" button to save and submit the election results to the System. Delegates may amend their election votes at any time before the close of the election voting period as directed by the Chairperson; however, they may not withdraw their election votes. The election results recorded by the System at the close of the voting period shall be deemed the final and valid election results of the Delegate. Upon the expiration of the election voting period, the System shall no longer accept or record any additional electronic election votes submitted by Delegates.

4. Validity of ballots

For invalid ballots, the electronic voting system will send a warning to delegates attending the online General Meeting of Shareholders and those who cast their votes electronically. Delegates are responsible for correcting their ballots to make them valid. The system will not record invalid ballots, and delegates will be considered as not having participated in the election through the electronic voting system.

Article 16. Minutes of Meeting, Resolutions of the General Meeting of Shareholders

The minutes and resolutions of the General Meeting of Shareholders must be read and approved before the closing of the meeting.

Article 17. Implementation of the Regulations

Delegates and guests attending the General Meeting must strictly comply with these Working and Voting Regulations, the company's current regulations, internal rules, and governance regulations, and relevant legal provisions. Delegates who violate these Rules will be subject to disciplinary action by the Presidium, depending on the severity of the violation, in accordance with the Company Charter and the Law on Enterprises.

These regulations consist of 17 articles and will take effect immediately after being approved by the Company's 2026 Annual General Meeting of Shareholders.

**OB. BOARD OF DIRECTORS
CHAIRMAN**

Nguyen Ngoc Xuan Trang

CÔNG TY CỔ PHẦN DƯỢC TRUNG ƯƠNG MEDIPLANTEX

Địa chỉ: 358 Đường Giải Phóng - Phường Phương Liệt - Hà Nội

Website: <http://www.mediplantex.com>



No. 01/2026/BC-MED

Hanoi, June 05, 2026

REPORT OF THE BOARD OF DIRECTORS ON THE 2025 PERFORMANCE AND THE PROPOSED OPERATIONAL PLAN FOR 2026

DRAFT

**To: The General Meeting of Shareholders
of Mediplantex National Pharmaceutical Joint Stock Company**

- Pursuant to the Law on Enterprises No. 59/2020/QH14 dated June 17, 2020, as amended by Law No. 03/2022/QH15 passed by the National Assembly of the Socialist Republic of Vietnam on January 11, 2022;
- Pursuant to the Charter on Organization and Operation of Mediplantex National Pharmaceutical Joint Stock Company;

The Board of Directors for the 2024–2029 term of Mediplantex National Pharmaceutical Joint Stock Company respectfully submits to the Annual General Meeting of Shareholders the Report of the Board of Directors on our performance in 2025 and the proposed operational plan for 2026 with the following main contents:

I. 2025 PERFORMANCE RESULTS

1. Board of Directors Personnel Structure

No.	Member	Position	Date of Commencement/Termination as BOD Member/Independent BOD Member	
			Date of appointment	Date of dismissal
1	Nguyen Ngoc Xuan Trang	BOD Chairman	30/06/2025	
2	Tran Nguyen Hoang Phuc	BOD Member	30/06/2025	
3	Tran Nguyen Hoang An	BOD Member	26/06/2024	
4	Nguyen Thi Thuy	BOD Member	26/06/2024	
5	Thai Khac Minh	BOD Independent member	26/06/2024	
6	Tran Hoang Dung	BOD Chairman		Deceased on 30/06/2025
7	Tran Xuan Dinh	BOD Member		30/06/2025

The composition of the BOD ensures a balanced structure among executive members, non-executive members, and independent members in accordance with the Company's Charter and the Internal Corporate Governance Regulations.

2. Resolutions/Decisions of the Board of Directors

In 2025, the Board of Directors held four (04) meetings in accordance with applicable laws and the Company's Charter to review, discuss, and decide on matters within its authority. On this basis, the Board of Directors issued thirteen (13) resolutions to implement governance, management, and operational direction for the Company.

The meetings of the Board of Directors were conducted in full compliance with the prescribed procedures and formalities. All members of the Board of Directors attended the meetings and actively contributed their opinions on the matters under consideration and decision-making. The Board of Supervisors attended the meetings in accordance with its statutory functions to perform supervisory duties and coordinate in corporate governance activities.

3. Activities of the Board of Directors

In 2025, the Board of Directors conducted periodic meetings and adopted written resolutions in accordance with the Law on Enterprises, the Company's Charter, and relevant legal regulations. The matters discussed at these meetings focused on issues within the authority of the Board of Directors, including corporate governance, business and production orientation, organizational restructuring, risk control, and other key matters of the Company. All members of the Board of Directors fully attended the meetings, and the Board of Directors issued timely directives, thereby contributing to the effective implementation of the targets set out in the resolutions of the General Meeting of Shareholders.

The Board of Directors regularly supervised the activities of the Board of Management in implementing business and production plans, financial management, investment activities, human resource management, and compliance with information disclosure obligations applicable to a public listed company.

Key matters reviewed, decided, and supervised by the Board of Directors during the year include:

- Issuance of a resolution appointing Mr. Mai Nhat Thanh as General Director, effective from January 2, 2025, in accordance with its authority and applicable legal regulations.
- Assignment of duties among members of the Board of Directors and election of Ms. Nguyen Ngoc Xuan Trang as Chairwoman of the Board of Directors, effective from June 30, 2025, in accordance with the Company's Charter and relevant legal regulations. Review and approval of amendments and supplements to the internal spending regulations to strengthen corporate governance, enhance management, supervision, and control of executive activities, thereby minimizing risks in production and business operations.

- Supervision of the Board of Management in implementing solutions to improve capital efficiency, cost management, receivables control, financial safety, and overall business performance, as well as operational and professional activities, in order to minimize professional errors in the Company's operations.

- Direction and supervision of the implementation of full, transparent, and timely information disclosure in accordance with securities laws and regulations of the Hanoi Stock Exchange.

4. Supervision Results of the Board of Directors over the General Director

In 2025, the Board of Directors exercised its supervisory function over the General Director and the Board of Management through periodic reports, specialized reports, Board meetings, and internal control mechanisms in accordance with applicable laws, the Company's Charter, and the Internal Governance Regulations. The Board of Directors promptly addressed issues arising within its authority.

The Board of Directors regularly reviewed and assessed the implementation of resolutions of the General Meeting of Shareholders and the Board of Directors, as well as the Company's business performance, financial position, investment activities, risk management, human resource management, and other governance and operational matters under the responsibility of the Board of Management. It also timely considered and decided on matters within its authority to ensure that the Company's operations were conducted in a stable, efficient manner and aligned with the approved development orientation.

Based on the supervisory results, the Board of Directors assessed that the General Director and the Board of Management fulfilled their assigned duties and responsibilities in accordance with applicable laws, the Company's Charter, resolutions of the General Meeting of Shareholders, and resolutions and decisions of the Board of Directors, as follows:

- The Board of Management fully complied with periodic and ad hoc reporting requirements as requested by the Board of Directors and the Chairman of the Board of Directors; and promptly provided information and proposed solutions for arising issues during operations for the Board of Directors' consideration and decision-making within its authority.

- Successfully organized the 2025 Annual General Meeting of Shareholders on June 30, 2025 in accordance with applicable laws, the Company's Charter, and relevant regulations.

- Effectively implemented key tasks and solutions in 2025 under the direction of the Board of Directors:

- + The Board of Management demonstrated proactive and flexible operational management, issuing decisions within the authority of the General Director to

enhance governance efficiency and control of production and business activities. In 2025, revenue reached VND 366.8 billion, exceeding the annual plan by 22%, while profit before tax reached VND 20.6 billion, exceeding the plan by 60% and increasing by 6% compared to 2024.

- + Strengthened receivables management and debt collection, particularly overdue receivables. Cash flow management was improved to optimize financial costs and reduce bank interest expenses.
- + Strengthened control over production costs and administrative expenses. Investment and procurement activities were carried out in strict compliance with the Company's internal regulations and applicable laws.
- + Invested in an additional HPLC system to enhance testing capacity and product research and development, serving quality control of raw materials, semi-finished products, and finished products, while meeting research, validation, and quality management standards under current GMP requirements.
- + Strictly complied with reporting obligations and ensured complete, transparent, and timely information disclosure in accordance with regulations of the Stock Exchange and the State Securities Commission of Vietnam.

Based on the results achieved in 2025, the Board of Directors acknowledges the efforts of the General Director and the Board of Management in maintaining stable production and business operations, achieving and exceeding key performance targets, and ensuring compliance with applicable laws and the Company's internal regulations.

5. Evaluation Results from the Independent Member on the Activities of the Board of Directors

As of December 31, 2025, the Company's Board of Directors has one (01) independent member.

- In 2025, the independent member of the Board of Directors participated in 100% of in-person meetings and written resolutions of the Board of Directors, and provided opinions, feedback, and recommendations on matters within the Board's authority for consideration and decision-making. Based on monitoring and participation in the Board's activities during 2025, the independent member provides the following assessment:

- Meetings of the Board of Directors were convened, organized, and conducted in full compliance with the procedures prescribed under the Law on Enterprises, the Company's Charter, and the Internal Regulations on Corporate Governance. Meeting materials were properly prepared and provided to members of the Board of Directors in accordance with regulations to support review, discussion, and voting.

- The Board of Directors has exercised its rights and fulfilled its duties in accordance Report of BOD on its performance in 2025 and the proposed operational plan for 2026

with applicable laws and the Company's Charter. Resolutions and decisions of the Board of Directors were made based on submitted dossiers and documents, discussion outcomes, and assessments of relevant factors affecting the Company's operations.

- Strategic directions, development orientations, business plans, and key policies were considered and approved by the Board of Directors in alignment with resolutions of the General Meeting of Shareholders, the Company's actual operational situation, and corporate governance requirements.

- The Board of Directors exercised its supervisory function over the General Director and the Board of Management through reporting, inspection, and periodic evaluation mechanisms; and paid attention to risk management, internal control, and legal compliance in the Company's operations. The Board of Directors has completed its assigned duties with a high level of responsibility and professionalism, in full compliance with applicable laws, the Company's Charter, and ethical standards in business conduct.

Based on the above, the independent member of the Board of Directors assesses that the Board of Directors has fully performed its functions, duties, and authority in accordance with regulations, and has effectively maintained governance, supervision, and strategic direction for the Company in 2025.

6. Remuneration and Salary Payment for the Board of Directors

The salary and remuneration for the Board of Directors were paid in accordance with the resolution of the 2025 Annual General Meeting of Shareholders *(The figures are reflected in the audited 2025 financial statements)*.

7. Transactions with Related Parties

No.	Name	Related Party Relationship	NSH No. / Issue Date / Place of Issue	Head Office Address	Transaction Time
1	An Hy Pharmaceutical Company Limited	Related Party of Ms. Nguyen Ngoc Xuan Trang – Chairman of the Board of Directors	Enterprise Registration Certificate No. 0309738339, issued on May 22, 2017 by the Department of Planning and Investment of Ho Chi Minh City	No. 506/15/34, 3/2 Street, Ward 14, District 10, Ho Chi Minh City	2025

II. ORIENTATION AND OPERATION PLAN FOR 2026

1. The Board of Directors will continue to maintain quarterly periodic meetings in accordance with regulations, and extraordinary meetings when necessary in compliance with applicable laws, the Company's Charter, and the Internal Regulations on Corporate Governance. The Board will also adopt written resolutions on matters within its authority

in order to implement the resolutions of the 2026 Annual General Meeting of Shareholders and perform the Company's governance responsibilities.

2. To continue improving corporate governance quality toward greater transparency, efficiency, and alignment with advanced governance practices; to strengthen supervision over the implementation of production and business targets, financial management, risk management, receivables management, capital utilization, and investment efficiency, thereby ensuring financial safety and sustainable development of the Company.
3. To provide orientation and supervision to the Board of Management in implementing solutions to strengthen production capacity and improve operational efficiency of manufacturing plants; to focus on developing strategic products, enhancing competitiveness, and optimizing the utilization of production resources.
4. To review and decide on investment policies, research and development activities, and product registration within its authority; to facilitate the Board of Management in promoting R&D activities, expanding the product portfolio, improving production capacity, and enhancing the Company's market competitiveness. Priority shall be given to high value-added products with strong research content and sustainable growth potential, while also reviewing and restructuring the product portfolio in line with the Company's development strategy and market trends.
5. To continue promoting digital transformation in corporate governance and business operations; to strengthen the application of information technology in management, internal control, and operational activities; and to gradually explore the adoption of artificial intelligence (AI) solutions appropriate to actual conditions in order to improve governance efficiency and productivity. Based on the assessment of the Company's 2025 performance, existing production capacity, development orientation, and market factors, the Board of Directors hereby submits the 2026 business plan to the General Meeting of Shareholders for consideration and approval as follows:

No	Indicator	Actual 2025	Plan 2026	2026 Plan / 2025 Actual (%)
1	Total Revenue	366,830	412,071	112%
2	Cost of Goods Sold	281,043	321,273	114%
3	Gross Profit	85,787	90,797	106%
4	Selling Expenses	4,734	4,949	105%
5	Administrative Expenses	58,627	62,822	107%
6	Profit Before Tax	20,659	15,005	73%

The 2026 profit plan has been prepared on a prudent basis, reflecting the Company's strategic direction to increase investment in research and development activities, new product registration, expansion of production capacity, digital transformation, and taking into account volatility factors in the pharmaceutical market. The Board of Directors will regularly monitor actual developments in order to implement appropriate management solutions to strive for the completion and potential overachievement of the targets approved by the General Meeting of Shareholders.

The above is the report of the Board of Directors on the assessment of the Board's performance in 2025 and the operational direction for 2026. The Board of Directors acknowledges and highly appreciates the efforts of the Board of Management and all employees in maintaining stable business operations in 2025. The achieved results serve as an important foundation for the Company to further strengthen its internal capacity, enhance governance capability, and move toward stable and sustainable development in the next stage.

On behalf of the Board of Directors, I would like to extend my sincere appreciation to the Board of Management and all employees for their continuous efforts and contributions to the development and success of Mediplantex.

Sincere thanks are also extended to our shareholders, investors, customers, and partners for their continued trust and support in Mediplantex's journey toward stable, sustainable, and efficient development.

Sincerely!

Recipients:

- BOD
- BOM
- Shareholders
- State Securities Commission
- Archived: Company Secretary

**OB. THE BOARD OF DIRECTORS
CHAIRMAN**

Nguyen Ngoc Xuan Trang



CÔNG TY CỔ PHẦN DƯỢC TRUNG ƯƠNG MEDIPLANTEX

Địa chỉ: 358 Đường Giải Phóng - Phường Phương Liệt - Hà Nội

Website: <http://www.mediplantex.com>

No. 02/2026/BC-MED

Hanoi, June 05, 2026

REPORT OF THE BOARD OF MANAGEMENT ON THE 2025 BUSINESS AND PRODUCTION RESULTS AND THE IMPLEMENTATION PLAN FOR 2026

To: The General Meeting of Shareholders
of Mediplantex National Pharmaceutical Joint Stock Company

I. BUSINESS PERFORMANCE RESULTS IN 2025:

1. Advantages Factors during the Year:

- Mediplantex is a reputable brand with high-quality products that are trusted by its partners.
- The Board of Directors provides close and consistent guidance, always setting strategic directions and creating favorable conditions for the Board of Management to operate in close alignment with approved policies and orientations. The leadership team demonstrates vision and innovation.
- The quality management system is maintained and operated effectively, with strict control from input materials to final product release, ensuring stable product quality and full compliance with legal regulations.
- The workforce is experienced and continuously improves the management system and production organization. This is a key factor enabling the Company to maintain stable operations and enhance operational efficiency.
- The strengthening of regulatory enforcement by state authorities in handling substandard products, counterfeit goods, and goods of unclear origin has contributed to a more transparent competitive environment, creating favorable conditions for compliant enterprises such as Mediplantex.
- The Company continues to receive consensus, support, and partnership from its shareholders in the implementation of its production and business activities.

2. Challenges in Implementing the Business and Production Plan:

- The domestic and international economic environment remained volatile, affecting production costs and the Company's operations. The prices of certain raw materials, particularly imported inputs, showed an increasing trend and longer supply lead times, creating pressure on production planning and cost control.

- Regulatory requirements in the pharmaceutical sector have become increasingly stringent. Requirements for product registration dossiers, maintenance of marketing authorizations, and product disclosure have become more demanding, while post-licensing inspections and regulatory audits have been strengthened. As a result, dossier evaluation and approval timelines have become longer than before.
- The workforce structure at manufacturing plants and intermediary departments remains relatively cumbersome and has not yet been streamlined. A large number of employees engaged in production has led to high personnel management costs. In the context of economic challenges, optimizing labor resources remains a significant challenge in balancing operational efficiency and cost control.

3. Business Results for 2025:

(Unit: Million VND)

No.	Indicators	Actual 2024	Plan 2025	Actual 2025	2025 Actual / 2024 Actual	% of 2025 Plan
A	Total Sales Revenue	443,136	299,907	366,830	83%	122%
1	Revenue from Sales	439,711	296,207	362,886	83%	123%
1.1	Sales Revenue – Business Division	364,909	284,925	300,696	82%	106%
1.2	Export Sales Revenue	72,601	11,282	60,410	83%	535%
1.3	Raw Material Sales Revenue	562		1,780	317%	
1.4	Sales Revenue – HCMC Branch	1,638		0		
2	Service Revenue	3,425	3,700	3,944	115%	107%
2.1	Entrusted Services	687	700	570	83%	81%
2.2	Leasing Services	2,738	3,000	3,374	123%	112%
B	Cost of Goods Sold	350,574	223,095	281,043	80%	126%
C	Gross Profit	92,561	76,812	85,787	93%	112%
4	Financial Income	2,194		1,371	62%	
5	Financial Expenses	5,882	3,850	3,675	62%	95%
6	Selling Expenses	7,956	5,009	4,734	60%	95%
7	Administrative Expenses	62,411	55,049	58,627	94%	106%
D	Operating Profit	18,506	12,904	20,122	109%	156%
8	Other Income	1,194		622	52%	
9	Other Expenses	282		85	30%	
E	Profit Before Tax	19,418	12,904	20,659	106%	160%

- Although revenue decreased by 17% compared to 2024, profit before tax reached VND 20.7 billion, increasing by 6% year-on-year, thanks to the Company's synchronized implementation of solutions to improve operational efficiency, focusing on cost of goods sold control, reduction of financial and selling expenses, optimization of the management structure, and enhancement of revenue structure efficiency. These efforts helped offset the impact of declining revenue and maintain overall business performance.
- In addition, in 2025, state regulatory authorities strengthened inspections and examinations in the pharmaceutical manufacturing and trading sector, particularly for functional foods, including periodic GMP re-evaluation inspections. The Company received a total of five (05) inspection and audit teams from competent authorities. As a result, the production of certain product lines was delayed or could not be supplied to customers on schedule. Furthermore, some customers also reduced order volumes compared to the initial annual plan. By the end of 2025, production and sales activities with key customers had stabilized again, resulting in improved business performance compared to the approved plan.
- Although administrative expenses decreased compared to 2024 actual levels, the Company did not fully achieve its planned cost reduction targets for administrative expenses.

4. Performance Indicators Achieved:

4.1. Human Resource Management

- In 2025, the Company streamlined approximately 10% of indirect and administrative workforce, while simultaneously recruiting additional specialized personnel for Research & Development (R&D), Quality Control (QC), and production departments to meet product development requirements and maintain GMP compliance.
- Following the organizational restructuring, average labor productivity increased by 5–7% compared to the same period in 2024. The current workforce is more specialized, with younger staff being trained and exposed to new technologies.
- In addition, the Company has continuously focused on employee training, sending staff to various training programs organized by the Ministry of Health to update regulations on drug registration, pharmaceuticals, and quality management. In the coming period, the Company plans to implement leadership and management skills training programs for key personnel.

4.2. Financial Management

- Effectively managed receivables, monitored overdue debts, and actively worked with customers to accelerate debt collection.
- Maintained a safe liquidity position, ensuring balanced cash flows to support regular production and business activities as well as investment needs.
- Strengthened the roles and responsibilities of internal control functions across the Company.

- Enhanced foreign exchange risk management to stabilize import input costs and improve financial planning flexibility.
- Reviewed inventory structure and optimized inventory turnover to reduce risks related to quality deterioration of raw materials and finished goods.

4.3. Product Quality Management

- Continued to effectively maintain the quality management system in compliance with GMP-WHO standards, ISO standards, and relevant legal regulations.
- Invested in an additional HPLC system to enhance testing capacity and product research and development, serving quality control of raw materials, semi-finished products, and finished products, while meeting requirements for research, validation, and quality management under current GMP regulations.

4.4. Production and Product Research & Development

- Total production output of the two factories in 2025 reached approximately 527 million product units, exceeding the 2025 production plan by 2.6%.
- Production activities were carried out stably, ensuring compliance with GMP requirements, occupational safety, and quality control throughout the entire production process. No occupational accidents or serious incidents affecting the Company's operations occurred during the year.
- The factories strengthened production process control, optimized equipment operations, reviewed raw material consumption norms, and reduced production costs to improve operational efficiency amid competitive pressure and fluctuating input costs.
- R&D activities remained stable. The Company promptly appointed the former Deputy Head of the R&D Department as Head of R&D following the resignation of the previous Head. The Board of Management focused on directing improvements in formulations, production processes, and quality standards for various existing products to enhance quality, optimize costs, and ensure compliance with approved registration dossiers.
- Many products were improved in line with approved drug registration dossiers, meeting updated regulatory requirements and contributing to risk reduction during production and commercialization, while strengthening GMP compliance.

Stt	Indicator	Unit	2024	2025
1	Newly granted marketing authorizations (registration numbers)	Products	23	24
2	Renewed marketing authorizations	Products	157	12
3	Approved variations, amendments, and updates	Products	192 (including 14	203 (including 32 active pharmaceutical

Stt	Indicator	Unit	2024	2025
			manufacturing site supplement dossiers)	ingredient/manufacturing site supplement dossiers)
4	Newly implemented products	Products	18	11
5	Products with formulation and manufacturing process improvements implemented	Products	5	14

II. BUSINESS OPERATION ORIENTATION FOR 2026

1. Challenges and Difficulties in Implementing the 2026 Plan

The year 2026 is forecast to remain challenging for the global economy across multiple sectors:

- Global geopolitical instability: Ongoing tensions in certain regions, including the Middle East, are expected to persist, disrupting global supply chains and causing difficulties in importing raw materials, excipients, and packaging materials for production.
- New tariff policies and trade protection measures: Policy adjustments in several countries may increase logistics costs, raise import expenses, and heighten risks in export expansion, thereby affecting the Company's international trade plans.
- Foreign exchange volatility: Fluctuations in foreign currencies, particularly USD and CNY, are expected to impact imported input costs—which account for a significant proportion of production costs—putting pressure on profit margins, pricing policies, competitiveness, and overall business performance. In some cases, this may even disrupt the supply of raw materials.
- Intensifying domestic pharmaceutical competition: The domestic pharmaceutical market is expected to remain highly competitive, especially in the generic drug and health supplement segments. Large-scale enterprises continue to invest heavily in distribution systems, product development, and market expansion, creating significant pressure on companies with similar scale and operating models such as Mediplantex.
- Regulatory and licensing challenges: Difficulties in drug registration, renewal, and variation approvals remain a major challenge for the pharmaceutical industry. Longer review and approval timelines may delay the launch of new products, limit portfolio expansion, and negatively affect revenue growth and customer acquisition.
- Increasing compliance requirements: Stricter standards in GMP, GSP, GDP, quality management, traceability, and drug registration dossiers are significantly increasing compliance costs for enterprises.

2. 2026 Production and Business Plan with Key Performance Indicators:

(Unit: Million dong)

No.	INDICATOR	UNIT	VALUE
I	Total Revenue	Million VND	412,071
II	Cost of Goods Sold	Million VND	321,273
III	Total Gross Profit	Million VND	90,797
IV	Total Selling Expenses	Million VND	4,949
	Financial Expenses	Million VND	5,120
V	Administrative Expenses	Million VND	62,822
VI	Profit Before Tax	Million VND	15,005

The 2026 business plan is developed on a prudent basis, fully reflecting the existing risk factors in the pharmaceutical industry, including:

- Difficulties in the drug registration approval process;
- Exchange rate fluctuations and rising imported raw material costs;
- International tariff and trade policy changes;
- Increasing competitive pressure in the market;
- Investment costs related to digital transformation, ERP implementation, and corporate restructuring.

The Board of Management determines that the approved plan represents the minimum target to be achieved, and at the same time commits to striving to exceed the plan in order to maximize benefits for shareholders

3. Operational Orientation:

- Continue implementing the restructuring plan toward a lean and efficient organization, and deploy an ERP enterprise resource planning system to modernize the management model, optimize operational efficiency, and standardize production and business processes through comprehensive digitalization.
- Strengthen market development by expanding customer networks and enhancing cooperation with both domestic and international partners. Maintain stable production volumes with key strategic customers and develop export markets through international trade promotion activities to expand revenue.
- Develop new products and improve formulations and production processes of existing products to enhance competitiveness and meet increasingly sophisticated market demand.
- Continue reviewing internal regulations, procedures, and professional guidelines to ensure full compliance with GMP, GSP, GDP, and corporate governance requirements. Standardize products to ensure consistent quality and minimize the risk of quality-related violations or product recalls.

- Improve production management efficiency to reduce waste, optimize material usage, and ensure rational labor allocation, thereby lowering production costs and increasing product competitiveness.
- Develop optimized inventory and procurement plans to achieve favorable supplier terms, reduce input costs for raw materials and packaging, and improve purchasing efficiency.
- Effectively implement financial management solutions in cash flow, inventory, and debt management, and restructure borrowing to ensure sufficient capital for production, business operations, and investment activities in 2026.

Overall Assessment:

- Although 2025 was a challenging year for the pharmaceutical industry and the Company's business operations, the Company maintained stable operations, ensured full compliance with applicable laws and regulations, and exceeded the profit targets assigned by the General Meeting of Shareholders.
- These results reflect the strong efforts of the entire workforce, the close direction and supervision of the Board of Directors and the Board of Supervisors, as well as the continuous support and companionship of shareholders throughout the Company's operations.
- In 2026, the Board of Management will continue to build on the achieved results, proactively respond to market challenges and uncertainties, focus on improving operational efficiency, and ensure sustainable growth while maximizing value for shareholders.

The above is the report of the Board of Management on the business performance in 2025 and the orientation for the implementation of the 2026 business plan.

Respectfully proposes to the General Meeting of Shareholders for consideration and approval.

GENERAL DIRECTOR

Recipients:

- BOD
- BOM
- Shareholders
- SSC
- Archived: Secretary

Mai Nhat Thanh



CÔNG TY CỔ PHẦN DƯỢC TRUNG ƯƠNG MEDIPLANTEX

Địa chỉ: 358 Đường Giải Phóng - Phường Phương Liệt - Hà Nội

Website: <http://www.mediplantex.com>



No: 03/2026/BC-MED

Hanoi, June 05, 2026

REPORT OF THE BOARD OF SUPERVISORS ON THE 2025 ACTIVITIES, SUPERVISORY WORK AND THE PROPOSED PLAN FOR 2026

To: The General Meeting of Shareholders

- Pursuant to the Law on Enterprises and the Charter of MediPlantex National Pharmaceutical Joint Stock Company stipulating the functions and authority of the Board of Supervisors;

- Pursuant to the Resolution of the 2024 General Meeting of Shareholders and the Resolutions of the Board of Directors in 2024;

- Pursuant to the business performance results and the audited 2025 financial statements;

The Board of Supervisors (BOS) of MediPlantex National Pharmaceutical Joint Stock Company respectfully submits to the Annual General Meeting of Shareholders (GMS) the report on its activities in 2025 and the proposed plan for 2026, with the following key contents:

I. Organization and Activities of the Board of Supervisors:

1. Personnel of the Board of Supervisors:

The Board of Supervisors consists of 3 members, including:

- Mr. Ho Ngoc Tuan : Head of the Board of Supervisors
- Ms. Ha Thi Bich Hanh : Member of the Board of Supervisors
- Ms. Do Ngoc Thuy : Member of the Board of Supervisors

2. Activities of the Board of Supervisors:

During the year, the Board of Supervisors fully performed its duties and responsibilities as assigned by the General Meeting of Shareholders, specifically overseeing, inspecting, and supervising the Company's governance, management, and business operations. The Board operated with a strong sense of responsibility, clearly delegated tasks to each member, and appointed representatives to attend meetings of the Board of Directors (BOD) and the Board of Management (BOM).

The Board of Supervisors maintained full and regular working relations with the BOD and the General Director in business operations, monitoring the Company's

activities to ensure compliance with applicable laws. It also regularly exchanged information with the BOD and General Director regarding the implementation of business plans and resolutions approved by the General Meeting of Shareholders.

Based on its functions and duties as stipulated by the Law on Enterprises, the Company's Charter, and the Regulations on Organization and Operation of the Board of Supervisors, the Board carried out the following activities during the year:

- Attended the Company's Annual General Meeting of Shareholders.
- Participated in regular and extraordinary meetings of the Board of Directors.
- Monitored financial and accounting activities, including review of the semi-annual and annual financial statements of the Company.
- Supervised the activities of the BOD and the Board of Management in accordance with the law and resolutions of the General Meeting of Shareholders.
- Oversaw the Company's information disclosure in compliance with legal regulations.
- Proposed the selection of an independent auditing firm to audit the Company's annual and semi-annual financial statements; assessed the financial statements before and after the audit.
- Provided input on the development of operating regulations for the Company by the BOD and the Board of Management.
- Cooperated with relevant departments to inspect and assess business operations.
- Held regular and extraordinary meetings of the Board of Supervisors to review, discuss, and evaluate the Company's performance.
- Performed other duties in accordance with the functions and responsibilities of the Board of Supervisors.

II. Evaluation by Task Group:

1. Evaluation by the BOS on the Activities of the BOD:

- Governance activities were carried out in accordance with the law, the Company's Charter, and the resolutions of the General Meeting of Shareholders.
- The BOD ensured transparency and openness in management, with a strategic focus on business development and efficiency.
- The BOD held regular meetings with clear agendas, documented minutes, and issued resolutions instructing the General Director to implement decisions.

However, in the past period, the BOD was unable to organize meetings as regularly planned due to the health condition of the Chairman. The BOS recommends that the BOD resume regular meetings as prescribed.

- During the year, the BOD amended, supplemented, and issued several regulations, documents, resolutions, and decisions, providing a structured, focused, and unified foundation for corporate governance.

2. Evaluation by the BOS on the General Director's Implementation of Resolutions of the GMS and the BOD:

- The General Director implemented various measures to strengthen financial management by controlling expenses, monitoring customer receivables, and managing operational activities in line with the objectives set by the General Meeting of Shareholders and the BOD.

- Took the initiative in executing the business plan, fully fulfilled obligations to the State and shareholders, and paid attention to employee welfare.

- Organized the year-end review conference to comprehensively evaluate business operations, identify limitations and shortcomings, and propose appropriate solutions and corrective actions.

- Focused on addressing internal weaknesses of the Company to improve operational efficiency and reduce costs.

- Regarding investment and co-investment projects that are behind schedule, the Board of Supervisors submitted recommendations to the BOD and the Board of Management, requesting a thorough review to ensure legal compliance and investment efficiency.

- For several resolutions issued by the BOD that have not yet been implemented, the Board of Supervisors recommends that the BOM promptly report back to the BOD.

III. Review and Evaluation of Financial Statements:

1. Preparation and Audit of Financial Statements:

- The Company's financial statements were prepared in accordance with current Vietnamese Accounting Standards. The annual and semi-annual financial statements were audited by AASC Auditing Firm Company Limited.

- The Board of Supervisors reviewed the financial statements and concurred with the reported business results. According to the audit opinion provided by AASC, the Company's financial statements were presented fairly, accurately, completely, and clearly, and were in compliance with applicable accounting standards.

However, the auditing firm issued a qualified opinion on the Company's 2025 audited financial statements, not an unqualified opinion, due to a limitation in the audit scope related to two business cooperation contracts: Contract No. 68/HDHTKD dated June 1, 2017 (cooperation in developing the project at the land lot located at 190 Dinh Thon Street, My Dinh 1 Ward, Nam Tu Liem District) and Contract No. 35/2009/HĐHT dated December 25, 2009 (cooperation in developing the project at the land lot located at 118 Nguyen Van Troi Street, Phuong Liet Ward, Thanh Xuan District). As the Company is currently working with its partners and relevant authorities on the implementation of these contracts, the information has not yet been provided to the auditors.

Regarding this matter, the Board of Supervisors has recommended that the Company engage a consulting firm to promptly resolve the issue and protect the Company's rights and interests in accordance with regulations. In addition, the Board of Supervisors has submitted its recommendations on this matter to the BOD and BOM, and requested that the BOD and BOM take appropriate action and implement necessary solutions.

2. Business Performance Results:

The Company closely followed the business targets set by the GMS and focused on implementing solutions to enhance production capacity, improve product quality, reduce costs, and increase operational efficiency.

IV. Recommendations for the Board of Directors and the General Director to continue addressing in the coming period:

- The BOD should consider developing a long-term business strategy to enhance proactiveness in operations.
- Improve and strengthen training and recruitment of qualified and experienced staff, as well as highly skilled technical workers, to support future business and production activities.
- Continue implementing more effective measures to recover due receivables and bad debts.
- Accelerate the implementation of the Pharmaceutical Science and Technology Center and the EU-GMP-standard Pharmaceutical Manufacturing Plant Project to bring it into efficient operation as soon as possible.

V. Report on Transactions between the Company and Members of the Board of Directors, the General Director, other executive officers, and their related persons; and transactions between the Company and companies in which members of the Board of Directors, the General Director, or other executive

officers are founders or managers within the last three (03) years prior to the transaction date

In 2025, all transactions between the Company and related parties were submitted to and approved by the Board of Directors in accordance with proper procedures and were fully compliant with disclosure obligations. Details of related-party transactions are presented in the audited Financial Statements for 2025 and the Company's Corporate Governance Report. The Board of Supervisors confirms that the transaction procedures complied with regulations, with no violations detected. The transactions were conducted in a transparent manner, ensuring effective control of conflicts of interest and safeguarding the interests of the Company and its shareholders.

V. Work Plan of the Board of Supervisors for 2026:

- Perform inspection and supervision duties over the governance and management activities of the Board of Directors and the Board of Management in accordance with the Company's Charter and the Law on Enterprises;
- Monitor the implementation of resolutions of the General Meeting of Shareholders and resolutions of the Board of Directors in the course of business operations, based on legal regulations and the Company's Charter;
- Review the appropriateness of internal documents and management regulations and their practical application to ensure alignment with the resolutions of the General Meeting of Shareholders. Propose amendments or supplements to internal regulations if deemed necessary;
- Examine accounting records, vouchers, and other Company documents when necessary or upon request of the General Meeting of Shareholders;
- Propose the selection of an independent auditing firm to audit the Company's semi-annual and annual financial statements;
- Review and evaluate financial statements and the Company's business performance on a quarterly, semi-annual, and annual basis;
- Maintain close coordination between the Board of Supervisors, the Board of Directors, the Board of Management, and other relevant units within the Company;
- Participate in major Company activities to stay informed about business operations;
- Attend BOD meetings and quarterly briefings to stay up to date on the Company's situation.

VI. General Assessment of the Activities of the Board of Supervisors:

- The Board of Supervisors performed its functions and duties in accordance with the Company's Charter and the relevant provisions of the Law on Enterprises relating to the Board of Supervisors.

- The Board of Supervisors fulfilled the responsibilities entrusted to it by shareholders, particularly in overseeing business operations and the effective use of capital.

- The performance of the Board of Supervisors during the term was the result of the efforts of each member, as well as the trust, support, and facilitation provided by the Board of Directors, the General Director, departments, and all employees of the Company.

On behalf of the Board of Supervisors, I would like to sincerely thank the General Meeting of Shareholders, the Board of Directors, and the General Director for their trust, support, and cooperation throughout the past year, which enabled the Board of Supervisors to fulfill its duties effectively.

Respectfully!

Recipient:

- *Shareholders;*
- *BOD; BOM;*
- *BOS;*
- *Archived: BOS; Secretary; Office.*

**ON BEHALF OF THE BOARD OF SUPERVISORS
HEAD OF THE BOARD**



Ho Ngoc Tuan



CÔNG TY CỔ PHẦN DƯỢC TRUNG ƯƠNG MEDIPLANTEX

Địa chỉ: 358 Đường Giải Phóng - Phường Phương Liệt - Hà Nội

Website: <http://www.mediplantex.com>

No.: 01/2026/TTr-ĐHĐCĐ

THE SOCIALIST REPUBLIC OF VIETNAM

Independence – Freedom – Happiness

Hanoi, June 05, 2026

DRAFT

PROPOSAL

Re: Approval of the 2025 Audited Financial Statements

**To: The General Meeting of Shareholders
of Mediplantex National Pharmaceutical Joint Stock Company**

- Pursuant to the Law on Enterprises No. 59/2020/QH14 adopted by the National Assembly of the Socialist Republic of Vietnam on June 17, 2020, and effective from January 1, 2021, as amended by Law No. 03/2022/QH15 adopted by the National Assembly on January 11, 2022, Law No. 76/2025/QH15 adopted by the National Assembly on June 17, 2025, and the guiding documents;
- Pursuant to the Charter on organization and operation of Mediplantex National Pharmaceutical Joint Stock Company;
- Pursuant to the 2025 financial statements of Mediplantex National Pharmaceutical Joint Stock Company, audited by AASC Auditing Firm Company Limited.

The Board of Directors respectfully submits to the General Meeting of Shareholders of the Company for consideration and approval the following matter:

In accordance with the Resolution of the 2025 Annual General Meeting of Shareholders regarding the selection of an independent auditing firm for the 2025 financial statements, the Company appointed AASC Auditing Firm Company Limited to conduct the independent audit of the 2024 financial statements.

The Company's 2025 financial statements were independently audited by AASC Auditing Firm Company Limited, with the audit report signed on March 06, 2026.

Respectfully submits to the General Meeting of Shareholders for consideration and approval./.

Recipients:

- Company Shareholders;
- BOD; BOM;
- BOS;
- Archived: Company Secretary.

**OB. THE BOARD OF DIRECTORS
CHAIRMAN**

Nguyen Ngoc Xuan Trang



CÔNG TY CỔ PHẦN DƯỢC TRUNG ƯƠNG MEDIPLANTEX

Địa chỉ: 358 Đường Giải Phóng - Phường Phương Liệt - Hà Nội

Website: <http://www.mediplantex.com>

THE SOCIALIST REPUBLIC OF VIETNAM

Independence – Freedom – Happiness

Hanoi, June 05, 2026

DRAFT

PROPOSAL

Re: Selection of the Independent Auditing Firm for the 2026 Financial Statements

To: The General Meeting of Shareholders

of Mediplantex National Pharmaceutical Joint Stock Company

- Pursuant to the Law on Enterprises No. 59/2020/QH14 passed by the National Assembly of the Socialist Republic of Vietnam on June 17, 2020, as amended by Law No. 03/2022/QH15 passed by the National Assembly on January 11, 2022, Law No. 76/2025/QH15 adopted by the National Assembly on June 17, 2025, and the guiding documents;
- Pursuant to the Charter on Organization and Operation of Mediplantex National Pharmaceutical Joint Stock Company.

The Board of Supervisors of Mediplantex National Pharmaceutical Joint Stock Company respectfully submits to the General Meeting of Shareholders for consideration and approval the following matter:

In order to ensure proactivity in selecting an appropriate auditing firm that meets the Company's requirements regarding the timing and quality of auditing services for the financial statements of the fiscal year 2026, the Board of Supervisors respectfully proposes that the General Meeting of Shareholders consider and approve the following contents:

1. Approval of criteria for selecting the independent auditing firm for the 2026 Financial statements:
 - The auditing firm must be an independent audit enterprise included in the list of entities eligible to provide audit services as announced by the Ministry of Finance at the time of selection. It must fully meet all professional standards and conditions, possess a team of qualified auditors, and be approved by the State Securities Commission to audit public interest entities operating in the securities sector in 2026.
 - The firm must have a strong reputation and extensive experience in the field.
 - The firm must not have any conflicts of interest in connection with auditing the Corporation's financial statements.
 - The proposed audit fee must be competitive and appropriate to the content, scope, and timeline of the audit engagement.

2. Approval of the following list of auditing firms proposed to conduct the audit of the financial statements for the fiscal year 2026 and the review of the quarterly and semi-annual financial statements (if required by State regulatory authorities) for Mediplantex National Pharmaceutical Joint Stock Company, including:
 - 1.1. KPMG Company Limited;
 - 1.2. AASC Auditing Firm Company Limited;
 - 1.3. PWC (Vietnam) Company Limited;
 - 1.4. Viet Nam Auditing & Evaluation Company Limited;
 - 1.5. An Viet Auditing Company Limited.
 - 1.6. Other audit firms included in the list of audit companies approved by the State Securities Commission to audit public interest entities in the securities sector for the year 2026.
3. Estimated auditing fee: From VND 200,000,000 to VND 500,000,000.
4. The Board of Supervisors respectfully submits to the General Meeting of Shareholders a proposal to authorize the Board of Directors to select one of the aforementioned auditing firms to conduct the audit and review of the 2026 financial statements. In case the selected auditing firm is unable to continue the audit and review, or if the Board of Directors deems that the selected firm cannot ensure timely issuance of the reports, the Board of Supervisors seeks the General Meeting's authorization for the Board of Directors to change the auditing firm, provided that the replacement meets the required criteria and is selected from the list previously approved by the General Meeting of Shareholders. Any change of auditing firm will be disclosed as an extraordinary information disclosure in accordance with the prevailing laws and regulations on information disclosure in the securities market.
5. The Board of Directors authorizes the General Director / Legal Representative to sign the audit contract with the selected auditing firm.

Respectfully submits to the General Meeting of Shareholders for consideration and approval.

Recipients:

- *Company Shareholders;*
- *BOD; BOM;*
- *BOS;*
- *Archived: Company Secretary.*

OB. THE BOARD OF SUPERVISORS
HEAD OF THE BOARD

Ho Ngoc Tuan





CÔNG TY CỔ PHẦN DƯỢC TRUNG ƯƠNG MEDIPLANTEX

Địa chỉ: 358 Đường Giải Phóng - Phường Phương Liệt - Hà Nội

Website: <http://www.mediplantex.com>

No.: 03/2026/TTr-ĐHĐCĐ

THE SOCIALIST REPUBLIC OF VIETNAM

Independence – Freedom – Happiness

Hanoi, June 05, 2026

DRAFT

PROPOSAL

Re: Approval of the profit distribution plan and dividend payout ratio for 2025, and the proposed profit distribution plan and dividend payout ratio for 2026

**To: The General Meeting of Shareholders
of Mediplantex National Pharmaceutical Joint Stock Company**

Pursuant to:

- Pursuant to the Law on Enterprises No. 59/2020/QH14 passed by the National Assembly of the Socialist Republic of Vietnam, on June 17, 2020, effective as of January 1, 2021, and amended by Law No. 03/2022/QH15 passed by the National Assembly on January 11, 2022, Law No. 76/2025/QH15 adopted by the National Assembly on June 17, 2025, and the guiding documents;
- Pursuant to the Charter on the organization and operation of Mediplantex National Pharmaceutical Joint Stock Company;
- Pursuant to the 2025 financial statements of Mediplantex National Pharmaceutical Joint Stock Company audited by AASC Auditing Firm Company Limited;
- The 2025 business and production results and the implementation plan for 2026.

The Board of Directors respectfully submits to the General Meeting of Shareholders for consideration and approval the following matter:

I. PROFIT DISTRIBUTION PLAN FOR 2025:

Indicators	Percentage (%)	Value (Unit: VND)
1. Profit before tax in 2025		20,659,417,001
2. Corporate income tax payable in 2025		4,825,980,517
3. Profit after tax in 2025		15,833,436,484
4. Profit distribution in 2025		15,833,436,484

Indicators	Percentage (%)	Value (Unit: VND)
4.1. Bonus allocation to the Board of Management		158,334,365
4.2. Bonus allocation to the Board of Directors and the Board of Supervisors		158,334,365
4.3. Allocation to the Development Investment Fund	0%	2,000,000,000
4.4. Remaining profit for dividend distribution		13,516,767,754
5. Retained earnings from previous years		365,519,888
6. Total profit for dividend distribution up to the end of 2025		13,882,287,642
7. Proposed dividend distribution	0%	0
8. Retained earnings for 2026		13,882,287,642

Reason for not paying dividends: To retain funds for working capital requirements and for payment of land clearance and site clearance costs relating to the GMP-EU Manufacturing Plant Project at Hoa Lac High-Tech Park.

II. PLAN FOR 2026

Based on the 2026 business and production plan of Mediplantex National Pharmaceutical Joint Stock Company, the Board of Directors proposes the allocation of bonuses and the dividend payout rate for 2026 as follows:

Projected for 2026	Percentage %	Amount VND
I. Profit Before Tax 2025		15,005,000,000
II. Profit After Tax 2025		12,004,000,000
1. Allocation for bonus to the Board of Management	1%	120,040,000
2. Allocation for bonus to the Board of Directors and the Board of Supervisors	1%	120,040,000
3. Allocation to the Development Investment Fund	0	
4. Remaining profit for dividend distribution	10% of charter capital	13,882,287,642
5. Retained earnings for 2027		12,410,000,000

- The allocation of bonuses to the Board of Management and to the Board of Directors and the Board of Supervisors at the above-mentioned rates shall only be implemented if the

profit after tax in 2026 reaches 90% to 100% of the 2026 approved plan.

- In the event that the 2026 performance exceeds the plan approved by the General Meeting of Shareholders:
 - + Additional bonus for the Board of Management at the rate of 05% of the excess amount over the plan.
 - + Additional bonus for the Board of Directors and the Board of Supervisors at the rate of 05% of the excess amount over the plan.

Respectfully submits to the General Meeting of Shareholders for consideration and approval./.



Recipients:

- Shareholders of Mediplantex National Pharmaceutical Joint Stock Company;
- BOD, BOS, BOM, Company Secretary
- Archived: Office, BOD.

**OB. THE BOARD OF DIRECTORS
CHAIRMAN**

Nguyen Ngoc Xuan Trang



CÔNG TY CỔ PHẦN DƯỢC TRUNG ƯƠNG MEDIPLANTEX

Địa chỉ: 358 Đường Giải Phóng - Phường Phương Liệt - Hà Nội

Website: <http://www.mediplantex.com>

No.: 04/2026/TTr-ĐHĐCĐ

THE SOCIALIST REPUBLIC OF VIETNAM

Independence – Freedom – Happiness

Hanoi, June 05, 2026

DRAFT

PROPOSAL

Re: Approval of remuneration for the Board of Directors and the Board of Supervisors for 2025 and the plan for 2026

To: The General Meeting of Shareholders

of Mediplantex National Pharmaceutical Joint Stock Company

- Pursuant to the Law on Enterprises No. 59/2020/QH14 passed by the National Assembly of the Socialist Republic of Vietnam, on June 17, 2020, effective as of January 1, 2021, and amended by Law No. 03/2022/QH15 passed by the National Assembly on January 11, 2022, Law No. 76/2025/QH15 adopted by the National Assembly on June 17, 2025, and the guiding documents;
- Pursuant to the Charter on the organization and operation of Mediplantex National Pharmaceutical Joint Stock Company;
- Pursuant to the 2025 financial statements of Mediplantex National Pharmaceutical Joint Stock Company audited by AASC Auditing Firm Company Limited;
- The 2025 business and production results and the implementation plan for 2025.

The Board of Directors respectfully submits to the General Meeting of Shareholders the following matter for consideration and approval:

In regard to the activities of the Board of Directors and the Board of Supervisors in carrying out their assigned duties in 2025, the Company hereby reports the remuneration of the Board of Directors and the Board of Supervisors for the year 2025:

1. Remuneration of the Board of Directors and the Board of Supervisors in 2025:

No.	Position	Number	Remuneration/year
Remuneration of the Board of Directors			
1	Chairman of the BOD	1	110,000,000
2	Independent member of the BOD	1	84,000,000
3	Member of the BOD (including Executive and Non-Executive Members)	3	252,000,000
	Total Remuneration of the Board of Directors in 2025		446,000,000

No.	Position	Number	Remuneration/year
	Additional Remuneration to be Paid for 2025		200,000,000
Remuneration of the Board of Supervisors, Company Secretary			
1	Head of the BOS	1	54,000,000
2	Member of the BOS	2	84,000,000
3	Company Secretary	1	54,000,000
	Total Remuneration of the Board of Supervisors in 2025		192,000,000
	Additional Remuneration to be Paid for 2025		12,000,000

Other benefits of members of the Board of Directors and the Board of Supervisors shall be provided in accordance with applicable laws, the Company's Charter and internal regulations, and have been fully disclosed in the audited Financial Statements for the fiscal year ended 2025.

2. Plan Remuneration for 2026:

To ensure the effective operation of the Board of Directors and the Board of Supervisors in carrying out their assigned duties in 2026, and based on the business plan of Mediplantex National Pharmaceutical Joint Stock Company for 2026, as well as relevant regulations of the State, the Company's Charter, and internal regulations, the Board of Directors respectfully submits for approval the plan total remuneration for 2026:

No.	Position	Number	Remuneration/year
Remuneration of the Board of Directors			648,000,000
1	Chairman of the BOD	1	360,000,000
	(In the case of a Non-Executive Chairman of the Board of Directors)	1	180,000,000
2	Independent member of the BOD	1	72,000,000
3	Member of the BOD (including Executive and Non-Executive Members)	3	216,000,000
Remuneration of the Board of Supervisors, Company Secretary			156,000,000
1	Head of the BOS	1	48,000,000
2	Member of the BOS	2	72,000,000
3	Company Secretary	1	36,000,000

Respectfully submits to the General Meeting of Shareholders for consideration and approval./.

Recipients:

- *Shareholders;*
- *BOD, BOS, BOM, Company Secretary*
- *Archived: Office, BOD.*

**OB. THE BOARD OF DIRECTORS
CHAIRMAN**

Nguyen Ngoc Xuan Trang



CÔNG TY CỔ PHẦN DƯỢC TRUNG ƯƠNG MEDIPLANTEX

Địa chỉ: 358 Đường Giải Phóng - Phường Phương Liệt - Hà Nội

Website: <http://www.mediplantex.com>



No. 06/2026/TTr-ĐHĐCĐ

DRAFT

THE SOCIALIST REPUBLIC OF VIETNAM

Independence – Freedom – Happiness

Hanoi, June 05, 2026

PROPOSAL

Re: Approval of the Dismissal and Election for the Additional Members of the Board of Directors for the 2024 – 2029 Term

**To: The General Meeting of Shareholders
of Mediplantex National Pharmaceutical Joint Stock Company**

- Pursuant to the Law on Enterprises No. 59/2020/QH14 passed by the National Assembly of the Socialist Republic of Vietnam, on June 17, 2020, as amended by Law No. 03/2022/QH15 passed by the National Assembly on January 11, 2022, Law No. 76/2025/QH15 adopted by the National Assembly on June 17, 2025, and the guiding documents;

- Pursuant to the Charter on Organization and Operation of Mediplantex National Pharmaceutical Joint Stock Company;

- Pursuant to the Regulation on the Operation of the Board of Directors of the Company;

- Based on the letter of resignation submitted by the member of the Board of Directors to the Board of Directors;

The Board of Directors respectfully proposes to the General Meeting of Shareholders of the Company for consideration and approval of the following matters:

1. Based on the resignation letter submitted by a member of the Board of Directors, the Board respectfully proposes that the General Meeting of Shareholders approve the dismissal of:

Ms. Nguyen Thi Thuy - Member of the Board of Directors for the 2024–2029 term

Reason for dismissal: Voluntary resignation

Upon the approval of Ms. Nguyen Thi Thuy's resignation, the Board of Directors of Mediplantex National Pharmaceutical Joint Stock Company for the 2024–2029 term will consist of only 04 members, thereby failing to meet the structural requirements of the Board of Directors as prescribed by the Company's Charter. Accordingly, the Board of Directors deems it necessary to propose the election of an additional member to the Board of Directors for the 2024–2029 term.

2. The Board of Directors respectfully proposes to the General Meeting of Shareholders of the Company for consideration and approval the election of additional members to the Board



of Directors for the 2024-2029 term as follows:

Number of additional members to be elected to the BOD: 01 member

- Criteria for selecting a member of the BOD: In accordance with Clause 2, Article 155 of the Law on Enterprises and Article 7 of the Regulations on the Operation of the BOD.
- Number of candidates: Unlimited.

Based on the nomination and self-nomination results submitted by shareholders and groups of shareholders in accordance with the Company's Charter, and considering the competence, qualifications, and reputation of the nominees, and in compliance with the criteria for BOD members as prescribed by the Company's Regulations on the Operation of the BOD and applicable laws, the BOD respectfully proposes to the General Meeting of Shareholders for approval the List of Candidates for the election of one (01) additional member of the BOD for the remainder of the 2024 – 2029 term as follows:

- Mr./Ms: Candidate for the Board of Directors
- Mr./Ms: Candidate for the Board of Directors

Curricula Vitae of the Candidates Attached to This Proposal.

Respectfully proposes to the General Meeting of Shareholders for consideration and approval./.

Recipients:

- Company Shareholders;
- BOD; BOS;
- Archived: Company Secretary.

**OB. THE BOARD OF DIRECTORS
CHAIRMAN**

Nguyen Ngoc Xuan Trang



CÔNG TY CỔ PHẦN DƯỢC TRUNG ƯƠNG MEDIPLANTEX

Địa chỉ: 358 Đường Giải Phóng - Phường Phương Liệt - Hà Nội

Website: <http://www.mediplantex.com>

No.: 05/2026/TTr-ĐHĐCĐ

THE SOCIALIST REPUBLIC OF VIETNAM

Independence - Freedom - Happiness

Hanoi, June 5, 2026

DRAFT

REPORT

Re.: Approval of the Amendments and Supplements to the Charter on Organization and Operation of the Company

To: The General Meeting of Shareholders of Mediplantex National Pharmaceutical Joint Stock Company

- Pursuant to the Law on Enterprises No. 59/2020/QH14 passed by the National Assembly of the Socialist Republic of Vietnam, on June 17, 2020, effective as of January 1, 2021, and amended by Law No. 03/2022/QH15 passed by the National Assembly on January 11, 2022, Law No. 76/2025/QH15 adopted by the National Assembly on June 17, 2025, and the guiding documents;
- Pursuant to the Charter on the organization and operation of Mediplantex National Pharmaceutical Joint Stock Company.

The Board of Directors respectfully submits the following to the General Meeting of Shareholders for consideration and approval:

Based on a review of the Company's Charter on Organization and Operation (the "Charter"), the Board of Directors has determined that certain provisions of the Charter should be amended and supplemented to ensure compliance with applicable laws and regulations and to meet practical requirements in the Company's governance and management. (Details of the proposed amendments and supplements are set out in the Appendix attached to this Proposal.)

The full draft of the amended Charter has been published in detail on the Company's website at: <https://www.mediplantex.com/>.

The General Meeting of Shareholders is respectfully requested to authorize the Board of Directors and the Company's Legal Representative to make amendments and supplements to, and to execute and promulgate, the Charter and related documents based on the amendments and supplements approved by the General Meeting of Shareholders.



Furthermore, with respect to any administrative procedures arising from the amendments and supplements to the Charter (including, but not limited to, amendments to the Company's registered business lines and changes to the Legal Representative), the General Meeting of Shareholders is respectfully requested to consider, approve, and authorize the Board of Directors and the Company's Legal Representative to carry out such procedures in accordance with the approved contents.

The amended and supplemented Charter on Organization and Operation shall take effect from the date of its approval by the Company's 2026 Annual General Meeting of Shareholders. Any administrative procedures arising therefrom shall be carried out within the time limits prescribed by applicable laws and regulations.

Respectfully submitted to the General Meeting of Shareholders for consideration and approval./.

Recipient:

- Company shareholders;
- Board of Directors, Supervisory Board, Company Secretary;
- Luu VT, Board of Directors.

OB. THE BOARD OF DIRECTORS

CHAIRMAN



Nguyen Ngoc Xuan Trang

THE SOCIALIST REPUBLIC OF VIETNAM
Independent - Freedom - Happiness

Ha Noi, June 05 2026

DRAFT

**CÔNG TY
CỔ PHẦN
DƯỢC TRUNG ƯƠNG
MEDIPLANTEX**

SUMMARY OF AMENDMENTS AND SUPPLEMENTS TO THE CHARTER OF MEDIPLANTEX NATIONAL PHARMACEUTICAL JOINT STOCK COMPANY

	ARTICLE	CURRENT CHARTER	PROPOSED AMENDMENTS/SUPPLEMENTS	NOTE
1	Article 1. Interpretation of Terms	c) Law on Enterprises means the Law on Enterprises No. 59/2020/QH14 adopted by the National Assembly of the Socialist Republic of Vietnam on June 17, 2020	c) Law on Enterprises means the Law on Enterprises No. 59/2020/QH14 adopted by the National Assembly of the Socialist Republic of Vietnam on June 17, 2020 and the Law Amending and Supplementing a Number of Articles of the Law on Enterprises No. 76/2025/QH15 dated June 17, 2025;	Amended to update the applicable legal basis and ensure that the Charter is aligned with the current enterprise law framework.
2	Article 2. Name, Form, Head Office, Branches, Representative Offices, Business Locations and Term of Operation of the Company	h) Enterprise Manager means a manager of the Company, including the Chairman of the Board of Directors, members of the Board of Directors and the Deputy Director; 3. Registered Head Office: - Address: 358 Giai Phong, Phuong Liet Ward, Thanh Xuan District, Hanoi.	h) Enterprise Manager means a manager of the Company, including the Chairman of the Board of Directors, members of the Board of Directors and the Board of Management; 3. Registered Head Office: - Address: 358 Giai Phong, Phuong Liet Ward, Hanoi City, Vietnam.	Amended to accurately reflect the Company's governance model and actual management structure, ensuring comprehensive coverage of the entire executive management apparatus. Amended in accordance with the new administrative divisions and address registration requirements currently applied by business registration authorities.
		4. The Company may establish branches, representative offices and business locations in order to achieve its business objectives, subject to resolutions of the Board of Directors and within the scope permitted by law.	4. The Company may establish one member limited liability companies, branches, representative offices and business locations in order to achieve its business objectives, subject to	Supplemented to provide a legal basis for the Company to proactively expand its investment model, organize its business operations more flexibly, and

			resolutions of the Board of Directors and within the scope permitted by law.	align with its development strategy in the new stage.
3	Article 3. Legal Representative of the Company	The Company shall have one (01) legal representative. The General Director is the legal representative of the Company.	The Company shall have one (01) legal representative. The Chairman of the Board of Directors is the legal representative of the Company.	Amended to strengthen consistency in corporate governance, enhance the effectiveness of supervision and management, and ensure the seamless implementation of strategic decisions of the Board of Directors.
4	Article 4. Objectives of the Company	<ul style="list-style-type: none"> - Manufacture of pharmaceuticals, medicinal chemicals and botanical products Including only: Pharmaceutical manufacturing. - Scientific research and experimental development in natural sciences and engineering Including only: Scientific research services; technology transfer; consultancy, training and professional coaching in medical and pharmaceutical fields (such business activities may only be conducted upon approval by the competent state authorities and only within the scope of the registered professional practice certificates). - Activities of general medical, specialized medical and dental clinics Including only: Traditional medicine diagnosis and treatment clinics (such business activities may only be conducted upon approval by the competent state authorities). - Retail sale of pharmaceuticals, 	Article chình theo phụ lục kèm theo	Amended to update and standardize the Company's business lines in accordance with Decision No. 36/2025/QĐ-TTg.

		<p>medical and orthopedic goods, cosmetics and toilet articles in specialized stores</p> <p>Including only: Trading of vaccines and medical biological products (such business activities may only be conducted upon approval by the competent state authorities).</p> <ul style="list-style-type: none"> - Real estate business and land use rights of owners, users or lessees - Including only: Leasing of houses, offices and warehouses; real estate business. - Cultivation of spices and medicinal plants - (Excluding pharmaceutical trading activities under this business line.) - Wholesale of agricultural and forestry raw materials (excluding wood, bamboo and rattan) and live animals - (Excluding agricultural and forestry products and animals prohibited from trading by the State.) - Wholesale of machinery, equipment and spare parts - Including only: Wholesale of medical machinery and equipment; trading of machinery and packaging equipment serving the manufacture of pharmaceuticals, traditional medicines, cosmetics and nutritional products. - Wholesale of other household goods <p>Details: Including only: Wholesale of medical instruments, perfumes, cosmetics and toilet preparations;</p>	
--	--	--	--

		<ul style="list-style-type: none"> - Pharmaceutical trading; - Trading of pharmaceutical ingredients, medicinal herbs, essential oils, flavorings, chemical excipients, additives and colorants used in pharmaceuticals, cosmetics, food products and industrial applications (such business activities may only be conducted upon approval by the competent state authorities). - Warehousing and storage - Renting and leasing of other machinery, equipment and tangible goods - Including only: Leasing of industrial, commercial and scientific machinery and equipment (excluding machinery prohibited from trading by the State). - Wholesale of food products - Details: Trading of functional foods. - Manufacture of other food products not elsewhere classified - Details: Manufacture of functional foods. - Agency, brokerage and auction activities - Details: - Agency, purchase, sale and consignment of goods; - Investment brokerage and commercial brokerage services. - Other business support service activities not elsewhere classified - Details: - Import and export entrustment services; - Export and 	
--	--	--	--

			from inheriting, the relevant shares shall be dealt with in accordance with the laws on inheritance and civil matters.	
7	Article 12. Rights of Shareholders	<p>Clause 1:</p> <p>d) Tự do chuyển nhượng cổ phần của mình cho người khác, except in the cases prescribed by Clause 3 Article 120, Clause 1 Article 127 of Law on Enterprises and other applicable laws;</p>	<p>d) Freely transfer shares that have been fully paid for in accordance with this Charter and applicable laws;</p>	Amended to align with the current provisions of the Enterprise Law, while maintaining flexibility in the event of future amendments and supplements to the law. The amendment also clarifies that only fully paid shares may be transferred, thereby minimizing disputes and ensuring legal certainty in share transfer transactions.
		<p>Clause 2:</p> <p>a) Request the Board of Directors to convene the General Meeting of Shareholders in accordance with Clause 3 Article 115 and Article 140 of Law on Enterprises;</p>	<p>a) Request the Board of Directors to convene the General Meeting of Shareholders in accordance with the Law on Enterprises;</p>	Amended through a general reference to the Enterprise Law in order to ensure consistency, avoid duplication of specific provisions, and allow automatic updates when relevant legal regulations are amended or supplemented.
	Article 14. General Meeting of Shareholders	<p>Clause 3:</p> <p>b) Số lượng thành viên Hội đồng quản trị, Ban kiểm soát còn lại ít hơn số lượng thành viên tối thiểu theo quy định của pháp luật.</p> <p>The number of members of the Board of Directors or the Board of Supervisors is less than the minimum number required by law.</p>	<p>b) The number of members of the Board of Directors or the Board of Supervisors is less than the minimum number required by law; or the number of members of the Board of Directors has been reduced by more than one-third (1/3) compared to the number prescribed in the Company's Charter.</p>	Supplemented in accordance with the Enterprise Law.
8	Article 15. Rights and Obligations of the General Meeting of Shareholders	<p>Clause 2:</p> <p>s) To approve transactions as prescribed in Clause 4, Article 293 of Decree No. 155/2020/ND-CP dated 31 December</p>	<p>s) To approve transactions as prescribed in Clause 4, Article 293 of Decree No. 155/2020/ND-CP dated 31 December</p>	The legal reference has been updated in accordance with the amendments and supplements introduced under Decree No. 245/2025/ND-CP.

		2020 of the Government detailing the implementation of a number of articles of the Law on Securities;	2020 of the Government detailing the implementation of a number of articles of the Law on Securities, amended by Clause 84, Article 1 of Decree No. 245/2025/ND-CP;	
		None	<p>4. Shareholders shall not be entitled to vote in the following cases:</p> <p>a) Approval of contracts specified in Clause 2 Article 16 where such shareholder or the shareholder's related person is a party to the contract;</p> <p>b) Repurchase of shares held by such shareholder or the shareholder's related person, except where the share repurchase is conducted on a pro rata basis applicable to all shareholders or is carried out through order matching or a public tender offer on a stock exchange.</p>	Supplemented to prevent shareholders or their related persons from influencing decisions that directly affect their own interests, thereby ensuring independence and objectivity in the adoption of resolutions of the General Meeting of Shareholders.
Article 25. Nomination and candidacy of members of the Board of Directors	4. Members of the Board of Directors must satisfy the criteria and conditions prescribed in Clause 1 and Clause 2 Article 155 of the Enterprise Law and the Company's Charter	4. Members of the Board of Directors must satisfy the criteria and conditions prescribed in Clause 1 and Clause 2 Article 155 of the Enterprise Law and the Company's Charter. A member of the Board of Directors of a public company may concurrently serve as a member of the Board of Directors, a member of the Members' Council, or the Chairman of a company in no more than five (05) other companies.	Supplemented with additional requirements regarding the qualifications and conditions of members of the Board of Directors in accordance with Decree No. 155/2020/ND-CP and Decree No. 245/2025/ND-CP.	
Article 26.	3. Composition of the Board of Directors:	3. Composition of the Board of Directors:	Amended to align with Decree No. 245/2025/ND-CP amending	

<p>Composition and term of the Board of Directors</p>	<p>The composition of the Board of Directors of a public company must ensure that at least one-third (1/3) of the total number of members of the Board of Directors are non-executive members. The Company shall, to the greatest extent possible, limit the appointment of members of the Board of Directors who concurrently hold executive positions within the Company in order to ensure the independence of the Board of Directors. The total number of independent members of the Board of Directors must include at least 01 independent member.</p>	<p>The composition of the Board of Directors of a public company must include at least 01 non-executive member. The Company shall, to the greatest extent possible, limit the appointment of members of the Board of Directors who concurrently hold executive positions within the Company in order to ensure the independence of the Board of Directors. The total number of independent members of the Board of Directors must include at least 01 independent member.</p>	<p>and supplementing a number of articles of Decree No. 155/2020/ND-CP.</p>
<p>Article 27. Rights and duties of the Board of Directors</p>	<p>None</p>	<p>Supplement: 4. Each independent member of the Board of Directors shall prepare an assessment report on the activities of the Board of Directors.</p>	<p>Supplemented with additional obligations applicable to independent members of the Board of Directors in accordance with Decree No. 155/2020/ND-CP and Decree No. 245/2025/ND-CP.</p>

APPENDIX ON AMENDMENTS TO BUSINESS LINES

No.	Business Line	Code	Principal business line
1	Wholesale of agricultural and forestry raw materials (excluding wood, bamboo and rattan) and live animals	4620	
2	Wholesale of machinery, equipment and other machine parts <i>Including only: wholesale of medical machinery and equipment; trading in machinery and packaging equipment serving the production of pharmaceutical products, traditional medicines, cosmetics and nutritional products.</i>	4659	
3	Wholesale of other household products <i>Including only: (i) wholesale of medical instruments, perfumes, cosmetics and sanitary products; (ii) pharmaceutical trading; (iii) trading in pharmaceutical ingredients, medicinal herbs, essential oils, flavorings, excipients, chemicals and colorants used in pharmaceuticals, cosmetics, food products and industrial applications (subject to approval by competent state authorities where required).</i>	4649	
4	Warehousing and storage	5210	
5	Manufacture of pharmaceuticals, medicinal chemicals and botanical products	2100	X
6	Activities of general and specialized medical clinics and dental clinics <i>Including only: traditional medicine clinics (subject to approval by competent state authorities where required).</i>	8620	
7	Retail sale of pharmaceuticals, medical goods, cosmetics and toilet articles	4772	
8	Real estate business, land use rights owned, used or leased <i>Including only: leasing of houses, offices and warehouses; real estate business.</i>	6810	
9	Wholesale of food products <i>Details: Trading in functional foods and health supplements.</i>	4632	
10	Manufacture of other food products not elsewhere classified <i>Details: Production of functional foods and health supplements.</i>	1079	
11	Other business support service activities n.e.c.	8299	

	<i>Details:</i> - <i>Entrustment of import and export activities;</i> - <i>Import and export of goods (excluding goods prohibited or temporarily suspended from import/export).</i>		
12	Growing of spice crops, medicinal plants and perennial aromatic plants	0128	
13	Scientific research and technological development in medical and pharmaceutical sciences <i>Scientific research services, technology transfer, consultancy, education and training in the medical and pharmaceutical fields (subject to approval by competent state authorities and only within the scope permitted by law).</i>	7213	
14	Renting and leasing of machinery, equipment and tangible goods without operator <i>Including only: leasing of industrial, commercial and scientific machinery and equipment (excluding machinery prohibited by law).</i>	7730	
15	Agents, brokers and auctioneers of goods <i>Details: Agency, purchase and sale, consignment of goods; investment brokerage and commercial brokerage services.</i>	4610	
16	Market research and public opinion polling	7320	
17	Organization of trade promotion activities	8230	

THE SOCIALIST REPUBLIC OF VIETNAM

Independent - Freedom - Happiness

DRAFT



CHARTER

MEDIPLANTEX NATIONAL PHARMACEUTICAL JOINT STOCK COMPANY

Ha Noi, 05 June , 2026

TABLE OF CONTENTS

PREAMBLE

I. DEFINITIONS OF TERMS IN THE CHARTER

Article 1. Interpretation of Terms

II. NAME, FORM, HEAD OFFICE, BRANCHES, REPRESENTATIVE OFFICES, BUSINESS LOCATIONS, TERM OF OPERATION AND LEGAL REPRESENTATIVE OF THE COMPANY

Article 2. Name, Form, Head Office, Branches, Representative Offices, Business Locations and Term of Operation of the Company

Article 3. Legal Representative of the Company

III. OBJECTIVES, SCOPE OF BUSINESS AND OPERATIONS OF THE COMPANY

Article 4. Objectives of the Company

Article 5. Scope of Business and Operations of the Company

IV. CHARTER CAPITAL, SHARES AND FOUNDING SHAREHOLDERS

Article 6. Charter Capital, Shares and Founding Shareholders

Article 7. Share Certificates

Article 8. Other Securities Certificates

Article 9. Transfer of Shares

Article 10. Inheritance of Shares

Article 11. Recovery of Shares

V. ORGANIZATIONAL STRUCTURE, MANAGEMENT AND SUPERVISION

Article 12. Organizational Structure, Management and Supervision

VI. SHAREHOLDERS AND THE GENERAL MEETING OF SHAREHOLDERS

Article 13. Rights of Shareholders

Article 14. Obligations of Shareholders

Article 15. General Meeting of Shareholders

Article 16. Rights and Obligations of the General Meeting of Shareholders

Article 17. Authorization to Attend the General Meeting of Shareholders

Article 18. Changes to Rights

Article 19. Convening Meetings, Meeting Agenda and Notice of Invitation to the General Meeting of Shareholders

Article 20. Conditions for Holding the General Meeting of Shareholders

Article 21. Procedures for Conducting Meetings and Voting at the General Meeting of Shareholders

Article 22. Conditions for Adoption of Resolutions of the General Meeting of Shareholders

Article 23. Authority and Procedures for Obtaining Written Opinions of Shareholders for the Adoption of Resolutions of the General Meeting of Shareholders

Article 24. Resolutions and Minutes of Meetings of the General Meeting of Shareholders

Article 25. Request for Cancellation of Resolutions of the General Meeting of Shareholders

VII. BOARD OF DIRECTORS

Article 26. Nomination and Candidacy for Membership of the Board of Directors

Article 27. Composition and Term of Office of Members of the Board of Directors

Article 28. Rights and Obligations of the Board of Directors

Article 29. Remuneration, Bonuses and Other Benefits of Members of the Board of Directors

Article 30. Chairperson of the Board of Directors

Article 31. Meetings of the Board of Directors

Article 32. Committees under the Board of Directors

Article 33. Company Secretary / Person in Charge of Corporate Governance

VIII. GENERAL DIRECTOR AND OTHER EXECUTIVES

Article 34. Management Organization Structure

Article 35. Executives of the Company

Article 36. Appointment, Dismissal, Duties and Powers of the General Director

IX. BOARD OF SUPERVISORS

Article 37. Nomination and Candidacy for Membership of the Board of Supervisors (Supervisors)

Article 38. Composition of the Board of Supervisors

Article 39. Head of the Board of Supervisors

Article 40. Rights and Obligations of the Board of Supervisors

Article 41. Meetings of the Board of Supervisors

Article 42. Salaries, Remuneration, Bonuses and Other Benefits of Members of the Board of Supervisors

X. RESPONSIBILITIES OF MEMBERS OF THE BOARD OF DIRECTORS, MEMBERS OF THE BOARD OF SUPERVISORS, THE GENERAL DIRECTOR AND OTHER EXECUTIVES

Article 43. Duty of Honesty and Avoidance of Conflicts of Interest

Article 44. Liability for Damages and Compensation

XI. RIGHT TO INSPECT COMPANY BOOKS AND RECORDS

Article 45. Right to Inspect Books and Records

XII. EMPLOYEES AND TRADE UNION

Article 46. Employees and Trade Union

XIII. PROFIT DISTRIBUTION

Article 47. Profit Distribution

XIV. BANK ACCOUNTS, FINANCIAL YEAR AND ACCOUNTING SYSTEM

Article 48. Bank Accounts

Article 49. Financial Year

Article 50. Accounting System

XV. FINANCIAL STATEMENTS, ANNUAL REPORTS AND INFORMATION DISCLOSURE OBLIGATIONS

Article 51. Annual, Semi-Annual and Quarterly Financial Statements

Article 52. Annual Report

XVI. AUDIT OF THE COMPANY

Article 53. Audit

XVII. COMPANY SEAL

Article 54. Company Seal

XVIII. DISSOLUTION OF THE COMPANY

Article 55. Dissolution of the Company

Article 56. Extension of the Company's Operation Term

Article 57. Liquidation

XIX. INTERNAL DISPUTE RESOLUTION

Article 58. Internal Dispute Resolution

XX. AMENDMENTS AND SUPPLEMENTS TO THE CHARTER

Article 59. Charter of the Company

XXI. EFFECTIVE DATE

Article 60. Effective Date

PREAMBLE

This Charter was adopted pursuant to Resolution No. ... of the General Meeting of Shareholders dated 2026.

I. DEFINITIONS OF TERMS IN THE CHARTER

Article 1. Interpretation of Terms

In this Charter, the following terms shall have the meanings set out below:

a) *Charter Capital* means the total par value of shares that have been sold or subscribed for upon the establishment of the joint stock company and as prescribed in Article 6 of this Charter;

b) *Voting Capital* means share that entitles its holder to vote on matters falling within the decision-making authority of the General Meeting of Shareholders;

c) *Law on Enterprises* means the Law on Enterprises No. 59/2020/QH14 adopted by the National Assembly of the Socialist Republic of Vietnam on June 17, 2020 and the Law Amending and Supplementing a Number of Articles of the Law on Enterprises No. 76/2025/QH15 dated June 17, 2025;

d) *Law on Securities* means the Law on Securities No. 54/2019/QH14 adopted by the National Assembly of the Socialist Republic of Vietnam on November 26, 2019;

đ) *Vietnam* means the Socialist Republic of Vietnam;

e) *Date of Incorporation* means the date on which the Company was first issued its Enterprise Registration Certificate (Business Registration Certificate or equivalent legal documents);

g) *Enterprise Executive* means the General Director, Deputy General Director, Chief Accountant and other executives as prescribed in the Charter of the Company;

h) *Enterprise Manager* means a manager of the Company, including the Chairman of the Board of Directors, members of the Board of Directors and the Board of Management;

i) *Related Person* means an individual or organization as defined in Clause 46, Article 4 of the Law on Securities;

k) *Shareholder* means an individual or organization owning at least one share of the Company;

l) *Founding Shareholder* means a shareholder owning at least one common share and whose name appears in the list of founding shareholders of the joint stock company;

m) *Major Shareholder* means a shareholder as defined in Clause 18, Article 4 of the Law on Securities;

n) *Term of Operation* means the period during which the Company operates as specified in Article 2 of this Charter and any extension period approved by the General Meeting of Shareholders;

o) *Stock Exchange* means the Vietnam Stock Exchange and its subsidiaries.

2. References in this Charter to any legal provisions or documents shall include any amendments, supplements or replacement documents thereof.

3. Headings (Sections and Articles) in this Charter are included for convenience only and shall not affect the interpretation of the provisions of this Charter.

II. NAME, FORM, HEAD OFFICE, BRANCHES, REPRESENTATIVE OFFICES, BUSINESS LOCATIONS, TERM OF OPERATION AND LEGAL REPRESENTATIVE OF THE COMPANY

Article 2. Name, FORM, Head Office, Branches, Representative Offices, Business Locations and Term of Operation of the Company

1. Company Name

- Vietnamese name: MEDIPLANTEX NATIONAL PHARMACEUTICAL JOINT STOCK COMPANY
- Foreign language name: MEDIPLANTEX NATIONAL PHARMACEUTICAL JOINT STOCK COMPANY
- Abbreviated name: MEDIPLANTEX

2. The Company is a joint stock company with legal entity status in accordance with the applicable laws of Vietnam.

3. Registered Head Office:

- Address: 358 Giai Phong, Phuong Liet Ward, Hanoi City, Vietnam.
- Telephone: (+84) 24 3864 3368
- Fax: (+84) 24 3864 1584
- Email: mp@mediplantex.com
- Website: www.mediplantex.com

4. The Company may establish one member limited liability companies, branches, representative offices and business locations in order to achieve its business objectives, subject to resolutions of the Board of Directors and within the scope permitted by law.

5. Unless terminated prior to the time specified in Clause 2, Article 49 or extended pursuant to Article 50 of this Charter, the Company's term of operation shall be indefinite from the Date of Incorporation.

Article 3. Legal Representative of the Company

The Company shall have one (01) legal representative. The Chairman of the Board of Directors is the legal representative of the Company.

The legal representative of the Company is the individual who represents the Company in exercising rights and performing obligations arising from the Company's transactions; represents the Company as petitioner, plaintiff, defendant, or person with related rights and obligations before arbitration tribunals, courts and other competent authorities; and exercises other rights and obligations in accordance with law.

III. OBJECTIVES, SCOPE OF BUSINESS AND OPERATIONS OF THE COMPANY

Article 4. Objectives of the Company

1. Business lines and sectors of the Company

No.	Business Line	Code	Principal business line
1	Wholesale of agricultural and forestry raw materials (excluding wood, bamboo and rattan) and live animals	4620	
2	Wholesale of machinery, equipment and other machine parts <i>Including only: wholesale of medical machinery and equipment; trading in machinery and packaging equipment serving the production of pharmaceutical products, traditional medicines, cosmetics and nutritional products.</i>	4659	
3	Wholesale of other household products <i>Including only: (i) wholesale of medical instruments, perfumes, cosmetics and sanitary products; (ii) pharmaceutical trading; (iii) trading in pharmaceutical ingredients, medicinal herbs, essential oils, flavorings, excipients, chemicals and colorants used in pharmaceuticals, cosmetics, food products and industrial applications (subject to approval by competent state authorities where required).</i>	4649	
4	Warehousing and storage	5210	
5	Manufacture of pharmaceuticals, medicinal chemicals and botanical products	2100	X
6	Activities of general and specialized medical clinics and dental clinics <i>Including only: traditional medicine clinics (subject to approval by competent state authorities where required).</i>	8620	

7	Retail sale of pharmaceuticals, medical goods, cosmetics and toilet articles	4772	
8	Real estate business, land use rights owned, used or leased <i>Including only: leasing of houses, offices and warehouses; real estate business.</i>	6810	
9	Wholesale of food products <i>Details: Trading in functional foods and health supplements.</i>	4632	
10	Manufacture of other food products not elsewhere classified <i>Details: Production of functional foods and health supplements.</i>	1079	
11	Other business support service activities n.e.c. <i>Details:</i> <i>- Entrustment of import and export activities;</i> <i>- Import and export of goods (excluding goods prohibited or temporarily suspended from import/export).</i>	8299	
12	Growing of spice crops, medicinal plants and perennial aromatic plants	0128	
13	Scientific research and technological development in medical and pharmaceutical sciences <i>Scientific research services, technology transfer, consultancy, education and training in the medical and pharmaceutical fields (subject to approval by competent state authorities and only within the scope permitted by law).</i>	7213	
14	Renting and leasing of machinery, equipment and tangible goods without operator <i>Including only: leasing of industrial, commercial and scientific machinery and equipment (excluding machinery prohibited by law).</i>	7730	
15	Agents, brokers and auctioneers of goods <i>Details: Agency, purchase and sale, consignment of goods; investment brokerage and commercial brokerage services.</i>	4610	
16	Market research and public opinion polling	7320	

17	Organization of trade promotion activities	8230	
----	--	------	--

In addition, where necessary, the General Meeting of Shareholders may decide to amend or expand the Company's business lines and sectors in accordance with applicable laws.

2. Objectives of the Company: The Company shall continuously develop its manufacturing, trading and import-export activities relating to pharmaceuticals, medical equipment, healthcare products and other activities within its registered business lines, with the objectives of: (i) Maximizing profits for the Company's shareholders; (ii) Enhancing the value of the Company; (iii) Continuously improving the living standards, working conditions and income of employees; (iv) Fulfilling tax and other financial obligations to the State in accordance with applicable laws.

Article 5. Scope of Business and Operations of the Company

The Company is permitted to conduct business activities in accordance with the business lines and sectors specified in this Charter, which have been duly registered, any amendments thereto have been notified to the business registration authority, and such information has been published on the National Enterprise Registration Portal.

IV. CHARTER CAPITAL, SHARES AND FOUNDING SHAREHOLDERS

Article 6. Charter Capital, Shares and Founding Shareholders

1. The charter capital of the Company is VND 124,100,000,000 (One hundred twenty-four billion one hundred million Vietnamese Dong).

The total charter capital of the Company is divided into 12,410,000 shares with a par value of VND 10,000 per share.

2. The Company may change its charter capital upon approval by the General Meeting of Shareholders and in compliance with applicable laws.

3. All shares of the Company as of the date of adoption of this Charter are common shares. The rights and obligations of shareholders holding each class of shares are stipulated in Articles 13 and 14 of this Charter.

4. The Company may issue other classes of preference shares upon approval by the General Meeting of Shareholders and in accordance with applicable laws.

5. The names, addresses, number of shares and other information relating to the founding shareholders as prescribed by the Law on Enterprises are set out in Appendix 01 attached hereto. Such Appendix forms an integral part of this Charter.

Common shares shall first be offered to existing shareholders in proportion to their ownership of common shares in the Company, unless otherwise resolved by the General Meeting of Shareholders. Any shares not subscribed for by existing shareholders shall be disposed of as determined by the Board of Directors. The Board of Directors may allocate such shares to shareholders and other persons on terms no more favorable than those offered to existing shareholders, unless otherwise approved by the General Meeting of Shareholders.

6. The Company may repurchase shares issued by itself in accordance with the provisions of this Charter and applicable laws.

7. The Company may issue other types of securities in accordance with the law.

Article 7. Share Certificates

1. Shareholders of the Company shall be granted with share certificates which specify the number of shares and the type of shares they hold.

2. Share is a type of securities that certify the lawful rights and interests of the shareholders to their proportion of the issuer's capital. A share certificate shall contain all information stipulated in the Law on Enterprises.

3. Within 02 months from the submission of complete application for transferring ownership of shares in accordance with the Company's regulation, or such other period as may be stipulated in the issuance terms from the date full payment for subscribed shares is made pursuant to the Company's share issuance plan, the holders of the shares shall not be required to bear the cost of printing the share certificate.

4. In case a share certificate is lost or damaged, the shareholder shall be granted with a new share certificate by the Company on the shareholder's request. The shareholder's request shall include:

a) Information about the lost or damaged share certificate;

b) Declaration to take responsibility for any dispute that arises from the reissuance of the share certificate.

Article 8. Other securities certificates

Bond certificates and other securities certificates issued by the Company shall bear the signatures of the legal representatives and seal of the Company.

Article 9. Transfer of shares

1. All shares may be transferred freely unless otherwise stipulated in this Charter and law. Shares listed, registered on Stock Exchanges may be transferred in accordance with regulations on securities and the securities market.

2. Shares that are not fully paid for are not permitted to be transferred and shall not receive relevant rights such as right to receive dividends, right to receive additional shares issued to increase Charter capital from equity capital, right to buy new shares in share issuance and other benefits in accordance with law.

Article 10. Inheritance of Shares

1. In the event of the death of an individual shareholder, the heir designated under a will or determined in accordance with the law shall become a shareholder of the Company.

2. The Company shall not resolve disputes among legal heirs.

3. In the event that a deceased shareholder leaves no heir, the heir refuses the inheritance, or is disqualified from inheriting, the relevant shares shall be dealt with in accordance with the laws on inheritance and civil matters.

Article 11. Reclamation of shares

1. In case a shareholder fails to pay in full and on time for the amount payable for the subscribed shares, the Board of Directors shall send a notice to the shareholder to request for payment of such amount and bearing responsibility for the Company's financial obligations in correspondence with the total face value of the subscribed shares due to the failure to pay in full and on time for the subscribed shares.

2. The above-mentioned notice shall specify the new deadline for payment (at least 07 days from the date of sending the notice), place for payment and clearly state that in the event that the payment is not made as required, the shares which have not yet been fully paid for will be reclaimed.

3. The Board of Directors may reclaim the shares that are not paid in full and on time for if the requirements mentioned in the notice are not fulfilled.

4. Shares reclaimed are considered as authorized shares stipulated in Clause 3 Article 112 of the Law on Enterprises. The Board of Directors may directly or authorize a third party to sell or redistribute these shares under the conditions and methods that the Board of Directors consider appropriate.

5. The shareholder holding the reclaimed shares will no longer have shareholder status to these shares but still bear responsibility for the Company's financial obligations in correspondence with the total face value of the subscribed shares that arise at the time of reclamation in accordance with the decision of the Board of Directors from the date of reclamation to the date of payment. The Board of Directors has the full authority to enforce payment of the total value of these shares at the time of reclamation.

6. The reclamation notice shall be sent to the holder of reclaimed shares prior to the time of reclamation. The reclamation shall be still valid even in case of error or negligence in sending reclamation notice.

V. ORGANIZATIONAL STRUCTURE, MANAGEMENT AND SUPERVISION

Article 12. Organizational Structure, Management and Supervision

The organizational structure, management and supervision of the Company shall comprise:

1. The General Meeting of Shareholders;
2. The Board of Directors and the Board of Supervisors (the Company is organized and operated in accordance with the model prescribed in Point a, Clause 1, Article 137 of the Law on Enterprises);
3. The General Director.

VI. SHAREHOLDERS AND GENERAL MEETING OF SHAREHOLDERS

Article 13. Rights of shareholders

1. Common shareholders have the rights to:
 - a) Attend, express opinions in the General Meeting of Shareholders; exercise the right to vote directly or vote by proxy or another method stipulated in the Company's Charter and the law. Each ordinary share has one vote;
 - b) Receive dividends at the rate decided by the General Meeting of Shareholders;
 - c) Be given priority in subscribing for new shares in proportion to the number of common shares each shareholder holds in the Company;
 - d) Freely transfer shares that have been fully paid for in accordance with this Charter and applicable laws;
 - đ) Access, look up and extract information about names and addresses of shareholders in the list of shareholders who have voting rights; request amendment of incorrect information;
 - e) Access, look up and extract or copy the Company's Charter, minutes and resolutions of the General Meeting of Shareholders;
 - g) Receive part of the remaining assets in proportion to the number of shares they own in the Company when the Company is dissolved or goes bankrupt;
 - h) Request the Company to repurchase shares in the cases stipulated in law on Enterprises;
 - i) Be treated equally. Each share of the same type gives its holder equal rights, obligations and interests. If the Company has preference shares, rights and obligations associated with these

preference shares must be approved by the General Meeting of Shareholders and informed to shareholders;

k) Access to periodic and irregular information disclosed by the Company in accordance with the law;

l) Have their lawful rights and interests protected; request for the suspension, cancellation of resolutions and decisions of the General Meeting of Shareholders and the Board of Directors in accordance with the Law on Enterprises;

m) Other rights stipulated in law and the Company's Charter.

2. A shareholder or group of shareholders holding at least 05% of total common shares shall have the rights to:

a) Request the Board of Directors to convene the General Meeting of Shareholders in accordance with the Law on Enterprises;

b) Access, look up, extract the minutes, resolutions and decisions of the Board of Directors, half year and annual financial statements, reports of the Board of Supervisors, contracts and transactions which must be approved by the Board of Directors and other documents, except documents including the Company's trade secrets and business secrets;

c) Request the Board of Supervisors to inspect each particular issue relevant to the management and operation of the Company whenever necessary. The request must be made in writing and contain: full names, mailing addresses, nationalities, identity card numbers of individual shareholders or names, business codes or numbers of legal documents and head office addresses of institutional shareholders; the number of shares and date of share registration of each shareholder, the total number of shares of the group of shareholders and the percentage of ownership; the issues that need to be inspected and purposes of the inspection;

d) Propose to add issues to the agenda of the General Meeting of Shareholders. The proposal must be made in writing and sent to the Company at least 03 business days prior to the meeting day. The proposal shall specify the shareholder's name, the number of shares of each type held by the shareholder and the issues proposed to add to the agenda

đ) Other rights stipulated in law and the Company's Charter.

3. A shareholder or group of shareholders holding at least 10% of total common shares shall have the rights to nominate candidates for the Board of Directors and the Board of Supervisors, candidates shall be nominated as follows:

a) The group of shareholders nominating candidates for the Board of Directors and the Board of Supervisors must inform the shareholders attending the General Meeting of Shareholders about the group of shareholders before the opening of the General Meeting of Shareholders;

b) Based on the number of members of the Board of Directors and the Board of Supervisors, the shareholder or the group of shareholders stipulated in this Clause may nominate one or more candidates for the Board of Directors and the Board of Supervisors according to the decision of the General Meeting of Shareholders. In case the number of candidates nominated by the shareholder or the group of shareholders is smaller than the number of candidates they have the rights to nominate according to the decision of the General Meeting of Shareholders, the remaining candidates shall be nominated by Board of Directors, the Board of Supervisors and other shareholders.

Article 14. Obligations of shareholders

Common shareholders have the obligations to:

1. Pay in full and on time for the subscribed shares.
2. Not withdraw the capital contributed as common shares from the Company in any form, unless these shares are repurchased by the Company or other persons. Otherwise, the shareholder and persons with related interests in the Company shall be jointly responsible for the debts and other liabilities of the Company within the value of shares withdrawn and the damage due to the withdrawal.
3. Comply with the Company's Charter and the Internal Regulations on Corporate Governance.
4. Comply with resolutions and decisions of the General Meeting of Shareholders and the Board of Directors.
5. Keep information provided by the Company in confidence in accordance with the Company's Charter and law; only use the provided information for exercising and protecting their lawful rights and interests; do not copy, send the information provided by the Company to the third parties.
6. Attend the General Meeting of Shareholders and exercise the voting right as follows:
 - a) Attend and vote in person at the meeting;
 - b) Authorize other organizations and individuals to attend and vote by proxy at the meeting;
 - c) Attend and vote in online meeting; cast electronic votes or in other electronic forms;
 - d) Send votes to the meetings by mail, fax or email;
 - đ) Send votes using other means stipulated in the Company's Charter.
7. Take personal responsibility when committing any of the following acts in the name of the Company:
 - a) Violating the law;

b) Conducting business and other transactions for personal benefit or the benefit of other organizations and individuals;

c) Paying undue debts when the Company is likely to be in financial danger.

8. Fulfilling other obligations stipulated in applicable law.

Article 15. General Meeting of Shareholders

1. The General Meeting of Shareholders consists of all shareholders who have voting rights and is the highest decision-making body of the Company. The General Meeting of Shareholders shall be held annually and within four (04) months from the end of the fiscal year. Unless otherwise stipulated in the Company's Charter, the time of holding the annual General Meeting of Shareholders may be extended by Board of Directors but not exceeding 06 months from the end of the fiscal year. Extraordinary General Meeting of Shareholders may be held besides annual General Meeting of Shareholders. The place of holding General Meeting of Shareholders is where the chair of the meeting attends and must be in the territory of Vietnam.

2. The Board of Directors shall convene the annual General Meeting of Shareholders and choose an appropriate venue. The annual General Meeting of Shareholders shall make decisions on the issues stipulated in law and the Company's Charter, especially the audited annual financial statement. In case the audited annual financial statement of the company contains a qualified opinion, adverse opinion or disclaimer of opinion, the Company shall invite the representative of the accredited audit organization auditing the Company's financial statement to attend the annual General Meeting of Shareholders. The invited representative of the audit organization has the responsibility for attending the annual General Meeting of Shareholders.

3. The Board of Directors shall convene an extraordinary General Meeting of Shareholders in the following cases:

a) The Board of Directors considers that it is necessary to do so in the Company's interests.

b) The number of members of the Board of Directors or the Board of Supervisors is less than the minimum number required by law; or the number of members of the Board of Directors has been reduced by more than one-third (1/3) compared to the number prescribed in the Company's Charter.

c) A shareholder or group of shareholders stipulated in Clause 2 Article 115 of Law on Enterprises request the convening of the General Meeting of Shareholders; the request shall be in writing, clearly state the reasons thereof and the purposes of the meeting, and be signed by all related shareholders, or the request may be made in several counterparts, which collectively contain the signatures of all relevant shareholders;

d) As requested by the Board of Supervisors;

đ) Other cases stipulated in law and this Charter.

4. Convening the extraordinary General Meeting of Shareholders

- a) The Board of Directors shall convene the General Meeting of Shareholders within 30 days from the date on which the number of members of the Board of Directors, independent directors or members of the Board of Supervisors does not satisfy the provision stipulated in Point b Clause 3 of this Article, or from the date of receipt of the request stated in Point c and Point d Clause 3 of this Article;
- b) Where the Board of Directors fails to convene the General Meeting of Shareholders as stipulated in Point a Clause 4 of this Article, the Board of Supervisors shall convene the General Meeting of Shareholders instead of the Board of Directors within the next 30 days as stipulated in Clause 3 Article 140 of the Law on Enterprises;
- c) Where the Board of Supervisors fails to convene the General Meeting of Shareholders as stipulated in Point b Clause 4 of this Article, a shareholder or a group of shareholders stipulated in Point c Clause 3 of this Article is entitled to request the Company's representatives to convene the General Meeting of Shareholders in accordance with the Law on Enterprises;
- d) The procedure of conducting the General Meeting of Shareholders shall be in accordance with Clause 5 Article 140 of the Law on Enterprises.

Article 16. Rights and duties of the General Meeting of Shareholders

1. The General Meeting of Shareholders has following rights and duties:

- a) Approving the Company's development orientations;
- b) Making decisions on the types of shares and the number of shares of each type authorized to be offered; annual dividend rate for each type of shares;
- c) Election, dismissal and removal members of the Board of Directors and members of the Board of Supervisors;
- d) Making decisions on investment or sale of assets of the Company with the value equal to or more than 35% of the value of the total assets recorded in the Company's latest financial statements;
- đ) Making decisions on the amendments and supplements of the Company's Charter;
- e) Approving audited annual financial statements;
- g) Making decisions on the repurchase of over 10% of issued shares of each type;
- h) Inspecting and dealing with breaches committed by members of the Board of Directors and the Board of Supervisors who cause loss and damage to the Company and its shareholders;

- i) Making decisions on re-organization and dissolution of the Company;
- k) Making decisions on the budget or total remunerations, bonuses and other benefits of the Board of Directors and the Board of Supervisors;
- l) Approving the Internal Corporate Governance Regulations, the Charter of Operation of the Board of Directors, and the Charter of Operation of the Board of Supervisors;
- m) Approving the list of accredited audit organizations; allowing accredited audit organizations to audit the Company's operation; dismissing accredited auditors if necessary;
- n) Other rights and duties stipulated in law.

2. The General Meeting of Shareholders shall discuss and approve the following issues:

- a) The Company's annual business plans;
- b) The audited annual financial statements;
- c) The report of the Board of Directors on corporate governance and performance of the Board of Directors and each Board member;
- d) The report of the Board of Supervisors on the Company's business performance, performance of the Board of Directors, the General Director;
- đ) The self-assessment report on performance of the Board of Supervisors and its members;
- e) Dividend rate for each type of shares;
- g) The number of members of the Board of Directors and the Board of Supervisors;
- h) Election, dismissal and removal of members of the Board of Directors and the Board of Supervisors;
- i) Decisions on the budget or total remunerations, bonuses and other benefits of the Board of Directors and the Board of Supervisors;
- k) Approval of the list of accredited audit organizations; allowing accredited audit organizations to audit the Company's operation; dismissing accredited auditors if necessary;
- l) Amendments and supplements of the Company's Charter;
- m) The types of shares and the number of additional shares of each type authorized to be issued and transfer of shares by founders within the first 03 years after the establishment date;
- n) Division, splitting, consolidation, merger or conversion of the Company;

- o) Re-organization and dissolution (liquidation) of the Company and appointment of the liquidator;
- p) Making decisions on investment or sale of assets of the Company with the value equal to or more than 35% of the value of the total assets recorded in the Company's latest financial statements;
- q) Repurchase of over 10% of issued shares of each type;
- r) Entering into the contracts and transactions with the value equal to or more than 35% of the Company's total assets recorded in the latest financial statements with the entities stipulated in Clause 1 Article 167 of the Law on Enterprises;
- s) To approve transactions as prescribed in Clause 4, Article 293 of Decree No. 155/2020/ND-CP dated 31 December 2020 of the Government detailing the implementation of a number of articles of the Law on Securities, amended by Clause 84, Article 1 of Decree No. 245/2025/ND-CP;
- t) Approval of the Internal Regulations on Corporate Governance, Regulations on operation of the Board of Directors and the Board of Supervisors;
- u) Other issues stipulated in law and this Charter.

3. All resolutions and issues included in the meeting agenda shall be discussed and voted on the General Meeting of Shareholders.

4. Shareholders shall not be entitled to vote in the following cases:

- a) Approval of contracts specified in Clause 2 Article 16 where such shareholder or the shareholder's related person is a party to the contract;
- b) Repurchase of shares held by such shareholder or the shareholder's related person, except where the share repurchase is conducted on a pro rata basis applicable to all shareholders or is carried out through order matching or a public tender offer on a stock exchange.

Article 17. Authorized representatives attending in the General Meeting of Shareholders

1. A shareholder, an authorized representative of a shareholder being an organization may attend or authorize another individual or organization to attend the General Meeting of Shareholders or using other methods stipulated in Clause 3 Article 144 of the Law on Enterprises.

2. The authorization stipulated in Clause 1 of this Article shall be made in writing. Letter of authorization must be in accordance with civil law and regulations and shall contain the name of the authorizing shareholder, the authorized individual or organization, the number of shares authorized, content, scope and duration of authorization, signatures of the authorizing party and the authorized party.

The authorized individual or organization shall submit the letter of authorization when registering for attending the meeting. In case an authorized party authorizes another party to attend the meeting, the letter of authorization written by the shareholder or authorized representative of the institutional shareholder shall be presented (in case it has not been registered with the Company yet).

3. Votes casted by the authorized representatives within the scope of authorization shall be effective unless:

- a) The authorizing person is dead, has a limitation on civil act capacity or loses civil act capacity;
- b) The authorizing person cancels the authorization;
- c) The authorizing person cancels the authority of the authorized person;

This Clause does not apply for the cases in which the Company receives a notification of any of the aforementioned events prior the opening of the General Meeting of Shareholders or before the General Meeting of Shareholders is re-convened.

Article 18. Change of rights

1. The change or cancellation of special rights attached to a type of preference shares shall take effect when such change or cancellation shall be approved by shareholders holding at least 65% of the number of common shares of all shareholders attending the General Meeting of Shareholders. The General Meeting of Shareholders's resolution that contains adverse changes in rights and obligations of shareholders holding preference shares shall be approved only when such changes are approved by shareholders holding at least 75% of the number of the same type of preference shares of all shareholders attending the General Meeting of Shareholders or by shareholders holding at least 75% of the number of the same type of preference shares in case the resolution of General Meeting of Shareholders is passed by collecting written opinions.

2. The organization of meeting of shareholders holding a type of preference shares to approve the aforementioned change of rights shall be valid only when there are at least 02 shareholders (or their authorized representatives) holding at least one third (1/3) of the face value of the issued shares of that type. Where the number of attendees as required above is insufficient, the meeting shall be re-organized within 30 days after that and the shareholders holding that type of shares (regardless of the number of attendees and the number of shares) who are present in person at the meeting or through their authorized representatives shall be deemed to constitute the quorum. At the meeting of shareholders holding the preference shares mentioned above, shareholders holding that type of shares being present in person or through their representatives may request a secret ballot. Each share of the same type shall have the equal voting rights at the meeting mentioned above.

3. The procedure for conducting such a separate meeting shall be implemented in the same way as stipulated in Articles 20, 21 and 22 of this Charter.

4. Unless otherwise stipulated in the terms of shares issuance, special rights attached to the different types of preference shares in respect to some or all issues related to the distribution of profit or assets of the Company shall not be changed when the Company issues additional shares of the same type.

Article 19. Convening the General Meeting of Shareholders, agenda and notice of the General Meeting of Shareholders

1. The Board of Directors shall convene annual and extraordinary General Meeting of Shareholders. The Board of Directors shall convene extraordinary General Meeting of Shareholders in the cases stipulated in Clause 3 Article 14 of this Charter.

2. The convenor of a General Meeting of Shareholders must carry out the following duties:

a) Make a list of shareholders who are eligible to attend and vote at General Meeting of Shareholders. This list shall be made no more than 10 days before the date of sending invitation letter. The Company shall disclose the information of making this list at least 20 days before the last registration date;

b) Prepare the meeting agenda and contents;

c) Prepare meeting documents;

d) Draft the resolution of the General Meeting of Shareholders based on the meeting contents;

đ) Determine the time and venue of the meeting;

e) Make an announcement on the organization of General Meeting of Shareholders and send invitations to all shareholders who are eligible to attend the General Meeting of Shareholders;

g) Perform other tasks related to the General Meeting.

3. The invitations to the General Meeting of Shareholders shall be sent to all shareholders by means to ensure reaching shareholders' addresses and at the same time shall be published on the website of the Company, State Securities Commission of Vietnam and the Stock Exchange where the Company's shares are listed or registered. The convenor of the General Meeting of Shareholders shall send invitations to all shareholders on the list of shareholders who are eligible to attend the General Meeting of Shareholders at least 21 days before the date of the General Meeting of Shareholders. The agenda of the General Meeting of Shareholders and documents relevant to the issues which will be voted on at the General Meeting of Shareholders shall be sent to shareholders or/and published on the Company's website. In case these documents are not enclosed with the invitations, the invitations must specify website address in order to enable shareholders to access such documents, including:

a) The meeting agenda and documents which will be used at the meeting;

b) The list and profiles of all candidates for members of the Board of Directors and the Board of Supervisors in case there is an election at the meeting;

c) Ballot paper;

d) Draft resolution on each issue mentioned in the meeting agenda.

4. A shareholder or group of shareholders stipulated in Clause 2 Article 12 of this Charter has the rights to propose other issues to be included in the agenda of the General Meeting of Shareholders. The proposal must be made in writing and sent to the Company at least 03 business days before the date of the General Meeting of Shareholders. The proposal shall specify tshareholders's name, the number of shares of each type held by the shareholders and the issues proposed to be included in the agenda.

5. The convenor of the proposed has the rights to reject the proposal mentioned in Clause 4 of this Article in any of the following cases:

a) The proposal sent does not comply with Clause 4 of this Article;

b) At the time of the proposal, a shareholder or a group of shareholders does not hold at least 5% of total common shares as stipulated in Clause 2 Article 13 of this Charter;

c) The proposed issues are outside the authority of the General Meeting of Shareholders for approval;

d) Other cases stipulated in law and this Charter.

6. The convenor of the General Meeting of Shareholders shall accept and include the proposed issues mentioned in Clause 4 of this Article to the intended meeting agenda, except the cases stipulated in Clause 5 of this Article; the proposed issues shall be officially included in the meeting agenda if they are approved by the General Meeting of Shareholders.

Article 20. Conditions for conducting the General Meeting of Shareholders

1. The General Meeting of Shareholders shall be conducted when shareholders attending the meeting represent over 50% of the total votes.

2. In case the General Meeting of Shareholders has an insufficient number of shareholders attending the meeting as stipulated in Clause 1 of this Article, invitations to the second meeting shall be sent within 30 days from the intended date of the first meeting. The second General Meeting of Shareholders shall be conducted when shareholders attending the meeting represent at least 33% of the total votes.

3. In case the second meeting has an insufficient the number of shareholders attending the meeting as stipulated in Clause 2 of this Article, invitations to the third meeting shall be sent within 20 days

from the intended date of the second meeting. The third General Meeting of Shareholders shall be conducted regardless of the number of shareholders attending the meeting.

Article 21. Procedures for conducting and voting at the General Meeting of Shareholders

1. Before the opening of the General Meeting of Shareholders, the Company shall conduct the procedures for shareholder registration until all shareholders having the rights to attend the meeting and being present at the meeting are registered in the following order:

a) When conducting shareholder registration, the Company shall issue to each shareholder or authorized representative with voting rights a ballot paper which specifies a registration number, full name of the shareholder, name of the authorized representative and the number of votes of the shareholder. The General Meeting of Shareholders shall discuss and vote on each issue on the agenda. Voting shall be conducted by voting for, voting against and abstentions. Votes for shall be collected first then votes against and finally votes for and against shall be counted to make the decision. The voting result shall be announced by the Chairman right before the end of the meeting. The General Meeting of Shareholders shall elect the people who are responsible for counting votes or supervising the vote counting at the request of the Chairman. The number of members of the Vote Counting Committee shall be decided by the General Meeting of Shareholders at the request of the Chairman;

b) Shareholders and authorized representatives who arrive after the opening of the meeting still have the rights to register immediately then attend and vote at the meeting. The Chairman does not have responsibility to suspend the meeting and the validity of the previous voted contents shall remain unchanged.

2. Election of the Chairman, secretary and Vote Counting Committee:

a) The Chairman of the Board of Directors shall be the Chairman or authorize another member of the Board of Directors to be the Chairman of the General Meeting of Shareholders convened by the Board of Directors. If the Chairman of the Board of Directors is absent or temporarily unable to work, the remaining members of the Board of Directors shall elect one of them as the Chairman under the majority rule. In case a Chairman of the meeting cannot be elected, the Chairman of Board of Supervisors shall arrange for General Meeting of Shareholders to elect the Chairman of the meeting among the attendees and the person with the highest number of votes shall be the Chairman of the meeting;

b) Except for the case stipulated in Point a of this Clause, the person who signs the decision to convene the General Meeting of Shareholders arrange for the General Meeting of Shareholders to elect the Chairman of the meeting and the person with the highest number of votes shall be the Chairman of the meeting;

c) The Chairman shall appoint one or some people as secretaries of the meeting;

d) The General Meeting of Shareholders shall elect one or some people to the Vote Counting Committee at the request of the Chairman.

3. The agenda and contents of the meetings shall be approved by the General Meeting of Shareholders in the opening session. The agenda shall specify contents and the timeline for each content.

4. The Chairman has the rights to implement necessary and reasonable measures to ensure that the conduct of the General Meeting of Shareholders is in a valid and orderly manner, follows the approved agenda and reflects the expectation of the majority of attendees.

a) Arrange seats at the meeting venue;

b) Ensure safety for all people who are present at the meeting venues;

c) Create favorable conditions for shareholders to attend (or continue to attend) the General Meeting of Shareholders. The convenor of the General Meeting of Shareholders has the full authority to change the aforementioned measures and implement all necessary measures. The measures implemented may be the issuance of entry cards or other form of selection.

5. The General Meeting of Shareholders shall discuss and vote on each issue in the agenda. Voting shall be conducted by voting for, voting against and abstentions. The voting result shall be announced right before the end of the meeting.

6. Shareholders and authorized representatives who arrive after the opening of the meeting are still permitted to register and have the rights to vote at the meeting after registration. The validity of the previous voted contents shall remain unchanged.

7. The convenor of the General Meeting of Shareholders or the Chairman of the meeting has the rights to:

a) Request all attendees to be checked or take other legal and reasonable security measures;

b) Request the authority to maintain the order during the meeting; expel those who do not comply with the Chairman, intentionally disrupt the order, obstruct the normal progress of the meeting or do not comply with the requirements for security check for General Meeting of Shareholders.

8. The Chairman is entitled to delay the meeting, which has a sufficient number of shareholders registering for attending, no more than 03 days from the intended meeting date and the General Meeting of Shareholders may only be delayed or relocated in the following cases:

a) The meeting venue does not have adequate convenient seats for all attendees;

b) The media at the meeting is not guaranteed for shareholders attending the meeting to discuss and vote;

c) There is an attendee who obstruct, disrupt the order, prevent the meeting from being conducted in a fair and lawful manner.

9. In case the Chairman delay or suspend the General Meeting of Shareholders which contravenes Clause 8 of this Article, the General Meeting of Shareholders shall elect another person among the attendees to replace the Chairman of the meeting for presiding over the meeting until the end; all resolutions passed at that meeting shall be effective.

10. In case the Company holds the General Meeting of Shareholders through an online meeting, the Company are responsible for ensuring that shareholders are able to attend, cast vote through electronic voting or by using another electronic method in accordance with Article 144 of the Law on Enterprises and Clause 3 Article 273 of Decree No. 155/ND-CP dated December 31, 2020 elaborating a number of articles of Securities Law.

Article 22. Conditions for passing resolutions of the General Meeting of Shareholders

1. Resolutions on the following issues shall be passed if they are approved by shareholders representing at least 65% of the total votes of all shareholders attending the meeting, except for the cases stipulated in Clauses 3, 4 and 6 Article 148 of the Corporate:

- a) Types of shares and the number of shares of each type;
- b) Changes of lines of business and business sector;
- c) Changes of the Company's organizational structure;
- d) Investment projects or sale of assets with the value equal to or more than 35% of the value of the total assets recorded in the Company's latest financial statements, unless another ratio or value is stipulated in the Company's Charter;
- đ) Re-organization, dissolution of the Company;

2. Resolutions shall be passed if they are approved by shareholders owning more than [50%] of the total votes of all shareholders attending the meeting, except for the cases stipulated in Clause 1 of this Article and Clauses 3, 4, 6 Article 148 of the Law on Enterprises.

3. Resolutions of the General Meeting of Shareholders that are passed with 100% of the total voting shares shall be lawful and effective even if the order, procedures for convening the meeting and passing the resolutions are not conformable with the Law on Enterprises and the Company's Charter.

Article 23. Authority and procedures for collection of written opinions of shareholders to pass resolutions of the General Meeting of Shareholders

The authority and procedures for collection of written opinions to pass resolutions of the General Meeting of Shareholders:

1. The Board of Directors is entitled to collect written opinions of shareholders to pass resolutions of the General Meeting of Shareholders when it is deemed necessary for the Company's interests, except for the cases stipulated in Clause 2 Article 147 of the Law on Enterprises.

2. The Board of Directors shall prepare and send a written opinion form, a draft of resolutions of the General Meeting of Shareholders, documents explaining the draft of resolutions to all shareholders with voting rights at least 10 days prior to the deadline for receiving written opinion forms in accordance with Clause 3 Article 18 of this Charter.

3. The written opinion form shall contain the following information:

- a) The Company's name, head office address, business code;
- b) Purposes of collecting written opinions;
- c) Full name, mailing address, nationality, identity card numbers of individual shareholders; names, business codes or numbers of legal documents and head office addresses of institutional shareholders; or full name, mailing address, nationality, identity card numbers of the representatives of institutional shareholders; the number of shares of each type and the number of votes of shareholders;
- d) The issues needed to obtain opinions in order to pass the resolutions;
- đ) Voting options for each issue, including approving, disapproving and no opinion;
- e) Deadline for returning completed written opinions forms to the Company;
- g) Full name and signature of the Chairman of the Board of Directors.

4. Shareholders may send their completed written opinion forms to the Company by mail, fax or email as follows:

- a) The completed written opinion form sent by mail shall bear the signature of the shareholder who is an individual or the signature of the authorized representative or legal representative of the shareholder that is an organization. The written opinion form shall be returned to the Company in a sealed envelope and no one shall be permitted to open the envelope prior to the vote counting;
- b) The opinion form sent by fax or email must be kept confidential prior to the vote counting;
- c) The opinion forms that are returned to the Company after the deadline written therein or opened (for those sent by mail) or revealed (for those sent by fax or email) shall be invalid. The opinion form that is not returned to the Company shall be considered not voting.

5. The Board of Directors shall count the votes and prepare the minute of vote counting in the presence of the Board of Supervisors or shareholders not holding managerial positions in the Company. The minute of vote counting shall contain the following information:

- a) The Company's name, head office address, business code;
- b) Purposes of collecting written opinions and the issues needed to obtain opinions in order to pass the resolutions;
- c) The number of shareholders and the total number of votes being cast, classifying the total number of votes into the number of valid and invalid votes, the method of sending votes and the appendix as a list of shareholders who cast their votes;
- d) The total number of votes for, votes against and abstentions on each issue;
- đ) The issues are passed and ratio of votes for;
- e) Full name and signature of the Chairman of the Board of Directors, the person counting votes and the person supervising vote counting.

The members of the Board of Directors, the person counting votes and the person supervising vote counting shall be jointly responsible for the truthfulness and accuracy of the minute of vote counting and any damage caused by the resolutions that are passed because of an untruthful and inaccurate vote counting.

- 6. The minute of vote counting and resolutions shall be sent to shareholders within 15 days from the date of completion of vote counting. The sending of the minute of vote counting and resolutions may be replaced by publishing those documents on the Company's website within 24 hours from the completion of vote counting.
- 7. The completed written opinion forms, the minute of vote counting, the resolutions which are passed and the related documents enclosed with the written opinion forms must be archived at the Company's head office.
- 8. The resolutions passed by the form of collecting written opinion of shareholders must be approved by shareholders owning more than 50% of the total votes of all shareholders with voting rights [or another specific ratio stipulated in the Company's Charter] and has the same value as those passed at the General Meeting of Shareholders.

Article 24. Resolutions, Minutes of the General Meeting of Shareholders

- 1. All General Meeting of Shareholders shall be recorded in written minutes or audio in other electronic forms. The minutes must be in Vietnamese and may also be in foreign languages with the following contents:
 - a) The Company's name, head office address, business code;
 - b) Time and location of the General Meeting of Shareholders;
 - c) Agenda and contents of the meeting;

- d) Full names of the Chairman and secretaries of the meeting;
 - đ) Summary of the happenings of the meeting and opinions expressed at the meeting on each issue on the meeting agenda;
 - e) The number of shareholders attending the meeting and their votes; the appendix as a list of shareholders registering for the meeting and representatives of shareholders attending the meeting with their number of shares and votes;
 - g) The total number of votes on each issue, the voting method, the number of valid and invalid votes, votes for, votes against and abstentions; corresponding ratios of these votes to the total number of votes of shareholders attending the meeting;
 - h) The issues are passed and ratio of votes for;
 - i) Full name and signatures of the Chairman and secretaries of the meeting. In case the Chairman, the secretary refuse to sign the minute, the minute is still effective if it bears the signatures of all other members of the Board of Directors attending the meeting and has all information stipulated in this Clause. The minute shall specify that the Chairman, secretary refuse to sign it.
2. The minute of General Meeting of Shareholders shall be completed and passed before the meeting ends. The Chairman and Secretaries or other persons who sign the minute shall be jointly responsible for its truthfulness and accuracy.
3. The minutes in Vietnamese and foreign languages have the same legal effect. In case of discrepancies between the minute in Vietnamese and the minute in foreign language, the former shall apply.
4. The resolutions, minutes of the General Meeting of Shareholders, appendix as a list of shareholders registering for the meeting with their signatures, letter of authorization for attending the meeting, all documents enclosed to the minutes (if any) and relevant documents enclosed to the meeting invitation shall be disclosed in accordance with regulations on information disclosure on the securities market and archived at the Company's head office.

Article 25. Request for cancellation of resolutions of the General Meeting of Shareholders

Within 90 days from the date of receipt of the resolutions or minutes of the General Meeting of Shareholders or the minutes of vote counting of collecting written opinion of shareholders, a shareholder or a group of shareholders stipulated in Clause 2 Article 115 of the Law on Enterprises is entitled to request the court or arbitrator to consider and cancel all or part of the resolutions of the General Meeting of Shareholders in the following cases:

1. The order and procedures for convening the meeting and making decision of the General Meeting of Shareholders seriously violate the Law on Enterprises and the Company's Charter, except the cases stipulated in Clause 3 Article 21 of this Charter.

2. The contents of the resolutions violate laws and regulations or this Charter.

VII. THE BOARD OF DIRECTORS

Article 26. Nomination and candidacy of members of the Board of Directors

1. If the candidates for the Board of Directors have been identified, the Company shall publish information about these candidates on the Company's website at least 10 days before the date of the General Meeting of Shareholders for shareholders reference before voting. Board of Directors candidates shall make a written declaration of the truthfulness and accuracy of their disclosed personal information and commit to perform their duties in an honest and prudent manner and for the best interests of the Company if they are elected to members of the Board of Directors. Information about Board of Directors candidates disclosed shall includes:

- a) Full name, date of birth;
- b) Qualifications;
- c) Work experience;
- d) Other managerial positions (including positions in the Board of Directors of other companies);
- đ) Interests relevant to the Company and the Company's related parties;
- e) Other information (if any) stipulated in the Company's Charter;

2. A shareholder or a group of shareholders owning at least 10% of the total common shares or a smaller ratio stipulated in the Company's Charter has a right to nominate candidates as members of the Board of Directors. A shareholder or group of shareholders holding from ten percent (10%) to less than twenty percent (20%) of the total voting shares shall be entitled to nominate one (01) candidate; from twenty percent (20%) to less than thirty percent (30%), up to two (02) candidates; from thirty percent (30%) to less than forty percent (40%), up to three (03) candidates; from forty percent (40%) to less than fifty percent (50%), up to four (04) candidates; from fifty percent (50%) to less than sixty percent (60%), up to five (05) candidates; from sixty percent (60%) to less than seventy percent (70%), up to six (06) candidates; from seventy percent (70%) to eighty percent (80%), up to seven (07) candidates; and from eighty percent (80%) to less than ninety percent (90%), up to eight (08) candidates.

3. In case the number of candidates nominated by the Board of Directors is insufficient as required in Clause 5 Article 115 of the Law on Enterprises, the incumbent Board of Directors shall nominate additional candidates or hold a nomination in accordance with the Company's Charter, the Internal Regulations on Corporate Governance and the Board Charter. The nomination of candidates to Board of Directors by the incumbent Board of Directors must be clearly announced before shareholders vote for members of the Board of Directors in accordance with the law and other regulations.

4. Members of the Board of Directors must satisfy the criteria and conditions prescribed in Clause 1 and Clause 2 Article 155 of the Enterprise Law and the Company's Charter. A member of the Board of Directors of a public company may concurrently serve as a member of the Board of Directors, a member of the Members' Council, or the Chairman of a company in no more than 05 other companies.

Article 27. Composition and term of the Board of Directors

1. The Board of Directors has 05 members;

2. The term of office of a member of the Board of Directors shall not exceed 05 years and members of Board of Directors may be re-elected with no term limit. An individual may only be elected to an independent member of Board of Directors of a company for no more than 02 consecutive terms. In case the terms of office of all members of the Board of Directors end at the same time, they shall still be members of the Board of Directors until new members are elected and take over the works of Board of Directors.

3. Composition of the Board of Directors:

The composition of the Board of Directors of a public company must include at least 01 non-executive member. The Company shall, to the greatest extent possible, limit the appointment of members of the Board of Directors who concurrently hold executive positions within the Company in order to ensure the independence of the Board of Directors. The total number of independent members of the Board of Directors must include at least 01 independent member.

4. A member of the Board of Directors loses his/her status as member of the Board of Directors when he/she is dismissed, removed or replaced by the General Meeting of Shareholders as stipulated in Article 160 of the Law on Enterprises.

5. Information about appointment of members of the Board of Directors shall be disclosed in accordance with regulations on information disclosure on the securities market.

6. Members of the Board of Directors are not necessarily shareholders of the Company;

Article 28. Rights and duties of the Board of Directors

1. The Board of Directors is the governing body of the Company and has the full authority to make decisions, exercise rights and obligations of the Company on behalf of the Company, except for the rights and duties under the authority of the General Meeting of Shareholders.

2. Rights and duties of the Board of Directors shall be stipulated in law, the Company's Charter and by the General Meeting of Shareholders. To be specific:

a) Deciding the strategy, medium-term development plans and annual business plans of the Company;

- b) Proposing types of shares and the total number of authorized shares of each type;
- c) Deciding to sell the unsold shares within the number of authorized shares of each type; deciding to raise additional capital in other forms;
- d) Deciding the selling prices of shares and bonds of the Company;
- đ) Deciding to repurchase shares in accordance with Clause 1 and Clause 2 Article 133 of the Law on Enterprises;
- e) Deciding the investment plans and investment projects within the authority and limits in accordance with the law and other regulations;
- g) Deciding the solutions for market development, marketing and technology;
- h) Approving the contracts for purchase, sale, borrowing, lending and other contracts and transactions with the value equal to or more than 35% of the value of the total assets recorded in the Company's latest financial statement, contracts and transactions within the authority of the General Meeting of Shareholders in accordance with Point d Clause 2 Article 138, Clause 1 and Clause 3 Article 167 of the Law on Enterprises;
- i) Electing, dismissing and removing the Chairman of the Board of Directors; appointing, dismissing, signing and terminating contracts with the General Director and other key managers as stipulated in the Company's Charter; deciding salaries, remunerations, bonuses and other benefits of these managers; appointing authorized representatives to the Board of Directors or attend General Meeting of Shareholders of other companies, deciding the remunerations and other benefits of the authorized representatives;
- k) Supervising and directing the day-to-day business management of the General Director and other managers;
- l) Deciding the organizational structure, internal management regulations of the Company, deciding to establish subsidiary, branches, representative offices, capital contribution and purchase of shares of other enterprises;
- m) Approving the agenda and documents of the General Meeting of Shareholders; convening the General Meeting of Shareholders or collecting opinions for the General Meeting of Shareholders to pass its resolutions;
- n) Submitting the audited annual financial statements to the General Meeting of Shareholders;
- o) Proposing dividend rate; deciding the time and procedures for dividends payment or dealing with losses incurred during business operation;
- p) Proposing re-organization, dissolution of the Company; requesting bankruptcy of the Company;

q) Deciding to promulgate the Board Charter and the Internal Regulations on Corporate Governance after they are passed by the General Meeting of Shareholders; deciding to promulgate the Charter of the Audit Committee which is a subcommittee of the Board of Directors, regulations on information disclosure;

s) Other rights and duties stipulated in the Law on Enterprises, the Securities Law, other regulations and the Company's Charter.

3. The Board of Directors shall submit the reports on its performance to the General Meeting of Shareholders in accordance with Article 280 of Decree No. 155/2020/ND-CP dated December 31, 2020 elaborating a number of Articles of the Securities Law.

4. Each independent member of the Board of Directors shall prepare an assessment report on the activities of the Board of Directors

Article 29. Remunerations, bonuses and other benefits of members of the Board of Directors

1. The company is entitled to pay remunerations and bonuses to members of the Board of Directors based on business performance.

2. Members of the Board of Directors are entitled to receive remunerations and bonuses. Remunerations are calculated based on the number of business days necessary for completing their tasks and the daily remuneration. The Board of Directors shall estimate the remuneration of each member under unanimity rule. The total remunerations and bonuses of the Board of Directors shall be decided by the annual General Meeting of Shareholders.

3. Remuneration of each member of the Board of Directors shall be recorded as the Company's operating costs in accordance with regulations on corporate tax, presented in a separate section of the Company's annual financial statements and reported at the annual General Meeting of Shareholders.

4. Members of the Board of Directors who are holding the executive positions or are members of subcommittees of the Board of Directors or performing duties outside the scope of normal duties of a member of the Board of Directors may be paid an additional remuneration in the form of a lump sum, salary, commission, profit percentage or another form decided by the Board of Directors.

5. Members of the Board of Directors are entitled to be paid all expense for travel, accommodation and other reasonable expenses incurred during performing of their duties as members of Board of Directors, including the expenses incurred in attending the General Meeting of Shareholders, the meeting of the Board of Directors or its subcommittees.

6. The Company may buy liability insurance for members of the Board of Directors after receiving the approval of the General Meeting of Shareholders. This insurance does not cover the responsibility of members of the Board of Directors relevant to their violations against the law and the Company's Charter.

Article 30. Chairman of the Board of Directors

1. The Chairman of the Board of Directors shall be elected among the members of the Board of Directors, dismissed and removed by the Board of Directors.
2. The Chairman of the Board of Directors must not concurrently act as General Director.
3. Rights and duties of the Chairman of the Board of Directors:
 - a) Preparing action plans and programs of the Board of Directors;
 - b) Preparing the agenda, contents and documents for the meetings; convening and chairing the meetings of the Board of Directors;
 - c) Organizing the ratification of resolutions and decisions of the Board of Directors;
 - d) Supervising the process of implementation of the resolutions and decisions of the Board of Directors;
 - đ) Chairing the General Meeting of Shareholders;
 - e) Other rights and duties stipulated in the Law on Enterprises and the Company's Charter.
4. In case the Chairman of the Board of Directors submits his/her resignation letter or is dismissed or removed, the Board of Directors shall elect a new Chairman within 10 days from the date of receiving his/her resignation letter or the date when he/she is dismissed or removed.
5. In case the Chairperson of the Board of Directors is absent or is unable to perform his duties, he/she shall authorize another member of Board of Directors in writing to perform the rights and duties of the Chairman of the Board of Directors in accordance with the Company's Charter. If no one is authorized or the Chairperson of the Board of Directors is dead, missing, detained, imprisoned, detained in a mandatory rehabilitation center or correctional institution, or if the Chairperson has fled the residence, had his/her capacity for civil acts restricted or lost his/her civil act capacity, had difficulties in awareness or controlling his/her behaviors, or he/she is prohibited by the Court from holding certain positions, practicing or doing certain works, the remaining members shall elect one of them as the Chairman of the Board of Directors under the majority rule until a new decision is made by the Board of Directors.

Article 31. Meetings of the Board of Directors

1. The Chairman of the Board of Directors shall be elected in the first meeting of the Board of Directors within 07 business days from the date of completing the election of the Board of Directors. This meeting shall be convened and chaired by the member with the highest number of votes. In case there are more than one member with the same highest number of votes, the members shall elect 01 person to convene the meeting of the Board of Directors under the majority rule.

2. The Board of Directors shall have at least 01 meeting per quarter and may have extraordinary meetings.

3. The Chairman of the Board of Directors shall convene a meeting of the Board of Directors in the following cases:

a) The meeting is requested by the Board of Supervisors or independent members of the Board of Directors;

b) The meeting is requested by the General Director or at least 05 other managers;

c) The meeting is requested by at least 02 members of the Board of Directors;

4. The requests for meeting mentioned in Clause 3 this Article must be in writing, specify the purposes of the meeting, issues to be discussed and decided under the authority of the Board of Directors.

5. The Chairman of the Board of Directors shall convene the meeting of Board of Directors within 07 business days from the date of receiving the request mentioned in Clause 3 of this Article. Otherwise, the Chairman of the Board of Directors shall be responsible for the damage caused to the Company; the person making the request is entitled to convene the meeting of the Board of Directors instead of the Chairman of the Board of Directors.

6. The Chairman of the Board of Directors or the person convening the meetings of the Board of Directors shall send invitations at least 03 business days prior to the meeting date. The invitation shall specify the meeting time, meeting venue, agenda, issues to be discussed and decided. The invitation shall be enclosed with documents used at the meeting and a ballot paper.

The invitations to the meeting of the Board of Directors may be sent physically, by phone, fax, email or other forms stipulated in the Company's Charter as long as they ensure the invitations reach the address of each member of the Board of Directors registered with the Company.

7. The Chairman of the Board of Directors or the person convening the meetings of the Board of Directors shall send the invitations and enclosed documents, which must be the same as those sent to members of Board of Directors, to members of the Board of Supervisors.

Members of the Board of Supervisors are entitled to attend the meetings of the Board of Directors; they are entitled to discuss but are not entitled to vote at the meetings.

8. The meeting of the Board of Directors shall be conducted when there are at least three fourths (3/4) of the members of the Board of Directors attending the meeting. In case the number of members attending the meeting is insufficient, the second meeting shall be convened within 07 days from the intended date of the first meeting. The second meeting shall be conducted when there are more than half of the members of the Board of Directors attending the meeting.

9. A member of the Board of Directors is considered to attend and vote at the meeting when:

- a) Attend and vote in person at the meeting;
- b) Authorize another person to attend and vote by proxy at the meeting in accordance with Clause 11 of this Article;
- c) Attend and vote in online meeting; cast electronic votes or in other electronic forms;
- d) Send votes to the meeting by mail, fax or email;
- đ) Sends votes using other means as stipulated in the Company's Charter.

10. In case the votes are sent to the meeting by post, they must be in sealed envelopes and delivered to the Chairman of the Board of Directors at least 01 hour before the opening of the meeting. The votes shall only be opened in the presence of all attendees.

11. The members shall attend all meetings of the Board of Directors. A member may authorize another person to attend the meeting and vote if that is approved by the majority of the members of the Board of Directors.

12. The resolution or decision of the Board of Directors will be passed if it is approved by the majority of the members attending the meeting. In case of a tie, the vote of the Chairman is used to make the final decision.

Article 32. Subcommittees of the Board of Directors

- 1. The Board of Directors may establish subcommittees taking charge of development policies, personnel, remuneration, internal audit and risk management. The number of members of each subcommittee shall be decided by the Board of Directors. The resolution of the subcommittee is only effective when there is a majority of its members attending the meeting of subcommittee and voting for the resolution.
- 2. The implementation of decisions of the Board of Directors or subcommittees shall be conformable with applicable laws and regulations, the Company's Charter and the Internal Regulations on Corporate Governance.

Article 33. Person in charge of corporate governance

- 1. The Board of Directors shall appoint at least 01 person in charge of corporate governance to assist corporate governance of the Company. He/she may also be the Company's secretary in accordance with Clause 5 Article 156 of the Law on Enterprises.
- 2. The person in charge of corporate governance must not concurrently work for the accredited audit organization auditing the Company's financial statements.
- 3. The person in charge of corporate governance has the following rights and duties:

- a) Consulting the Board of Directors about organizing the General Meeting of Shareholders in accordance with regulations and performing tasks related to issues between the Company and its shareholders;
- b) Preparing for meetings of the Board of Directors, the Board of Supervisors and the General Meeting of Shareholders at the request of the Board of Directors or the Board of Supervisors;
- c) Consulting about meeting procedures;
- d) Attending meetings;
- đ) Consulting about the procedure for preparing resolutions of the Board of Directors in accordance with laws and regulations.
- e) Providing financial information, copies of minutes of the Board of Directors's meetings and other information to members of the Board of Directors and the Board of Supervisors;
- g) Supervising and reporting to the Board of Directors on the Company's information disclosure;
- h) Assisting in contact between interested parties;
- i) Protecting confidential information in accordance with law and the Company's Charter;
- k) Other rights and duties stipulated in laws and the Company's Charter.

VIII. GENERAL DIRECTOR AND OTHER MANAGERS

Article 34. Organization of the management apparatus

The managerial system of the Company must ensure that the management apparatus shall be responsible to the Board of Directors, shall be under the supervision and leadership of the Board of Directors in the Company's day-to-day business operation. The Company has a General Director, Deputy General Directors, a Chief Accountant and other managerial positions appointed by the Board of Directors to hold. The appointment, dismissal and removal of the persons holding these positions must be passed by resolutions or decisions of the Board of Directors.

Article 35. Managers of the Company

1. The Company's management personnel are the General Director, Deputy General Director, Chief Accountant and other management personnel stipulated in the Company's Charter;
2. At the request of the General Director and with the approval of the Board of Directors, the Company may recruit other management positions with the number and qualifications of management personnel conformable to the organizational structure and regulations on management of the Company prescribed by the Board of Directors. Management personnel shall

have responsibility for assisting the Company in achieving its organizational and business objectives.

3. The General Director shall be paid salary and bonuses, which are decided by the Board of Directors.

4. Salaries of management personnel shall be recorded as the Company's operating costs in accordance with regulations on corporate tax, presented in a separate section of the Company's annual financial statements and reported at the annual General Meeting of Shareholders.

Article 36. Appointment, dismissal, duties and power of the General Director

1. The Board of Directors shall appoint a member of the Board of Directors or hire another person as the General Director.

2. The General Director shall manage the Company's day-to-day business operation; be supervised by the Board of Directors; is responsible to the Board of Directors and the law for his/her performance on his/her rights and duties.

3. The term of office of the General Director shall not exceed 05 years and he/she can be reappointed with no term limit. The General Director shall satisfy the requirements and conditions in accordance with laws and the Company's Charter.

4. The General Director has the following rights and duties:

a) Deciding matters related to the Company's day-to-day business operation outside the authority of the Board of Directors;

b) Implementing the resolutions and decisions of the Board of Directors;

c) Implementing the Company's business and investment plans;

d) Proposing organizational structure and internal regulations on management of the Company

đ) Appointing, dismissing and removing managerial positions in the Company, except for the positions within the authority of the Board of Directors to appoint, dismiss and remove;

e) Deciding the salaries and other benefits of the Company's employees, including the managers appointed by the General Director;

g) Recruiting employees;

h) Proposing plans for dividend payment or dealing with business loss;

i) Other rights and duties in accordance with laws and the Company's Charter, resolutions and decisions of the Board of Directors.

5. The Board of Directors may dismiss the General Director when that is approved by the majority of members of the Board of Directors who have voting right and attending the meeting, and appoint a new General Director.

IX. THE BOARD OF SUPERVISORS

The Company operates under the governance model prescribed in Point a, Clause 1, Article 137 of the Law on Enterprises. The Company shall establish a Board of Supervisors in accordance with the Law on Enterprises, Decree No. 155/2020/ND-CP dated 31 December 2020 of the Government detailing the implementation of certain provisions of the Law on Securities, and Articles 36 through 41 of this Charter.

Article 37. Nomination and candidacy of members of the Board of Supervisors (Supervisor)

1. The nomination and candidacy of members of the Board of Supervisors shall be made in accordance with Clause 1 and Clause 2 Article 25 of this Charter.

2. In case the number of nominated and self-nominated candidates is insufficient, the incumbent Board of Supervisors shall nominate additional candidates or hold a nomination in accordance with the Company's Charter, the Internal Regulations on Corporate Governance and the Regulations on operation of Board of Supervisors Charter. The nomination of candidates to Board of Supervisors by the incumbent Board of Supervisors must be clearly announced before shareholders vote for members of the Board of Supervisors in accordance with the law and other regulations.

Article 38. Composition of the Board of Supervisors

1. The Board of Supervisors has 03 members. The term of office of members of the Board of Supervisors shall not exceed 05 years and they can be re-elected with no term limit.

2. Members of the Board of Supervisors shall satisfy the requirements and conditions in accordance with Article 169 of the Law on Enterprises and the Company's Charter and shall not:

- a) Work in the Company's accounting or finance department;
- b) Be a Board member or an employee of the independent accredited audit organization auditing the Company's financial statements in the last 03 years.

3. A member of the Board of Supervisors will be dismissed in the following cases:

- a) Do not satisfy the requirements and conditions to be a member of Board of Supervisors specified in Clause 2 of this Article;
- b) Submitting resignation letter which is accepted;

4. A member of the Board of Supervisors will be removed in the following cases:

- a) Failing to complete the assigned tasks and duties;
- b) Failing to perform his/her rights and duties for 06 consecutive months, except in case of force majeure;
- c) Committing multiple violations or serious violations against duties of members of the Board of Supervisors stipulated in the Law on Enterprises and the Company's Charter.
- d) Other cases in accordance with the resolutions of the General Meeting of Shareholders.

Article 39. Head of the Board of Supervisors

1. The Board of Supervisors elect one of its members to be the Head of the Board of Supervisors; the election, dismissal and removal of members of the Board of Supervisors are decided under the majority rule. More than half of the members of the Board of Supervisors shall reside in Vietnam. The Head of the Board of Supervisors shall have a bachelor's degree or higher in economics, finance, accounting, audit, law, business administration or other majors relevant to the enterprise's operation.

2. Rights and duties of the Head of the Board of Supervisors:

- a) Convening meetings of the Board of Supervisors;
- b) Requesting the Board of Directors, the General Director and other managers to provide relevant information for reporting to the Board of Supervisors;
- c) Preparing and signing reports of the Board of Supervisors to submit to the General Meeting of Shareholders after consulting with the Board of Directors.

Article 40. Power and duties of the Board of Supervisors

The Board of Supervisors has the rights and duties in accordance with Article 170 of the Law on Enterprises and the following rights and duties:

- 1. Proposing the list of accredited audit organizations auditing the Company's financial statements to the General Meeting of Shareholders for approval; choosing the accredited audit organization auditing the Company's operation; removing accredited auditors if necessary.
- 2. Taking responsibility to the shareholders for the supervision tasks performed by the Board of Supervisors.
- 3. Supervising the Company's finance, regulatory compliance of members of the Board of Directors, the General Director and other managers.

4. Ensuring the cooperation with the Board of Directors, the General Director and shareholders.
5. In case discovering violations against laws or the Company's Charter committed by members of the Board of Directors, General Director or other managers of the Company, the Board of Supervisors must send a written report to the Board of Directors within 48 hours after the discovery of violations, and request the violator to stop committing the violations and take remedial measures.
6. Preparing and submitting the Board of Supervisors Charter to the General Meeting of Shareholders for approval.
7. Submitting reports to the General Meeting of Shareholders in accordance with Article 290 of Decree No. 155/2020/ND-CP dated December 31, 2020 elaborating a number of Articles of the Securities Law.
8. Having the rights to access the Company's files, documents archived at its head office, branches and other places; enter the working places of the Company's managers and employees during office hours.
9. Having the right to request the Board of Directors, its members, the General Director and other managers to provide adequate, accurate information and documents about the management and operation of the Company in a timely manner.
10. Other rights and duties in accordance with laws, regulations and this Charter.

Article 41. Meetings of the Board of Supervisors

1. The Board of Supervisors shall have at least 02 meetings per year and there must be at least two thirds (2/3) of its members attending a meeting. The meeting minutes must be detailed and clear, bear the signatures of the minute taker and the members of the Board of Supervisors attending the meeting. All meeting minutes of the Board of Supervisors must be archived in order to attribute responsibility of each member.
2. The Board of Supervisors is entitled to request members of the Board of Directors, the General Director and representatives of the accredited audit organization to attend its meetings and clarify the raised issues.

Article 42. Salaries, remunerations, bonuses and other benefits of members of the Board of Supervisors

The salaries, remunerations, bonuses and other benefits of members of the Board of Supervisors shall comply with the following regulations:

1. Members of the Board of Supervisors shall be paid salaries, remunerations, bonuses and other benefits in accordance with the decision of the General Meeting of Shareholders. The General

Meeting of Shareholders shall decide the total salaries, remunerations, bonuses, other benefits and annual budget for the operation of the Board of Supervisors.

2. Members of the Board of Supervisors shall be paid all reasonable expenses for accommodation, travel and independent counseling services. The total remunerations and expenses must not exceed the annual budget of the Board of Supervisors which is approved by the General Meeting of Shareholders, unless otherwise decided by the General Meeting of Shareholders.

3. Salaries and operating costs of the Board of Supervisors shall be recorded as the Company's operating costs in accordance with regulations on corporate tax and related regulations and must be presented in a separate section of the Company's annual financial statements.

X. DUTIES OF MEMBERS OF BOARD OF DIRECTORS, MEMBERS OF BOARD OF SUPERVISORS, GENERAL DIRECTOR AND OTHER MANAGEMENT PERSONNEL

Members of the Board of Directors, members of the Board of Supervisors, the Director (General Director), other managers shall have responsibility for performing their duties including duties of members of subcommittees of the Board of Directors in a honest and prudent manner for the interests of the Company.

Article 43. Responsibility for honesty and avoidance of conflict of interest

1. Members of the Board of Supervisors, members of the Board of Supervisors, General Director and other managers shall disclose their relevant interests in accordance with the Law on Enterprises and relevant legislative documents.

2. Members of the Board of Directors, members of the Board of Supervisors, the General Director, other managers and their related persons may only use the information obtained from their positions to serve the interests of the Company.

3. Members of the Board of Supervisors, members of the Board of Supervisors, the General Director and other managers shall send written notices to the Board of Directors and the Board of Supervisors of the transactions between the aforementioned individuals or their related persons and the Company, its subsidiary companies and companies over 50% of charter capital of which is held by the Company as prescribed by law. The Company shall disclose information about the transactions that are approved by the General Meeting of Shareholders or the Board of Directors in accordance with regulations of the Securities Law on information disclosure.

4. Members of the Board of Supervisors must not vote on the transactions that bring interests to themselves or their related persons as prescribed by the Law on Enterprises and the Company's Charter.

5. Members of the Board of Directors, members of the Board of Supervisors, the General Director, other managers and their related persons must not use or reveal internal information for carrying out relevant transactions.

6. Transactions between the Company with one or some members of the Board of Directors, members of the Board of Supervisors, the General Director, other managers and their related persons shall not be invalidated in the following cases:

a) For transactions whose value do not exceed 35% of the total assets written in the latest financial statement, important contents of the contracts or transactions as well as relationships and interests of members of the Board of Directors, members of the Board of Supervisors, the General Director, other managers have been reported to the Board of Directors and are approved by the majority of the members of the Board of Directors without relevant interests;

b) For transactions with a value exceeding 35%, or transactions resulting in the aggregate value of transactions incurred within 12 months from the date of the first transaction reaching 75% or more of the total assets recorded in the most recent financial statements, the material details of such transactions, together with the relationships and interests of the members of the Board of Directors, members of the Board of Supervisors, the General Director, and other executives, must be disclosed to the shareholders and approved by the General Meeting of Shareholders through voting by shareholders having no related interests.

Article 44. Responsibility for damage and compensation

1. Any members of the Board of Directors, members of the Board of Supervisors, the General Director or other managers that fail to fulfill their duties and obligations in a truthful and prudent manner shall be held responsible for their violations.

2. The Company shall pay compensation to the persons who have become or may become a related party in the complaints, lawsuits, charges (including administrative and civil cases that are not lawsuits filed by the Company) if they were or are members of the Board of Directors, members of the Board of Supervisors, General Director, other managers, employees or authorized representatives of the Company who have performed their duties as authorized by the Company, acted in a lawful, honest and prudent manner for the Company's interests and there are no credible evidence of their breach of duty.

3. Costs of compensation include judgment costs, fines, costs incurred (including lawyer payment) while settling these cases within the confines of law. The Company may purchase insurance for these people in order to avoid this liability.

XI. RIGHTS TO ACCESS THE COMPANY'S DOCUMENTS AND RECORDS

Article 45. Rights to access the Company's documents and records

1. Common shareholders have the rights to access the Company's documents and records. To be specific:

a) Common shareholders are entitled to examine, search for and extract information about names and addresses of shareholders from the list of shareholder with the rights to vote; request the

rectification of incorrect information about themselves; examine, search, extract or copy the Company's Charter, minutes and resolutions of the General Meeting of Shareholders;

b) A shareholder or a group of shareholders that hold at least 05% of common shares are entitled to examine, search and extract the minutes, resolutions and decisions of the Board of Directors, semiannual and annual financial statements, reports by the Board of Supervisors, contracts and transactions required to be approved by the Board of Directors and other documents, except documents relevant to the Company's trade secrets or business secrets.

2. If a representative authorized by a shareholder or a group of shareholders to request access to documents and records, the request must be enclosed with the authorization letter or its notarized copy issued by a shareholder or a group of shareholders.

3. Members of the Board of Directors, members of the Board of Supervisors, General Director and other managers are entitled to access the Company's shareholder register, list of shareholders, other documents and records for the purposes relevant to their positions, under the condition that aforementioned information is kept confidential.

4. The Company shall retain this Charter and its revisions, the Enterprise Registration Certificate, regulations, documents proving the ownership of assets, resolutions of the General Meeting of Shareholders and the Board of Directors, minutes of the General Meeting of Shareholders and the Board of Directors, reports by the Board of Directors and the Board of Supervisors, annual financial statements, accounting records and other documents in accordance with the law at its headquarters or another location, under the condition that the shareholders and business registration authorities are informed of the location where these documents are retained.

5. The Company's Charter must be published on the Company's website.

XII. Employees and Trade Union

Article 46. Employees and Trade Union

1. The General Director must formulate a plan for the Board of Directors to approve issues related to hiring, layoff, salaries, social insurance, benefits, commendation and discipline of employees and executives.

2. The General Director must formulate a plan for the Board of Directors to approve issues related to the Company's relationships with trade Law on Enterprise organizations according to the best standards, practices and management policies, as well as according to the practice and policies specified in this Charter, the Company's regulations and applicable laws.

XIII. PROFIT DISTRIBUTION

Article 47. Profit distribution

1. The General Meeting of Shareholders shall decide the dividends and method of annual dividend payment from the Company's retained earnings.
2. The Company shall not pay interest on dividends or on payments related to any type of shares.
3. The Board of Directors may request the General Meeting of Shareholders to approve the payment of all or parts of dividends in shares, and the Board of Directors shall execute this decision.
4. If the dividends or other amounts relevant to a type of shares are paid in cash, the Company must pay in VND. Payments may be carried out directly or through banks according to detailed information about bank accounts provided by the shareholders. The Company is not responsible if a shareholder does not receive payment after the Company has transferred money according to the information provided by that shareholder. Dividend payments of stocks listed/registered on Stock Exchanges may be paid via securities companies or Vietnam Securities Depository.
5. In accordance with the Law on Enterprises and the Law on Securities, the Board of Directors shall approve the resolution or decision which specifies the record date of shareholder list. On the basis of this date, registered shareholders or holders of other securities are entitled to receive dividends in cash/shares, notice and other documents.
6. Other issues relevant to profit distribution are proceeded in accordance with the law.

XIV. BANK ACCOUNTS, FISCAL YEARS, AND ACCOUNTING REGIMES

Article 48. Bank accounts

1. The Company shall open accounts at Vietnamese banks or branches of foreign banks that are permitted to operate in Vietnam.
2. With the permission of competent authorities, out of necessity, the Company may open foreign bank accounts in accordance with the law.
3. The Company shall carry out all payments and accounting transactions through its domestic currency accounts or its foreign currency accounts at the banks that The Company has opened an account at.

Article 49. Fiscal year

The Company's fiscal year begins on January 01 and ends on December 31 every year. T

Article 50. Accounting regimes

1. The Company shall apply corporate accounting regime or specialized accounting regimes promulgated and approved by competent authorities.

2. The Company's accounting records shall be written in Vietnamese and retained in accordance with accounting laws and relevant laws. These records shall be accurate, up-to-date, systematic, and sufficient to prove and account for the Company's transactions.

3. The Company shall use VND as the accounting currency. If the Company's transactions primarily use a foreign currency, the Company may use the currency as accounting currency, take legal responsibility and send a notice to its direct tax authority.

XV. FINANCIAL STATEMENTS, ANNUAL REPORTS, AND THE OBLIGATION TO DISCLOSE INFORMATION

Article 51. Annual, half-year and quarterly financial statements

1. The Company shall prepare annual financial statements, which must be audited in accordance with the law. The Company shall disclose the audited annual financial statements in accordance with the law on information disclosure on the securities market and submit them to competent authorities.

2. The annual financial statements shall have adequate contents, appendices and descriptions prescribed by corporate accounting laws. Annual financial statements shall truthfully and objectively reflect the Company's operation.

3. The Company shall prepare and disclose audited half-year financial statements and quarterly financial statements in accordance with the law on information disclosure on the securities market and submit them to competent authorities

Article 52. Annual Report

The Company shall prepare and disclose its Annual Report in accordance with the provisions of the laws on securities and the securities market.

XVI. COMPANY AUDIT

Article 53. Auditing

1. The General Meeting of Shareholders shall appoint an independent audit company, or agree on a list of independent audit companies and authorize the Board of Directors to select one from the aforementioned list to audit the Company's financial statements of the next year under an agreement with the Board of Directors.

2. Auditor's reports shall be enclosed with the Company's annual financial statements.

3. Independent auditor that audits the Company's financial statements is entitled to participate in the General Meeting of Shareholders, receive notices and information relevant to the General Meeting of Shareholders and express opinions at the General Meeting of Shareholders on the issues relevant to the audit of the Company's financial statements.

XVII. THE COMPANY'S SEALS

Article 54. The Company's seals

1. Seals include physical seals and digital signatures as prescribed by the laws on electronic transactions.
2. The Board of Directors shall decide the types, quantity, forms, and content of the Company's seals, its branches' seals, and its representative offices' seals (if applicable).
3. The Board of Directors and the Directors (CEOs) shall use and manage the seals in accordance with the current laws.

XVIII. DISSOLUTION OF THE COMPANY

Article 55. Dissolution of the Company

1. The Company can be dissolved in the following cases:
 - a) The operating period specified in the Company's Charter expires without a further decision to extend;
 - b) By a resolution or decision of the General Meeting of Shareholders;
 - b) The Enterprise Registration Certificate is revoked, unless prescribed otherwise by the Law on Tax Administration;
 - d) Other cases prescribed by law.
2. Premature dissolution of the Company (including extensions) must be decided by the General Meeting of Shareholders and executed by the Board of Directors. Such dissolution decision must be announced or approved by competent authorities (if mandatory) as per regulations.

Article 56. Extension of operating period

1. The Board of Directors shall convene the General Meeting of Shareholders at least 7 months before the expiry of the operating period for shareholders to vote on extension of the operating period of the Company at the request of the Board of Directors.
2. The operating period shall be extended if the extension is voted affirmative by a number of shareholders that represent at least 65% of the votes of all shareholders that are present at the General Meeting of Shareholders.

Article 57. Liquidation

1. At least 06 months before the expiry of the Company's operating period or after a decision on dissolution of the Company is issued, the Board of Directors shall establish a liquidation board, which consists of 03 members, 02 of whom shall be appointed by the General Meeting of Shareholders and 01 by the Board of Directors from 01 independent audit company. The liquidation board shall formulate its own operating regulations. Members of the liquidation board may be selected from the Company's employees or independent experts. Priority shall be given to payment of liquidation costs over payment of other debts of the Company.

2. The liquidation board shall inform the business registration authority of its establishment date and commencement date. From that date, the liquidation board shall perform all liquidation tasks on behalf of the Company in court and under the supervision of administrative authorities.

3. Proceeds from the liquidation shall be spent in the following order:

a) Liquidation costs;

b) Unpaid salaries, severance pay, social insurance and other employee benefits according to the collective bargaining agreement and employment contracts;

c) Tax debts;

d) Other debts of the Company;

đ) The remaining proceeds after payment of the debts specified in (a) to (d) shall be divided among the shareholders. Priority shall be given to preferred shares.

XIX. SETTLEMENT OF INTERNAL DISPUTES

Article 58. Settlement of internal disputes

1. If there are disputes and complaints related to the Company's operation, rights and obligations of shareholders as prescribed by the Law on Enterprises, the Company's Charter, other laws or agreements between:

a) The shareholders and the Company;

b) The shareholders and the Board of Directors, the Board of Supervisors, the Director (General Director) or other managers;

The parties shall attempt to settle these disputes through negotiation and mediation. Except for disputes that involve the Board of Directors or the Chairperson of the Board of Directors, the Chairperson of the Board of Directors shall lead the settlement of disputes and request each party to provide information about their dispute within 30 working days from the occurrence of the dispute. If the dispute involves the Board of Directors or the Chairperson of the Board of Directors, either party is entitled to request the Board of Supervisors to appoint an independent expert as a mediator.

2. If the dispute cannot be settled through mediation within 06 weeks or if the mediator's decision is not accepted by the parties, either party may bring the case to court or arbitration.

3. The parties shall pay the cost of negotiation and mediation. Court fees shall be paid according to the court's judgment.

XX. SUPPLEMENTS OR AMENDMENTS TO THE COMPANY'S CHARTER

Article 59. The Company's Charter

1. Additions or amendments to this Charter are subject to approval by the General Meeting of Shareholders.

2. If the laws that are relevant to the Company's operation are not mentioned in this Charter or a new law contradicts the contents of this Charter, the laws shall take precedence to regulate the Company's operation.

XXI. EFFECTIVE DATE

Article 64. Effective date

1. This Charter, consisting of 21 Chapters and 60 Articles, was unanimously adopted by the General Meeting of Shareholders of Mediplantex National Pharmaceutical Joint Stock Company on ____ [day] ____ [month] 2026, and its full contents were approved to take effect on the same date.

2. This Charter shall be made into 30 copies of the same legal validity and retained at the Company's headquarters.

3. This is the only official Charter of the Company.

4. Copies and extracts of this Charter shall be effective when they bear the signature of the Chairperson of the Board of Directors or at least half (1/2) of the members of the Board of Directors.

THE LEGAL REPRESENTATIVE OF THE COMPANY

No.: 01/2026/NQ-DHDCD/MED

Hanoi, June 5, 2026



RESOLUTION

2026 ANNUAL GENERAL MEETING OF SHAREHOLDERS MEDIPLANTEX NATIONAL PHARMACEUTICAL JOINT STOCK COMPANY

Pursuant to:

- Pursuant to the Law on Enterprises No. 59/2020/QH14 adopted by the National Assembly of the Socialist Republic of Vietnam on June 17, 2020, and effective from January 1, 2021, as amended by Law No. 03/2022/QH15 adopted by the National Assembly on January 11, 2022, Law No. 76/2025/QH15 adopted by the National Assembly on June 17, 2025, and the guiding documents;
- Pursuant to the Law on Securities No. 54/2019/QH14 dated November 26, 2019, passed by the National Assembly of the Socialist Republic of Vietnam, as amended by Law No. 56/2024/QH15 passed by the National Assembly of the Socialist Republic of Vietnam on November 29, 2024, and its guiding documents;
- Pursuant to the Charter on organization and operation of MediPlantex National Pharmaceutical Joint Stock Company;
- Pursuant to the Minutes of the 2026 Annual General Meeting of Shareholders No. ... dated June 26, 2026;
- Pursuant to the Vote Counting Minutes of the 2026 Annual General Meeting of Shareholders of MediPlantex National Pharmaceutical Joint Stock Company dated June 26, 2026.

The 2026 Annual General Meeting of Shareholders (“AGM” or “GMS”) of MediPlantex National Pharmaceutical Joint Stock Company shall be conducted in the form of an online meeting with electronic voting. The meeting venue for the Chairperson, the Presidium, and the Organizing Committee (the principal venue from which the Meeting is conducted) shall be located at: No. 358 Giai Phong Road, Phuong Liet Ward, Hanoi, Vietnam.

RESOLUTION

Article 1. Approval of the following reports:

- Report of the Board of Directors on the 2025 performance and the proposed operational plan for 2026;
- Report of the Board of Management on the 2025 Business and Production results and the implementation plan for 2026;
- Report of the Board of Supervisors on the 2025 activities, supervisory work and the proposed plan for 2026;

Accordingly, the business and production plan for the year 2026 is as follows:

No.	INDICATOR	UNIT	VALUE
I	Total Revenue	Million VND	412,071
II	Cost of Goods Sold	Million VND	321,273
III	Total Gross Profit	Million VND	90,797
IV	Total Selling Expenses	Million VND	4,949
	Financial Expenses	Million VND	5,120
V	Administrative Expenses	Million VND	62,822
VI	Profit Before Tax	Million VND	15,005

Article 2. Approval of the 2025 Audited Financial Statements (*Pursuant to Proposal No. 01/2026/TTr-DHĐCĐ dated June 26, 2026*).

Article 3. Approval of the Selection of the Independent Auditor for the 2026 Financial Statements (*Pursuant to Proposal No. 02/2026/TTr-DHĐCĐ dated June 26, 2026*).

Article 4. Approval of the profit distribution plan and dividend payout ratio for 2025, and the proposed profit distribution plan and dividend payout ratio for 2026 (*Pursuant to Proposal No. 03/2026/TTr-DHĐCĐ dated June 26, 2026*).

Article 5. Approval of the remuneration for the Board of Directors and the Board of Supervisors for 2025 (*Pursuant to Proposal No. 04/2026/TTr-DHĐCĐ dated June 26, 2026*).

Article 6. Approval of the amendments and supplements to the Charter on Organization and Operation of the Company (*Pursuant to Proposal No. 05/2026/TTr-DHĐCĐ dated June 26, 2026*).

Article 7. Approval of the Dismissal for the Additional Members of the Board of Directors for the 2024 – 2029 Term (*Pursuant to Proposal No. 06/2025/TTr-DHĐCĐ dated June 26, 2026*)

- ❖ Dismissal of Ms. Nguyen Thi Thuy from the position of member of the Board of Directors as from the date of approval by the General Meeting of Shareholders.
- ❖ Elect Mr./Ms. ... as an additional member of the Board of Directors for the 2024–2029 term, effective from the date of approval by the General Meeting of Shareholders.

This Resolution shall take effect from the date of issuance. The Board of Directors, the Board of Supervisors, the Board of Management, and all relevant departments shall be responsible for implementing this Resolution.

**OB. THE 2026 GENERAL MEETING OF SHAREHOLDERS
CHAIRPERSON**



MEDIPLANTEX NATIONAL PHARMACEUTICAL JOINT STOCK COMPANY
2026 ANNUAL GENERAL MEETING OF SHAREHOLDERS

VOTING BALLOT
DELEGATE ID:



Full name:

Number of votes owned: votes

Number of votes authorized: votes

Total number of votes represented: votes

(Check the corresponding box for your choice in each content)

CONTENT	Approve	Disapprove	Abstain
Content 01: Agenda of the 2026 Annual General Meeting of Shareholders	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Content 02: Working and Voting Regulations of the 2026 Annual General Meeting of Shareholders	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Content 03: Presidium for the 2026 Annual General Meeting of Shareholders	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Content 04: The Vote Counting Committee for the 2026 Annual General Meeting of Shareholders	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>

Guide:

Shareholders tick (X) in one of 3 boxes:

Approve/Disapprove/Abstain each Content.

June 26th 2026

DELEGATE

(Signature and full name)



MEDIPLANTEX NATIONAL PHARMACEUTICAL JOINT STOCK COMPANY
2026 ANNUAL GENERAL MEETING OF SHAREHOLDERS

VOTING BALLOT
DELEGATE ID:



Full name:

Number of votes owned: votes

Number of votes authorized: votes

Total number of votes represented:votes

(Check the corresponding box for your choice in each content)

CONTENT	Approve	Disapprove	Abstain
Content 01: Report of the Board of Directors on 2025 performance results and the implementation plan for 2026 activities	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Content 02: Report of the Board of Management on the 2025 business and production results and the implementation plan for 2026	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Content 03: Report of the Board of Supervisors on the 2025 activities, supervisory work and the proposed plan for 2026	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Content 04: Approval of the 2025 Audited Financial Statements	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Content 05: Approval of the Selection of the Independent auditing firm for the 2026 Financial Statements	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Content 06: Approval of the profit distribution plan and dividend payout ratio for 2025, and the proposed profit distribution plan and dividend payout ratio for 2026	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Content 07: Approval of remuneration report for the Board of Directors, Board of Supervisors for 2025 and the plan for 2026	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Content 08: Approval of the Amendments and Supplements to the Charter on Organization and Operation of the Company	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Content 09: Approval of the Dismissal and Election for the Additional Members of the Board of Directors for the 2024 – 2029 Term	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>

Guide:

Shareholders tick (X) in one of 3 boxes:

Approve/Disapprove/Abstain each Content.

June 26th 2026

DELEGATE

(Signature and full name)

MEDIPLANTEX NATIONAL PHARMACEUTICAL JOINT STOCK COMPANY
2026 ANNUAL GENERAL MEETING OF SHAREHOLDERS



MEDIPLANTEX

VOTING BALLOT
DELEGATE ID:



Full name:

Number of votes owned: votes

Number of votes authorized: votes

Total number of votes represented:votes

(Check the corresponding box for your choice in each content)

CONTENT	Approve	Disapprove	Abstain
Content 01: Resolution of the 2026 Annual General Meeting of Shareholders	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Content 02: Meeting Minutes of the 2026 Annual General Meeting of Shareholders	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>

Guide:

Shareholders tick (X) in one of 3 boxes:

Approve/Disapprove/Abstain each Content.

June 26th 2026

DELEGATE

(Signature and full name)



MEDIPLANTEX NATIONAL PHARMACEUTICAL JOINT STOCK COMPANY
2026 ANNUAL GENERAL MEETING OF SHAREHOLDERS



VOTE ON THE BOARD OF DIRECTORS
DELEGATE ID:

Full name:

Number of votes owned: votes

Number of votes authorized: votes

Total number of votes represented: votes

Total number of voting rights voting rights

I hereby agree to cast the votes for the chosen Additional Member of the Board of Directors

No	Full Name	Cumulative voting	Number of votes
1	...	<input type="checkbox"/>	<input type="text"/>
2	...	<input type="checkbox"/>	<input type="text"/>

Guide:

1. The maximum number of candidates that delegates are eligible to elect is equal to the number of candidates needed to elect (01 member)
2. If accumulative elect the entire elect for one or several candidates, delegates mark in "Cumulative voting" of the corresponding candidates.
3. If the number of elections is uneven for many candidates, the delegate must specify the number of elections in the "Number of votes" of the corresponding candidates.

June 26th, 2026

DELEGATE

(Signature and full name)

Hanoi, June 05, 2026



**NOTICE OF NOMINATION, SELF-NOMINATION , AND ELECTION
FOR SUPPLEMENTARY MEMBER OF THE BOARD OF DIRECTORS
FOR THE REMAINING 2024 – 2029 TERM**

Pursuant to:

- *The Law on Enterprises No. 59/2020/QH14 passed by the National Assembly of the Socialist Republic of Vietnam on June 17, 2020, as amended and supplemented by Law No. 03/2022/QH15 passed by the National Assembly on January 11, 2022, and its guiding documents, Law No. 76/2025/QH15 adopted by the National Assembly on June 17, 2025, and the guiding documents;*
- *The Law on Securities No. 54/2019/QH14 passed by the National Assembly of the Socialist Republic of Vietnam on November 26, 2019, as amended by Law No. 56/2024/QH15 passed by the National Assembly on November 29, 2024, and its guiding documents;*
- *Decree No. 155/2020/ND-CP dated 31 December 2020 of the Government detailing the implementation of a number of articles of the Law on Securities, as amended and supplemented by No. 245/2025/ND-CP dated 11 September 2025, and its guiding documents;*
- *The Charter on Organization and Operation of Mediplantex National Pharmaceutical Joint Stock Company;*
- *The Company's Internal Regulation on Corporate Governance, the Operational Regulations of the Board of Directors of Mediplantex National Pharmaceutical Joint Stock Company;*

The Board of Directors of Mediplantex National Pharmaceutical Joint Stock Company hereby notifies the esteemed shareholders of the specific regulations regarding the nomination and self-nomination for the election of additional member to the Board of Directors for the remaining 2024 – 2029 term, as follows:

**I. ELECTION ADDITIONAL MEMBERS OF THE BOARD OF DIRECTORS
FOR THE REMAINING 2024 – 2029 TERM**

- Number of additional members of the BOD to be elected (expected): **01 member**.
- Term of the additional member: The remaining duration of the 2024–2029 term.
- Structure of the Board of Directors:

The structure of the Board of Directors must ensure that at least one-third (1/3) of the total number of Board members are non-executive members (i.e., members of the Board of Directors who are not the General Director, Deputy General Directors, Chief Accountant, or other executive managers as defined by the Company's Charter).

The number of independent member of the Board of Directors must be at least 01 member.

II. CRITERIA AND CONDITIONS FOR NOMINATION AND SELF-NOMINATION OF MEMBERS OF THE BOARD OF DIRECTORS FOR THE 2024 - 2029 TERM

2. Criteria for Independent Members of the Board of Directors: Independent members of the Board of Directors shall meet the qualifications and eligibility requirements set out in Clause 2, Article 155 of the Law on Enterprises and Article 7 of the Regulation on Operations of the Board of Directors

a. Shareholders holding ordinary shares shall have the right to aggregate their voting rights for the purpose of nominating candidates to the Board of Directors. Shareholders or groups of shareholders holding 10% or more of the total number of ordinary shares shall have the right to nominate candidates for election to the Board of Directors, as follows:

- A shareholder or group of shareholders holding from 80% to less than 90% of the total voting shares may nominate up to eight (08) candidates.
- b. Ordinary shareholders forming a group to nominate candidates to the Board of Directors must notify the shareholders attending the General Meeting of Shareholders of such grouping prior to the opening of the General Meeting of Shareholders.
- c. In the event that the number of candidates for the Board of Directors nominated and self-nominated remains insufficient, the incumbent Board of Directors may nominate additional candidates or organize nominations in accordance with a mechanism specified in the Company's internal corporate governance regulations. This nomination mechanism or the procedure for nomination by the incumbent Board of Directors must be clearly disclosed and must be approved by the General Meeting of Shareholders prior to its implementation.

III. NOMINATION AND SELF-NOMINATION DOCUMENTS:

Shareholders or groups of shareholders holding the required percentage as stipulated above, when nominating or applying as candidates for the Board of Directors of the Company, must submit the following documents to the Company either in person or by postal mail:

- Self-Nomination or nomination letter for candidacy to the Board of Directors (using the attached form);
- Information disclosure form (using the attached form);
- Copies of the candidate's legal identification documents;
- Minutes of the shareholders' group meeting (in case a group of shareholders aggregates voting shares to nominate a Board member) (using the attached form);
- Certified copies of relevant academic qualifications (if any) of the candidate/nominee.

IV. DEADLINE AND ADDRESS FOR SUBMISSION OF SELF-NOMINATION/ NOMINATION DOCUMENTS

For the convenience of organizing the election process and preparing election materials, the Company respectfully requests eligible shareholders/shareholder groups wishing to nominate or stand for election to submit by fax or email the nomination/self-nomination dossier as prescribed in Section III above, and concurrently send the original dossier to the Company no later than 3:00 p.m. on 15 June 2026, using the following contact information:

- Contact Address: Mediplantex National Pharmaceutical Joint Stock Company – 358 Giai Phong Street, Thanh Xuan District, Hanoi.
- Contact Person: Ms. Chu Huyen Trang – Position: Company Secretary.
- Tel: 0916117939
- Email: trang.chuh@mediplantex.com.

In the event that a shareholder or group of shareholders fails to submit the original copies of the self-nomination/nomination documents as stipulated in Section IV above to the Company prior to the approval of the list of nominees/candidates at the General Meeting, such self-nomination/nomination shall be deemed non-compliant with the provisions of the Law on Enterprises and the Company's Charter, and consequently, the self-nomination/nomination shall be considered invalid at the General Meeting.

Based on the nomination and self-nomination dossiers submitted by shareholders and groups of shareholders, together with the supporting documents of the candidates, the Board of Directors shall compile a list of candidates who satisfy the prescribed eligibility requirements and submit such list to the General Meeting of Shareholders for approval prior to the election of members of the Board of Directors. If, by the date preceding the opening of the General Meeting of Shareholders, the number of nominated and self-nominated candidates for the Board of Directors is less than the number of Board members to be elected, the remaining candidates shall be nominated by the Board of Directors or through a nomination process organized in accordance with applicable laws and the Company's Charter.

**ON BEHALF OF THE BOARD OF DIRECTORS
CHAIRMAN**

Nguyen Ngoc Xuan Trang



**MEDIPLANTEX NATIONAL
PHARMACEUTICAL JOINT
STOCK COMPANY**

SOCIALIST REPUBLIC OF VIETNAM

Independence – Freedom – Happiness

**NOMINATION LETTER
FOR MEMBER OF THE BOARD OF DIRECTORS
IN 2024 – 2029 TERM**

To: Mediplantex National Pharmaceutical Joint Stock Company

Shareholder's Full Name:.....

Citizen ID/Passport/Business Registration No:.....

Date of Issue: Place of Issue:

Legal Representative (if applicable):.....

Currently holding at 28/05/2026: shares.

Equivalent to% of the total voting shares.

I hereby respectfully propose that Mediplantex National Pharmaceutical Joint Stock Company allow me/ my company to nominate:

Mr./Ms.:

Citizen ID/Passport No.: Date of Issue:Place of Issue:

Permanent Address:

Educational Qualification: Major:

Currently holding: shares.

Equivalent to the total nominal value of: VND

To be a candidate for the Board of Directors of Mediplantex National Pharmaceutical Joint Stock Company for the remaining term of 2024–2029.

I hereby certify that the information provided above is accurate, and I take full responsibility before the law and before the General Meeting of Shareholders for the authenticity and accuracy of the enclosed documents.

Sincerely.

Enclosed Documents:

- A valid copy of Citizen ID/Passport;
- Copies of academic degrees/certificates;
- Curriculum vitae of the nominee;

..., date ... month ... 2026

Nominator

(Signature, full name, and seal – if applicable)



**MEDIPLANTEX NATIONAL
PHARMACEUTICAL JOINT
STOCK COMPANY**

THE SOCIALIST REPUBLIC OF VIETNAM

Independence – Freedom – Happiness

**SELF-NOMINATION LETTER
MEMBER OF THE BOARD OF DIRECTORS
IN 2024 – 2029 TERM**

To: Mediplantex National Pharmaceutical Joint Stock Company

My name is:

Citizen ID/Passport/Business Registration No:.....

Date of Issue: Place of Issue:.....

Permanent Address:

Educational Qualification:

Major:

Currently holding at 28/05/2026: shares.

Equivalent to% of the total voting shares.

I respectfully request Mediplantex National Pharmaceutical Joint Stock Company to allow me to self-nominate as a candidate for the Board of Directors of Mediplantex National Pharmaceutical Joint Stock Company.

If entrusted and elected by the shareholders as a member of the Board of Directors, I pledge to devote my full capabilities and dedication to contributing to the development of Mediplantex National Pharmaceutical Joint Stock Company.

I hereby affirm that all the information I have provided is accurate, and I shall bear full responsibility before the law and the General Meeting of Shareholders for the truthfulness and accuracy of the documents submitted.

Sincerely thanks.

Enclosed Documents:

- A valid copy of Citizen ID/Passport;
- Copies of academic degrees/certificates;
- Curriculum vitae of the nominee;

..., 2026

Candidate

(Signature, full name, and seal – if applicable)



**MEDIPLANTEX NATIONAL
PHARMACEUTICAL JOINT
STOCK COMPANY**

THE SOCIALIST REPUBLIC OF VIETNAM

Independence – Freedom – Happiness

**MINUTES OF SHAREHOLDERS' GROUP MEETING
NOMINATION OF CANDIDATES FOR THE BOARD OF DIRECTORS**

- Pursuant to the Charter on organization and operation of Mediplantex National Pharmaceutical Joint Stock Company;
- Pursuant to the Operational Regulations of the Board of Directors;

Today, on at, we, the shareholders of Mediplantex National Pharmaceutical Joint Stock Company, collectively hold shares (in words: shares), representing% of the total voting shares of the Company at the record date 28/05/2026, as listed below:



No.	Shareholder's Full Name	Citizen ID/Passport/Business Registration No.	Permanent Address	Number of Shares Owned / Representatively owned	Signature and Full Name
	Total				

After reviewing the Company's regulations on nomination and self-nomination, we unanimously agree to nominate the following candidate to serve on the Board of Directors of Mediplantex National Pharmaceutical Joint Stock Company for the remaining term of 2024-2029 at the 2026 Annual General Meeting of Shareholders as follows:

Mr./Ms.:

Citizen ID/Passport No.:

Date of Issue:Place of Issue:.....

Permanent Address:

Educational Qualification: Major:.....

Currently holding at 28/05/2026: shares.

Equivalent to% of the total voting shares.

Corresponding total par value: (VND)

Simultaneously, we unanimously appoint:

Mr./Ms.:

Identification Number (Citizen ID/Passport):

Date of Issue: Place of Issue:

Permanent Address:

Currently holding at 28/05/2026: shares.

Equivalent to% of the total voting shares.

to act as the representative of the group to carry out the nomination procedures in accordance with the Company's regulations on participation in nominating candidates for the Board of Directors of Mediplantex National Pharmaceutical Joint Stock Company.

This minute is made at hour on the day of month year at

We hereby certify that the information provided is true and accept full responsibility regarding the accuracy and honesty of the attached documents before the Company's General Meeting of Shareholders and under applicable laws.

....., dated.....

SHAREHOLDER

(Nominee – Representative of the Group)

(Signature and full name)¹

¹For Institutional Shareholders:

- The legal representative shall sign and affix the official seal; or
- In case the institution appoints a capital contribution representative (authorized representative), the appointed representative shall sign and enclose the relevant appointment documents in accordance with applicable regulations.

4 x 6
Photograph

(most
recent
photo)

SOCIALIST REPUBLIC OF VIETNAM
Independence – Freedom – Happiness

CURRICULUM VITAE

(For individuals self-nominating or nominated for election as a member of the Board of Directors)

1. Full name: Gender: Male/Female
2. Date of birth: Place of birth:
3. Nationality:
4. Citizen ID/Passport number: Issued on:/...../..... at:
5. Permanent address:
6. Contact number: Email:
7. Educational background:
8. Professional qualification:
9. Work experience:

Period	Employment History, Occupation, and Positions Held <i>(Job title, workplace)</i>	Note

10. Current position at Mediplantex National Pharmaceutical Joint Stock Company (if applicable):
.....

11. Other positions currently held at other organizations:

Company Name	Address	Business Registration Certificate	Date/Place of Issue	Position	Shareholding/Capital Contribution Ratio

12. Number of shares held (as of the record date) at Mediplantex National Pharmaceutical Joint Stock Company: shares, accounting for..... % of charter capital, including:

+ Representing ownership of (name of the organization as State/strategic shareholder/other entity):
.....

+ Individually owned:

13. Shareholding commitments (if any):

14. List of related persons of the declarant ^{*} :

No.	Name of Individual/Organization	Passport Number (for individuals) or Enterprise Registration Certificate/Operating License/Equivalent Legal Document Number, Date of Issue, Place of Issue (for organizations)	Number of Shares Held and Ownership Ratio in the Charter Capital of Company (if any)	Relationship to the Declarant

15. Related interests with Mediplantex National Pharmaceutical Joint Stock Company (if any):

.....
.....
.....

16. Conflicting interests with Mediplantex National Pharmaceutical Joint Stock Company (if any):

.....
.....
.....

17. Conflicting interests with Mediplantex National Pharmaceutical Joint Stock Company (if any):

.....
.....
.....

I hereby certify that the above statements are completely accurate. I shall bear full legal responsibility for any false or misleading declarations.

**CONFIRMATION BY LOCAL
AUTHORITIES OR EMPLOYING
ORGANIZATION (IF NECESSARY)**

DECLARANT
(Signature and full name)